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The exponential growth in medical pharmaceuticals and related clinical trials 
have created a need to better understand the decision-making factors in the processes 
for developing hospital medication formularies. The purpose of the study was to identify, 
rank, and compare major factors impacting hospital formulary decision-making among 
three prescriber groups serving on a hospital’s pharmacy and therapeutics (P&T) 
committee. Prescribers were selected from the University of Texas, MD Anderson 
Cancer Center which is a large, multi-facility, academic oncology hospital. Specifically, 
the prescriber groups studied were comprised of physicians, midlevel providers, and 
pharmacists. A self-administered online survey was disseminated to participants. Seven 
major hospital formulary decision-making factors were identified in the scientific 
literature. Study participants were asked to respond to questions about each of the 
hospital formulary decision-making factors and to rank the various formulary decision-
making factors from the factor deemed most important to the factor deemed least 
important. There are five major conclusions drawn from the study including three 
similarities and two significant differences among the prescriber groups and factors. 
Similarities include: (1) the factor “pharmacy staff’s evaluation of medical evidence 
including formulary recommendations” was ranked highest for all three prescriber 
groups; (2) “evaluation of medications by expert physicians” was ranked second for 
physicians and midlevel providers while pharmacists ranked it third; and (3) the factor, 
“financial impact of the treatment to the patient” was fifth in terms of hospital formulary 
 
decision-making statement and ranking by all three prescriber groups. Two significant 
differences include: (1) for the hospital-formulary decision making statement, “I consider 
the number of patients affected by adding, removing, or modifying a drug on the 
formulary when making hospital medication formulary decisions,” midlevel providers 
considered this factor of significantly greater importance than did physicians; and (2) for 
the ranked hospital formulary decision-making factor, “financial impact of treatment to 
the institution,” pharmacists ranked this factor significantly higher than did physicians. 
This study contributes to a greater understanding of the three prescriber groups serving 
on a P&T committee. Also, the study contributes to the body of literature regarding 
decision-making processes in medicine and specifically factors impacting hospital 
formulary decision-making. Furthermore, this study has the potential to impact the 
operational guidelines for the P&T committee at the University of Texas, MD Anderson 
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Medical knowledge is proliferating at an unprecedented rate within the United 
States.  One example of this proliferation of knowledge is the published results of 
clinical trials for pharmaceutical agents.  Clinical trials are the mechanism by which new 
or reformulated drugs are studied and deemed safe for the treatment of a wide range of 
health conditions.  The U.S. Department of Health and Human Services, National 
Institutes of Health (2017) reports that in 2009 a total of 1,859 clinical trials posted 
results.  By 2016 that number had grown to over 24,867 clinical trials with posted 
results.  In other words, over 8 years the number of clinical trials reporting or posting 
results to the U.S. Food and Drug Administration has increased by greater than a factor 
of 13.  With this rapid increase in the volume of clinical trials and the resulting reported 
data, it is virtually impossible for prescribers including physicians, midlevel providers, 
and pharmacists to critically appraise the results of clinical trial data. 
Drug trials originate when drug manufacturers seek to study the safety and 
efficacy of a new or reformulated drug.   Furthermore, drug monitoring activities 
routinely extend well beyond the conclusion of clinical trials to ensure long term safety.  
Most industrialized nations closely regulate human drug trails and have created 
governmental agencies responsible for overseeing these activities.  In the United 
States, drug safety is under the purview of U.S. Department of Health and Human 
Services, Food and Drug Administration referred to as the FDA.  According to the U.S. 
Department of Health and Human Services, Food and Drug Administration (2014): 
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FDA is responsible for protecting the public health by assuring the safety, 
efficacy and security of human and veterinary drugs, biological products, 
medical devices, our nation’s food supply, cosmetics, and products that 
emit radiation. 
 
FDA is also responsible for advancing the public health by helping to 
speed innovations that make medicines more effective, safer, and more 
affordable and by helping the public get the accurate, science-based 
information they need to use medicines and foods to maintain and 
improve their health. FDA also has responsibility for regulating the 
manufacturing, marketing and distribution of tobacco products to protect 
the public health and to reduce tobacco use by minors. 
(para. 1-2) 
 
Drugs approved for routine use comprise a national drug formulary.  This national drug 
formulary or list of approved drugs referred to as the “Orange Book”: 
The publication Approved Drug Products with Therapeutic Equivalence 
Evaluations (the List, commonly known as the Orange Book) identifies 
drug products approved on the basis of safety and effectiveness by the 
Food and Drug Administration (FDA) under the Federal Food, Drug, and 
Cosmetic Act (the Act).  (U.S. Department of Health and Human Services, 
Food and Drug Administration, 2015, para. 1) 
 
Although the FDA is responsible for maintaining a list of approved drugs at the 
national level, many organizations develop medication formularies the meet the needs 
of their specific patient populations as well as to meet certain business objectives.  
Medication formularies are often tailored to an institution’s healthcare delivery 
environment and the types of patients it serves.  For the purpose of this study hospital 
medication formularies will be explored.  These hospital medication formularies serve 
several purposes including to aid prescribers within the organization in medication 
selection, limit medication use to those deemed most effective for the hospital’s patient 
population, and to manage medication costs.  Scroccaro (2000) states the following:  
At the hospital level, the formulary is a list of available drugs meeting the 
medication needs of patients.  The hospital formulary is often limited or 
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closed by listing only those drugs judged by the institution as the current 
drugs of choice for given diseases or for a given therapeutic class.  
(p. 317S) 
 
Hospital formularies require constant oversight and careful management.  Hospital 
formularies are generally managed by a formal committee comprised of medical staff 
commonly referred to as the pharmacy and Therapeutics (P&T) committee.   
P&T committees play an important role in managing the hospital formulary and 
more broadly the entire medication-use process.  Tyler et al. (2008) state, “The P&T 
committee is responsible for managing the formulary system.  The committee is 
composed of actively practicing physicians, other prescribers, pharmacists, nurses, 
administrators, quality improvement managers, and other health care professionals and 
staff who participate in the medication-use process” (p. 172).  The authors further assert 
that the role of P&T committee is to support and state publicly the objectives of the 
hospital formulary system, objectively evaluate clinical data regarding new drugs or 
agents, review the use of these drugs in the institution, established standards, and to 
educate medical staff. 
As stated previously, the sheer volume of reported clinical trial data is daunting.  
For prescribers to optimally treat their patients using drug therapies they are required to 
continually monitor and evaluate this daunting volume of drug data.  Furthermore, P&T 
committees work to ensure that the hospital formulary remains current and reflects the 
safest and most effective drugs available.  P&T committees must routinely evaluate new 
medical evidence and decide which agents will be added to the medication formulary.  
They must also decide if new medications should replace older drugs in light of new 
medical evidence and reported drug efficacy.  A potential mechanism to assist P&T 
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committees in decision-making is the use of Evidence Based Medicine (EBM). 
EBM is defined by Shortliffe, Perreault, Wiederhold, and Fagan (2001) as, “an 
approach to medical practice whereby the best possible evidence from the medical 
literature is incorporated in decision making” (p. 769).  However, the term “best possible 
evidence” is problematic.  For the purpose of this study, EBM taxonomy is one of the 
information organization constructs investigated.  However, the determination of what 
medical evidence is considered “best possible” among individual prescribers, groups, 
and P&T committees is unclear.  It is also unclear what additional factors affect hospital 
formulary decision-making.   
EBM taxonomies provide a hierarchical categorization of the relative strength of 
medical evidence as it is presented in clinical trials.  The categorization is based on 
clinical study characteristics as presented in the scientific literature.  For example, multi-
center systematic reviews are assigned a higher degree of credibility than would a 
single case report.  The U.S. Department of Health and Human Services, Agency for 
Healthcare Research and Quality (2002) concluded that over 100 various EBM 
taxonomies exist to aid prescribers in their evaluation of clinical trial evidence.  
However, it is unclear if prescribers and P&T committees accept the basic premise of 
EBM, if EBM taxonomies are deemed helpful, and what other factors impact hospital 
formulary decision-making.   
 
Statement of the Problem 
The exponential growth in medical pharmaceuticals and related clinical trials 
have created a need to better understand the decision-making factors in the processes 
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for developing hospital medication formularies.  Furthermore, the degree of variability 
among the decision-making factors is not clearly understood among the various groups 
of prescribers. 
 
Purpose of the Study  
The purpose of the study was to identify, rank, and compare major factors 
impacting hospital formulary decision-making among three prescriber groups serving on 
a hospital P&T committee.  Prescribers were selected from the University of Texas, MD 
Anderson Cancer Center which is a large, multi-facility, academic oncology hospital.  
Specifically, the prescriber groups studied were comprised of physicians, midlevel 
providers, and pharmacists.  To participate in the study, prescribers must have served 
on the University of Texas, MD Anderson Cancer Center P&T committee and still on the 
medical staff of the hospital. 
 
Definition of Terms  
Antibiotic use review:  Retrospective evaluation of antibiotic use.  Usually quantitative 
and limited to identifying patterns of use.  (Malone, Kier, & Stanovich, 2012, p. 
706) 
Blinding:  A way of making sure that the people involved in a research study — 
participants, clinicians, or researchers — do not know which participants are 
assigned to each study group. Blinding usually is used in research studies that 
compare two or more types of treatment for an illness. Blinding is used to make 
sure that knowing the type of treatment does not affect a participant's response 
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to the treatment, a health care provider's behavior, or assessment of the 
treatment effects. (The U.S. Department of Health and Human Services, Agency 
for Healthcare Research and Quality, 2015a, para. 1) 
Clinical expertise:  means the ability to use clinical skills and past experience to rapidly 
identify each patient’s unique health state and diagnosis, individual risks and 
benefits of potential interventions, and personal values and expectations. (U.S. 
Institute of Medicine, 2001, p. 147) 
Cognition:  1.  The mental activities associated with thinking, learning, and memory.  2.  
Any process whereby one acquires knowledge.  (cognition, 2005, p. 305) 
Decision-making:  Decisions involve choosing a course of action among a set of options 
in order to meet a particular objective.  (Patel, Kaufman, & Kannampallil, 2013, p. 
165) 
Drug evaluation monograph:  The drug evaluation monograph provides a structured 
method to review the major features of a drug product.  (Malone, Kier, & 
Stanovich, 2012, p. 706) 
Drug use evaluation:  see: Medication use evaluation 
Drug use review:  Retrospective evaluation to monitor medication use patterns.  Usually 
quantitative and limited to trending.  (Malone, Kier, & Stanovich, 2012, p. 706) 
Evaluation:  An evaluation reflects one’s current appraisal of the stimulus, including 
whether it should be approached or avoided. (Cunningham & Zelazo, 2007,  
p. 97) 
Evaluation of medications by expert physician(s):  for the purpose of this study, the 
Evaluation of medication by one or more expert physicians and is characterized 
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by the opinion [or evaluation] without explicit critical appraisal, or based on 
physiology, bench research or first principles. (Phillips, Ball, Sackett, Badenoch, 
Straus, Haynes, & Dawes, 2009, Table 1 Row 5) 
Evidence based medicine:  The practice of evidence-based medicine (EBM) involves 
integrating individual clinical expertise with the best available external clinical 
evidence from systematic research.  Development and application of clinical 
practice guidelines are tools used in EBM.  (Malone, Kier, & Stanovich, 2012, p. 
307) 
Evidence based medicine taxonomy: taxonomies are used to rate the quality of an 
individual study and the strength of a recommendation based on a body of 
evidence.  (Ebell, Siwek, Weiss, Woolf, Susman, Ewigman, & Bowman, 2004, p. 
59) 
Factor:  A variable that is controlled or manipulated by the researcher.  A categorical 
variable used to form the groupings of observations.  (Hinkle, Wiersma, & Jurs, p. 
735, 2003) 
Formulary system:  An ongoing process whereby a healthcare organization, through its 
physicians, pharmacists, and other health care professionals, establishes policies 
on the use of drug products and therapies and identifies drug products and 
therapies that are the most medically appropriate and cost-effective to best serve 
the health interests of a given patient population.  (Tyler et al., 2008, p. 181) 
Heuristics:  A heuristic is a rule of thumb or mental shortcut that simplifies a decision. 
(Patel, Kaufman, & Kannampallil, 2013, p. 166) 
Hospital formulary: At the hospital level, the formulary is a list of available drugs meeting 
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the medication needs of patients.  The hospital formulary is often limited or 
closed by listing only those drugs judged by the institution as the current drugs of 
choice for given diseases or for a given therapeutic class. (Scroccaro, 2000, p. 
317S) 
Information behavior: how people need, seek, manage, give, and use information in 
different contexts. (Fisher, Erdelez, and McKechnie, p. xix) 
Information quality:  The perceived attributes of information that make it of value to a 
potential user in a specific context.  Some components of quality include 
relevance, timeliness, accuracy, specificity, comprehensiveness, and 
authoritativeness (Case, 2008, p. 333) 
Medication management process:  planning, selection and procurement, storage, 
ordering [may include transcription], preparing and dispensing, administration, 
monitoring, evaluation (The Joint Commission on Hospital Accreditation, 2014, p. 
MM-1) 
Medication use evaluation:  The component of a health care organization’s quality 
improvement program that should examine all aspects of medication use 
including prescribing, dispensing, administration, and monitoring of medication 
use.  Prior to 1986, this function was commonly referred to as a drug use (or 
usage) evaluation (DUE).  (Malone, Kier, & Stanovich, 2012, p. 1128)   
Medication use process:  The original definition of the medication use process included 
prescribing [or ordering], dispensing, administration, monitoring, and systems 
and management control … Currently, systems and management control is often 
not included within the description of the medication use process as it applies to 
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virtually all aspects of patient care.  Medication acquisition, storage, distribution, 
and disposal may also be addressed if pertinent.  (Malone, Kier, & Stanovich, 
2012, pp. 704-705) 
Midlevel provider:  Midlevel providers can be grouped into two categories, advanced 
practice nurses (APNs) and physician's assistants (PA). Under the umbrella of 
APN are several specialties including the nurse practitioner (NP), clinical nurse 
specialist (CNS), certified nurse midwife, and certified nurse anesthetist. (Beach, 
Swischuk, & Smouse, pp. 329-330) 
Pharmacist:  One who is licensed to prepare and dispense drugs and compounds and is 
knowledgeable concerning their properties.  (pharmacist, 2005, p. 1119) 
pharmacy benefit manager:  A pharmacy benefit manager (PBM) processes 
prescriptions for the groups that pay for drugs, usually insurance companies or 
corporations, and use their size to negotiate with drug makers and pharmacies.  
(Gryta, 2011, para. 2) 
pharmacy and therapeutics committee:  A P&T committee is responsible for managing 
the formulary system.  It is composed of actively practicing physicians, other 
prescribers, pharmacists, nurses, administrators, quality-improvement managers, 
and other health care professionals and staff who participate in the medication-
use process.  Customarily, P&T committee member appointments are based on 
guidance from medical staff.  (Tyler, Cole, May, Millares, Valentino, Vermeulen, 
& Wilson, 2008, p. 172) 
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Physician: A person skilled in the art of healing; specifically: one educated, clinically 
experienced, and licensed to practice medicine as usually distinguished from 
surgery.  (physician, n.d., merriam-webster's online dictionary) 
Randomization:  A method of assigning participants in clinical trials into two or more 
groups randomly (by chance). One group receives the treatment or drug being 
researched, and one group receives either no treatment, a placebo (inactive 
substance), or another drug. Participants are assigned to a group by various 
methods. (The U.S. Department of Health and Human Services, Agency for 
Healthcare Research and Quality, 2015b, para. 1) 
pharmacy staff evaluation of medical evidence including formulary recommendation:  for 
the purpose of this study, a pharmacy staff evaluation of medical evidence 
including formulary recommendation is comprised of a Drug use review (DUR), 
Antibiotic use review (AUR), Drug use evaluation (DUE), Medication use 
evaluation (MUE), or Drug evaluation monograph accompanied by a hospital 
formulary recommendation prepared by pharmacy staff (Malone, Kier, and 
Stanovich, 2012) 
Taxonomy:  A classification, usually in a restricted subject field, that is arranged to show 
presumed natural relationships.  (Taylor, 2004, p. 380) 
 
Research Questions and Hypotheses 
For the purpose of this study, a total of seven factors were identified from the 
scientific literature (Anagnostis, Wordell, Guharoy, Beckett, & Price, 2011; Evidence-
Based Medicine Working Group, 1993; Kelly & Bender, 1983; Malone, Kier, and 
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Stanovich, 2012; Pedersen, Schneider, & Scheckelhoff, 2014; Segal & Pathak, 1988; 
U.S. Institute of Medicine, Committee on Quality of Health Care in America, 2001).  
Hospital formulary decision-making factors fall within three broad categories including 
individual, social, and environmental.  All seven factors are briefly described in the 
following sections and are explained in greater detail in Chapter II. 
The first factor is individual evaluation of medical evidence.  Kelly and Bender 
(1983) contend that “the objective evaluation of clinical data regarding new drugs or 
agents requested for use in the hospital is the most important task of the P&T 
committee.  Each member should have exceptional literature evaluation skills and 
respect this responsibility” (pp. 976-977).  However, evaluation of medical literature can 
be subjective.  In other words, how one prescriber evaluates medical evidence may 
differ from how another prescriber evaluates the same evidence.  Such differences may 
lead to disagreement and affect hospital formulary decision-making.  Recent efforts 
have been made to de-emphasize individual opinion in medical decision-making.  The 
Evidence-Based Medicine Working Group (1993), a working group of the American 
Medical Association, states the following: “A new paradigm for medical practice is 
emerging.  Evidence-based medicine de-emphasizes intuition, unsystematic clinical 
experience, and pathophysiological rationale as sufficient grounds for clinical decision 
making and stresses the examination of evidence from clinical research” (p. 2420).  
However, it is unclear if the individual evaluation of prescribers remains influential in 
hospital formulary decision-making. 
The second factor is pharmacy staff evaluation of medical evidence including 
formulary recommendations.  To assist the P&T committee in their decisions, the 
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pharmacy staff within hospitals routinely prepare documentation.  Such documents may 
include a drug use review (DUR), antibiotic use review (AUR), drug use evaluation 
(DUE), medication use evaluation (MUE), or drug evaluation monograph (Malone, Kier, 
and Stanovich, 2012).  Furthermore, these formal documents may be accompanied by 
hospital formulary recommendations which are also prepared and presented by 
pharmacy staff.  Formulary recommendations may include adding, removing, or 
changing the formulary status or restrictions associated with the medications being 
considered.  These formal documents are provided and presented to P&T committee 
members during routine P&T committee meetings.  The purpose of which is to aid P&T 
committee members in hospital formulary decision-making.  Pedersen, Schneider, and 
Scheckelhoff (2014) explain: 
The most common sources used to develop materials for presentation at P&T 
committee meetings were drug information references, followed by 
pharmaceutical manufacturers, the Internet or PubMed, and therapeutic reviews 
obtained from the hospital’s group purchasing organization.  Less common 
sources included a formulary monograph service, a colleague at another hospital 
outside the health system, the health system’s corporate office, Cochrane 
collaborative reviews, and wholesaler-provided therapeutic reviews.  (p. 929) 
 
Segal & Pathak (1988), state that in some cases a hospital’s pharmacy department 
prepares materials for presentation to the P&T committee.  It is unclear how such 
materials prepared by pharmacy staff for the purpose of augmenting P&T committee 
decision-making compare to the other decision-making factors. 
The third factor explored is the evaluation of medications by expert physicians.  
In a study conducted by Segal and Pathak (1988) identifying factors that influence P&T 
committee drug evaluations, the authors find, “ . . . more importance is attached to 
information collected by the hospital’s own resources, such as the pharmacy 
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department’s recommendation, comments of key physicians [emphasis added] in their 
own institution, and a review of good clinical studies” (p. 178).  Although expert or key 
physicians are an indispensable part of frontline patient care.  It is also possible that the 
evaluation of medical evidence by expert or key physicians is prone to bias or 
subjectivity.  Kahneman and Klein (2009) state: “People, even experts, do not appear to 
be skilled in detecting patterns in the internal situation in order to identify the basis of 
their judgements.  Therefore, reliance on subjective confidence may contribute to 
overconfidence” (p. 523).  The influence of key or expert physicians either during 
interactions in the workplace or during P&T committee meeting discussions may be a 
factor affecting the hospital formulary decision-making process. 
The fourth factor is the number of patients affected by adding, removing, or 
modifying a formulary medication.  According to Kelly and Bender (1983) prescribers 
requesting the addition of a new drug to a hospital formulary should estimate the 
number of patients who will benefit from the new medication therapy.  If the drug will not 
be used frequently or if it is difficult to procure, the P&T committee may decide not to 
add it to the hospital formulary.  Therefore, the estimated number of patients who will 
benefit from a new or a change to an existing drug may also be a determining factor as 
P&T committees make formulary decisions. 
The fifth factor is the financial impact of the treatment for the institution.  
According to Anagnostis, Wordell, Guharoy, Beckett, and Price (2011), “institutions 
assess a combination of factors including the cost per course of therapy against other 
formulary agents, well-designed clinical trials, and reimbursement from third-party 
payers if the drug is used in outpatient settings” (pp. 412-413).  In addition to the 
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acquisition costs associated with medications, Chambers, Rane, and Neumann (2016) 
evaluated the impact of drug exclusion policies on affected patients.  Such exclusions 
stem from policy or formulary changes made by insurers and pharmacy Benefits 
Managers (PBMs) and what medication costs they will or will not reimburse.  The 
authors state: 
Decision makers should thus be mindful of the potential negative clinical and 
economic consequences of drug exclusion policies.  Decision makers can help 
mitigate this risk by using formal cost-effectiveness analyses and budget impact 
models to account for all potential costs and benefits in their decisions.  Drug 
exclusion policies should be transparent, with the evidence that informed the 
policy clearly communicated to patients and physicians, and implemented with a 
goal of maximizing continuity of patient care. (p. 530).   
 
However, it is unclear how the financial impact of treatment for the institution ranks 
when compared to other hospital formulary decision-making factors.  
The sixth factor considered in the study is the financial impact of the treatment for 
the patient.  According to Deangelis (2016):  
Equally troubling are the enormous profits that pharmaceutical companies make 
on the sales of their drugs and how pharmaceutical executives determine the 
costs of those drugs, which must be paid by the public, either through their 
insurance companies or directly out of pocket (p. 30).  
 
When P&T committees add or change medications on their hospital’s formulary, 
committee members likely consider the out-of-pocket costs of medication therapies for 
patients and their families.  The out-of-pocket costs for medications can become 
problematic.  In addition, high drug prices result in ever increasing insurance premiums 
for consumers.  Skyrocketing drug costs are of particular concern in oncology care.  
Ramsey, Lyman, and Bangs (2016) assert that “as oncology drug costs continue to rise 
and many patients experience financial distress in part owing to out-of-pocket drug 
costs, calls to reduce oncology drug prices are gaining public support and political 
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traction” (p. 425).  In light of drug costs passed along to patients through insurance 
premiums and out-of-pocket expenses, P&T committees likely consider the costs 
incurred by patients when making formulary decisions. 
The seventh and final factor is the opportunity for new treatment options.  Newly 
available drugs present new treatment options for prescribers.  However, in some cases 
medical evidence may not exist for rare or complicated disease states.  Instead 
prescribers must rely on clinical expertise.  Clinical expertise is defined by the U.S. 
Institute of Medicine, Committee on Quality of Health Care in America (2001) as “the 
ability to use clinical skills and past experience to rapidly identify each patient’s unique 
health state and diagnosis, individual risks and benefits of potential interventions, and 
personal values and expectations” (p. 147).  In cases in which a dearth of medical 
evidence exists for a new drug therapy, do prescribers consider the novelty of a new 
drug and its potential for treatment outside of its approved indications as a factor when 
making hospital formulary decisions? 
 
Research Questions and Hypotheses 
Group 1:  Physicians 
Q1. What is the ranked order of factors that influence hospital formulary decision-
making by physicians? 
 
Hypothesis 1.1:  For physicians, individual evaluation of medical evidence 
has a lower ranking of influence on hospital formulary decision-making 
than does the evaluation of medications by expert physicians.  
Hypothesis 1.2:  For physicians, the evaluation of medications by expert 
physicians has a higher ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations. 
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Hypothesis 1.3:  For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the number of 
patients affected. 
Hypothesis 1.4:  For physicians, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the institution. 
Hypothesis 1.5:  For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the patient. 
Hypothesis 1.6:  For physicians, individual evaluation of medical evidence 
has a higher ranking of influence on hospital formulary decision-making 
than does the opportunity for new treatment options. 
Group 2:  Midlevel Providers 
Q2. What is the ranked order of factors that influence hospital formulary decision-
making by midlevel providers? 
 
Hypothesis 2.1:  For midlevel providers, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-
making than does the evaluation of medications by expert physicians. 
Hypothesis 2.2:  For midlevel providers, the evaluation of medications by 
expert physicians has a higher ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations.  
Hypothesis 2.3:  For midlevel providers, a pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has a higher 
ranking of influence on hospital formulary decision-making than does the 
number of patients affected. 
Hypothesis 2.4:  For midlevel providers, pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has a higher 
ranking of influence on hospital formulary decision-making than does the 
financial impact of the treatment for the institution. 
Hypothesis 2.5:  For midlevel providers, a pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has higher 
ranking of influence on hospital formulary decision-making than does the 
financial impact of the treatment for the patient. 
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Hypothesis 2.6:  For midlevel providers, individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-
making than does the opportunity for new treatment options. 
Group 3:  Pharmacists 
Q3. What is the ranked order of factors that influence hospital formulary decision-
making by pharmacists? 
 
Hypothesis 3.1:  For pharmacists, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-
making than does the evaluation of medications by expert physicians. 
Hypothesis 3.2:  For pharmacists, the evaluation of medications by expert 
physicians has a lower ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence 
including formulary recommendations. 
Hypothesis 3.3:  For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the number of 
patients affected. 
Hypothesis 3.4:  For pharmacists, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the institution. 
Hypothesis 3.5:  For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the patient. 
Hypothesis 3.6:  For pharmacists, individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-
making than does the opportunity for new treatment options. 
 
Significance of the Study 
 The number of clinical trials for medications is increasing at an unprecedented 
rate.  As a consequence, prescribers find it increasingly difficult to stay abreast of new 
and constantly changing medical evidence.  Furthermore, hospitals and hospital 
systems are under increasing pressure to reduce cost while at the same time improving 
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the quality of healthcare delivery and health outcomes.  To address these issues, the 
vast majority of hospitals and hospital systems utilize a hospital formulary managed by 
a P&T committee.  P&T committees are required to evaluate medications and determine 
which agents will be used to treat patients. 
Overall, the study provides a greater understanding of the three prescriber 
groups comprised of physicians, midlevel providers, and pharmacists who routinely 
serve on P&T committees.  Furthermore, the study identifies and ranks the major 
factors affecting hospital formulary decision-making.  The study contributes to the body 
of literature regarding decision-making processes in medicine and specifically factors 
impacting hospital formulary decision-making. Furthermore, the results presented in the 
study have the potential to impact the operational guidelines for P&T committees. 
 
Assumptions 
 Three major assumptions underlie this study: (1) the study participants selected 
are currently serving on or have served on the University of Texas, MD Anderson 
Cancer Center P&T committee; (2) the study participants provided truthful answers to 
the questions posed in the online surveys; (3) the study participants selected had 




 The limitation of this study is that it is focused on three distinct prescriber groups 
including physicians, midlevel providers, and pharmacists.  The study does not 
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encompass hospital formulary decision-making that occurs outside P&T committees.  
Finally, the study focuses on a single large, academic, oncology hospital with more than 
500 staffed inpatient beds. 
 
Summary 
 The introductory chapter provides sections including the background of the study, 
statement of the problem, purpose of the study, definition of terms, research questions, 
hypotheses, significance of the study, assumptions, and limitations.  The following 






 The chapter presents a synthesis of the scientific literature relevant to the study.  
The introduction and theoretical framework presented serve to contextualize and 
provide a rationale for the subject areas reviewed.  Subject areas within the published 
literature include:  hospital formularies, decision-making for hospital formularies, clinical 
trials, evidence based medicine (EBM) taxonomies, and aspects of pharmacy and 
therapeutics (P&T) committees.   
 
Hospital Formularies 
 The hospital formulary is a list of drugs that a hospital deems cost effective, safe, 
and efficacious for treating its patients.  Scroccaro (2000) states the following:  
At the hospital level, the formulary is a list of available drugs meeting the 
medication needs of patients.  The hospital formulary is often limited or closed by 
listing only those drugs judged by the institution as the current drugs of choice for 
given diseases or for a given therapeutic class.  
(p. 317S)    
 
The author goes on to describe additional activities involved in maintaining a hospital 
formulary.  Such activities include continually monitoring adherence to the formulary, 
determining equivalent drugs, special acquisition and pricing programs, and the 
continual monitoring of new evidence resulting from clinical trials.  The author goes on 
to state that an ongoing educational strategy for prescribers is important to ensure 
adherence to an institution’s drug use policy including adherence to its medication 
formulary.  It is difficult to pinpoint exactly when the widespread adoption of hospital 
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formularies and interest in their management occurred.  However, such adoption 
appears to have begun in the early 1980s and continued into the early 1990s (Kelly & 
Bender, 1983; Rucker, 1982; Segal & Pathak, 1988; Sutters, 1990).  The publications 
from this time period cover a wide swath of topics including the creation of hospital 
formularies, best practices for drug selection and exclusion, and methods for continuous 
formulary optimization. 
Although the promises of the hospital formulary are to contain costs, improve 
patient safety, and increase efficiency some disadvantages exist.  By the late 1990s a 
fervent debate was underway regarding whether hospital formularies were achieving 
their intended goals.  Horn (1996) states: 
While “restrictive” formularies are associated with reduced drug costs in some 
situations, many previously conducted studies have supported our findings.  
These studies found such restrictions to be linked with increased use of other 
services, and showed that the predominant effect of formulary restrictions was to 
shift costs by increasing the utilization either of non-restricted drugs or of other 
health care services. (p. 2204) 
 
Another publication questioning the effects of restrictive hospital formularies was 
authored by Levy and Cocks (1999) and published by the National Pharmaceutical 
Council.  This report reviewed an extensive array of published literature and included 7 
chapters entitled: the economics of restricting resource allocation in healthcare, 
integrated pharmaceutical care, formularies in manage care plans, Medicaid 
formularies, physician authority curtailed by formularies, and use of formularies by 
hospitals and other providers.  The report’s executive summary states: 
The general failure of formularies and other limitations to contain total costs and 
improve outcomes has important implications for health care policy and the 
design of the health care delivery and reimbursement systems of the next 
millennium.  The reviewed literature shows that component management, in the 
form of restrictions on pharmaceuticals, does not result in overall savings and 
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that a system-wide, population-based approach integrating all components of 
heath care is needed to control health care spending and maintain quality of 
care. (p. VII) 
 
Levy and Cocks make a number of compelling arguments against the use of hospital 
formularies.  However, currently hospital formularies and pharmacy and therapeutics 
committees comprised of medical staff to manage them have been broadly adopted 
across the U.S. 
 Pedersen, Schneider, and Scheckelhoff (2014) conducted a study on behalf of 
the American Society of Health-System Pharmacists (ASHP) which included responses 
from 414 hospitals of varying sizes based on inpatient beds.  The authors state: 
Overall, 60.4% of hospitals had limited, strict formulary with tight restriction on 
non-formulary medication use, and 39.6% had an open formulary, with few 
restrictions on prescribers … Over the past three years, 47.5% of hospitals have 
maintained the same type of formulary; however, 41.5% of hospitals have 
adopted a more limited formulary, and 11.0% of hospitals have transitioned 
toward a more open formulary. (p. 924) 
 
In summary, the Pederson, Schneider, and Scheckelhoff study concluded that of the 
hospitals surveyed all had adopted a medication formulary.  Of that total 60.4% of the 
hospitals use a limited or strict formulary while 39.6% use an open formulary.  
Furthermore, over the previous three years 41.5% of hospitals surveyed had moved to a 
more limited formulary while only 11.0% had moved to a more open formulary. 
 The hospital formulary is not a static list of drugs.  Instead, the hospital formulary 
is a dynamic list that changes frequently and requires constant monitoring.  Hospital 
formulary management involves complex and consensus based decision-making by 
medical staff.  Hospital formulary decision-making is a complex process involving 
numerous factors.  Hospital formulary decision-making impacts virtually every aspect of 
patient care.  The scientific literature related to the decision-making process for hospital 
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formularies and decision-making in general is described in greater detail in the following 
section.  
 
Decision-Making for Hospital Formularies 
Decision-Making 
For the purpose of this study, two information behavior models related to task-
oriented information seeking will be examined (Hansen, 2005; Leckie, Pettigrew, & 
Sylvain, 1996).  These models serve to illustrate how task-oriented information 
behaviors within professional groups including healthcare professionals involve both 
social and individual factors.  A complimentary premise is that quality information leads 
to “better” decision-making (Case, 2008).  Finally, relevant literature from the field of 
Biomedical Informatics related to medical decision-making was explored (Patel, 
Kaufman, & Kannampallil, 2013). 
Decision-making is a primary theoretical framework of Information Science.  In 
short, Information Science theory contends that decision-making is enhanced when 
decision are made with quality information which is reliable, verifiable, and trusted.  Tan 
(2001) describes ten desirable data characteristics including: “accessibility, accuracy, 
appropriateness, comprehensibility, comprehensiveness, consistency, relevance, 
reliability, timeliness, and usefulness” (p. 57, Table 3-1).  Cleveland and Cleveland 
(2009) state: 
Information fuels healthcare endeavors.  Timely and accurate information is 
essential at every part of the healthcare continuum from the patient to the highest 
level of healthcare management.  The quality of the information depends on the 




Patient treatment decisions are often gleaned from various datum collected from various 
sources and from all forms of patient encounters.  These data are analyzed, 
synthesized, and ultimately used to inform treatment, operational, and financial 
decisions.  In complex healthcare environments, decision-making is likely impacted by 
various factors including individual, collaborative, social, and environmental factors.  
However, it is unclear which of these factors or combinations of factors influence 
decision-making and to what degree. 
Paisley (1968) in the third volume of the Annual Review of Information Science 
and Technology authored a chapter entitled Information Needs and Uses.  The author 
comments on the complex factors affecting the flow of information and the importance 
of conceptualizing these factors: 
Shallow conceptualization is something else again.  Even small projects can 
demonstrate awareness of the complex systems that affect the flow of 
information.  Shallow conceptualization implies a failure to consider these factors: 
 
1. The full array of information sources that are available. 
2. The uses to which the information will be put. 
3. The background, motivation, professional orientation, and other individual 
characteristics of the user. 
4. The social, political, economic, and other systems that powerfully affect 
the user and his work. 
5. The consequences of information use – e.g., productivity. 
 
As a result, in many studies, it is hard to glimpse a real scientist or technologist at 
work, under constraints and pressures, creating products, drawing upon the 
elaborate communication network that connects him with sources of necessary 
knowledge.  (p. 2) 
 
In a much later work Patel, Kaufman, and Kannampallil (2013) explain that 
“decision making has been an active subject of psychological inquiry since the 
beginning of experimental psychology” (p. 165).  The authors go on to state that 
“decisions involve choosing a course of action among a set of options in order to meet a 
25 
 
particular objective” (p. 165).  P&T committees are comprised of medical professionals 
operating within a collaborative committee structure to make medical decisions involving 
the hospital formulary.  Individuals serving on P&T committees are likely influenced by a 
complex interplay of individual, social, and collaborative decision-making factors.  To 
explore hospital formulary decision-making within the context of these factors, literature 
will be reviewed as it relates to task oriented information behaviors.    
For the purpose of this study, an exploration of two task oriented information 
seeking models were undertaken.  The two models explored were authored by Hansen 
(2005) and Leckie, Pettigrew, and Sylvain (1996).  These models illustrate the 
processes by which individuals within certain professions, including the healthcare 
professions, seek information in order to fulfill an information need.  It is important to 
note that most information behavior models are based on individual information 
behaviors.  Such models do not account for the additional complexities of social and 
collaborative interactions described by Paisley (1968) and by Patel, Kaufman, and 
Kannampallil (2013).  The notable exception is the task-oriented information behavior 
model developed by Hansen (2005).  This model addresses social factors that impact 
task oriented decision-making and studied the process in healthcare environments.  
Furthermore, recent literature published in the field of biomedical informatics by Patel, 
Kaufman, and Kannampallil (2013) acknowledges the role of social and collaborative 
factors in medical decision-making. 
 
Task Oriented Information Behavior 
A foundational research domain within the field of Information Science is 
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information behavior also commonly referred to as information seeking.  Case (2006) 
suggests that information behavior research may be divided into four categories 
including: “[1] information seekers by occupation (e.g., scientists, managers), [2] 
information seekers by role (e.g., patient or student), [3] information seekers by 
demographics (e.g., by age or ethnic group), [4] theories, models, and methods used to 
study information seekers” (p. 295). 
Information seeking for the purpose of this study most closely aligns with 
information seeking by occupation and is task-oriented in nature.  Various scientists 
have developed task-oriented information seeking models based on observations from 
studying individuals seeking information to perform various work tasks.  These models 
were selected from observational research conducted within work environments 
including healthcare settings.  Two such models were developed by Hansen (2005) and 
Leckie, Pettigrew, and Sylvain (1996). 
The first model, work task information-seeking and retrieval processes, was 
proposed by Hansen (2005) and may be seen in Figure 1.  The author suggests, “the 
rationale for developing a framework for work task information seeking and retrieval is 
grounded in the belief that IS&R [Information Seeking and Retrieval] should not be 
treated in isolation, but rather as embedded in a larger task context” (p. 392).  Based on 
Hansen’s model (see: Figure 1) information-seeking originates from a high-level 
organizational or social information need.  An information need may also originate from 
a lower-level situational or individual information need.  According to the model, the 
information need culminates in a work task comprised of one or more information 
seeking and information retrieval tasks.  The information seeking and retrieval tasks 
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consist of task initiation, the task process, and task completion.  The result of the 
completed information seeking and retrieval tasks results in the completion of the larger 
work task.  Finally, the completed work task flows back to the situational or individual 




Figure 1. Conceptual framework of information search and retrieval tasks embedded 
in work task (Hansen, 2005, p. 393). 
 
The second and more general task oriented information seeking model is 
proposed by Leckie, Pettigrew, and Sylvain (1996).  In this model, represented in Figure 
2, information seeking tasks are associated with a specific work role.  Work roles lead to 
a determination of what characterizes the information needed.  After the characteristic 
of the information needed is determined the information is sought.  If the outcome of the 
information seeking step is unsatisfactory, feedback occurs.  This feedback may result 
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in awareness of an additional need for information with potentially different 
characteristics or an awareness that the required information has been obtained.  
Additionally, feedback may lead to additional information seeking.  This cycle continues 




Figure 2. A model of the information seeking of professionals (Leckie, Pettigrew, & 
Sylvain, 1996, p. 393). 
  
 The task oriented information behavior models described provide insight into how 
recorded information is used to support specific tasks within a work environment.  The 
task oriented information behavior model proposed by Hansen (2005) seems to provide 
the greatest degree of insight related to the task oriented decision-making activities of 
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P&T committees.  Of the two models presented, the Hansen (2005) model accounts for 
the larger social context of information seeking.  
 
Medical Decision-Making 
Recent publications in the field of Biomedical Informatics expand upon the 
information behavior models described.  Patel, Kaufman, and Kannampallil (2013) 
contend that traditional information-processing models may be insufficient to adequately 
address social and collaborative factors affecting medical decision-making.  They state: 
The study of diagnostic reasoning and medical decision-making was constituted 
within the classical information–processing approach to cognition, which has 
come under criticism for its narrow focus on the rational/cognitive processes of 
the solitary individual.  The distributed view of cognition represents a shift in the 
study of cognition from being the sole property of the individual to being 
“stretched” across groups, material artifacts and cultures … Distributed cognition 
has two central points of inquiry, one that emphasizes the social and 
collaborative nature of cognition (e.g., doctors, nurses, and other personnel 
jointly contributing to a decision process) and one that characterizes the 
mediating effects of technology or other artifacts on cognition. (p. 151) 
 
Recent research indicates that additional social and collaborative factors are associated 
with medical decision-making.  It seems appropriate, based on the collaborative nature 
of P&T committees, to expand the scope of hospital formulary decision-making research 
to include social and collaborative factors.  In the following section, the hospital 
formulary is described as well as the various decisions that P&T committee members 
are required to make in order to appropriately manage the hospital formulary.  
 
Hospital Formulary Management Considerations 
Scroccaro (2000) states, “The hospital formulary is not simply a list of drugs; it 
reflects the policy of the institution with regard to the rational use of drugs” (p. 317S).  
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According the author, in a closed formulary system, the policy for managing the hospital 
formulary and for formulary decision-making should include consideration of six factors.   
First, the author states that formulary considerations involve the selection of 
drugs that are cost-effective.  This involves close examination of the efficacy of drugs in 
the same therapeutic class.  For example, if two drugs are used to treat the same health 
condition and both are effective, the hospital may choose the less expensive of the two 
drugs for formulary inclusion.  This serves to reduce the costs of drugs for both the 
hospital and the patient. 
A second factor is to determine the benefit of drugs based also in relation to the 
cost of the drug.  Scroccaro (2000) states: 
Many new and often more expensive drugs offer real advantages only in selected 
patients.  For example, most newly marketed antibiotics may provide an 
advantage only to those patients who do not respond to the older product; also, 
the safety profile of a new drug may offer an advantage for those patients who do 
not tolerate, or may have risk factor for, the adverse events associated with the 
less expensive drug.  (p. 318S) 
 
As the author states, although a new or reformulated drug may be more expensive, it 
may prove more effective for some patients with certain conditions.  Although one 
medication may be preferred to treat a certain condition, if the patient has an allergy to 
the drug, it is more desirable to use an alternative and potentially more expensive drug 
to avoid an allergic reaction.  Additionally, P&T committees may choose to place 
restrictions on the use of specific drugs to ensure that they are only used under certain 
circumstances.  For example, suppose that two drugs are available to treat the same 
condition and one medication is preferred and the more expensive medication is non-
preferred.  For a certain subset of patients meeting certain clinical criteria, the non-
preferred drug is better tolerated or more effective.  In these cases, it is appropriate to 
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treat the patient using the non-preferred and more expensive medication.  In this 
scenario, monitoring drug use becomes important to ensure that the preferred 
medication is used in the majority of situations and non-preferred medication is only 
when certain pre-defined clinical criteria are met. 
Another factor considered in hospital formulary management are drug which are 
considered equivalent.  In this case, if two drugs are found to be equivalent in terms of 
“efficacy, tolerability, and compliance” (p. 319S).  In these cases, the P&T committee 
may deem that an automatic interchange or substitution may be used.  The less 
expensive of the equivalent drugs is chosen for addition to the formulary.  In this 
scenario, if a medication order is written for a drug and an equivalent drug is to be 
substituted, an automatic substation for the preferred equivalent drug will occur. 
Another consideration of P&T committees is what Scroccaro refers to as “special 
acquisition and pricing programs” (p. 319s).  In these cases, hospitals may choose to 
negotiate pricing directly with a drug manufacturer or drug wholesaler.  Price reductions 
may be warranted if a hospital uses a high volume of a particular drug and contractually 
agrees to only acquire that drug from a single manufacturer or wholesaler.  Such 
agreements allow the hospital to acquire selected drugs at reduced cost. 
The sixth and final consideration affecting hospital formulary management 
according to Scroccaro (2000) is participation in investigational drug services.  The 
author contends “participation by the hospital pharmacy department in conducting 
clinical trials allows the staff to acquire a wider knowledge about the use of drugs and 
offers the patients an opportunity to benefit from innovative therapies” (p. 319S).  The 
author states that participation in clinical trials through investigational drug services 
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reduces costs for the hospital and its patients. Investigational drugs are generally 
provided at no cost to hospitals or patients by the pharmaceutical company conducting 
the drug trial.  As the author states, such investigational pharmacy services provide 
valuable benefits to both the hospital’s patients and to its medical staff. 
In addition to considering the cost of medications for hospitals, patients, and their 
families are affected by rising insurance premiums and out-of-pocket expenses.  
Deangelis (2016) states,  
equally troubling are the enormous profits that pharmaceutical companies make 
on the sales of their drugs and how pharmaceutical executives determine the 
costs of those drugs, which must be paid by the public, either through their 
insurance companies or directly out of pocket. (p. 30) 
 
Chambers, Rane, and Neumann (2016) performed a study reporting how drug exclusion 
policies for hospitals, pharmacy benefits managers (PBMs), and governmental payers.  
Such drug exclusion policies affect costs including, “drug expenditures, and costs 
related to physician office visits, hospitalizations, laboratory tests, and so on” (p. 32). 
The authors conclude: 
Faced with the introduction of innovative technology and rising costs, insurers 
and PBMs will continue to search for ways to make their drug designs more 
efficient.  Payers may be prepared to accept some degree of disruption to patient 
care.  Removing drugs from formularies for which equally effective, but less 
expensive, alternatives are available is an attractive option.  Our study suggests 
that, for the most part, these policies have been successful in reducing costs 
while minimizing the impact of patient care, although the exceptions provide 
room for caution. (p. 530) 
 
For oncology care outpatient prescription medications can be quite expensive resulting 
in tremendous out-of-pocket expenses for patients.  Ramsey, Lyman, and Bangs (2016) 
provide a scenario, “for example, a 50% copay for lanalidomide (Revlimid; Celgene) for 
myelodysplastic syndrome would translate to an out-of-pocket cost of nearly $5000 per 
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month, eliminating it as an option for most patients” (p. 425).  If drugs selected for the 
hospital formulary place an excessive financial burden on patients, the patient may 
request less expensive treatment options or simply discontinue medication therapy 
altogether. 
All formulary considerations described necessitate the evaluation of new drugs in 
terms of their associated costs for hospitals and patients.  Furthermore, for new and 
reformulated medications the medication’s efficacy must be evaluated based on the 
results of clinical trials.  Evaluation of clinical trial data requires an in-depth 
understanding of the various forms of clinical trial studies and resulting data also known 
as medical evidence.  Evaluation of medical evidence involves a complex evaluation of 
the reported outcomes of clinical trials.  Howick et al. (2011a) explains that published 
clinical trial results may take many forms including: mechanistic reasoning reports, case 
studies, cohort studies, randomized trials, or systematic reviews.  A description of the 
clinical trial process is presented in the subsequent section.   
 
Clinical Trials 
In most cases, new chemical or biological agents are studied in laboratory 
animals.  Once animal studies conclude and the agent or drug is deemed appropriate 
for human use, it must then undergo rigorous clinical trials in humans.  Hollon and 
Komaromy (2000) explain: 
Before a new drug, surgical procedure, or therapy becomes available to the 
public, it must go through a rigorous testing process and be evaluated by the US 
Food and Drug Administration (FDA).  This testing process consists of a series of 
clinical trials that are designed to test the safety and usefulness of the new drug 




As stated, the clinical trial process starts by registering the drug with the FDA.  The drug 
then enters the first of three clinical trial phases.  Each clinical trial phase serves to 
ensure that the drug is both safe and effective.  The three phases of clinical trials are 
described in the subsequent paragraphs.  
According to Hollon and Komaromy (2000) Phase I clinical trials are designed to 
study the safety of a drug, examine how the drug is metabolized and excreted, and to 
identify potential side effects. Phase I trials usually have a small number of trial 
participants rarely more than 100.  Healthy individuals are usually selected for 
participation in phase I clinical trials and are preferred since their metabolic functions 
are normal.  The selection of healthy individuals serves to insure the trial is not affected 
by study participants with preexisting conditions or who have undergone previous 
medical treatment which may alter the metabolism of the chemical agent.  Another 
reason for selecting healthy participants is they are more likely to recover from any 
unexpected side effects produced by the chemical agent. 
The authors go on to state that exceptions exist for the selection of individuals for 
phase I trials.  One such exception is for drugs used to treat cancer also known as 
oncology drugs.  Oncology drugs are often cytotoxic.  Cytotoxic drugs are known to be 
harmful to healthy human cells.  In clinical trials involving cytotoxic drugs, testing them 
in healthy patients would prove harmful to the study participants due to the known 
cytotoxic characteristics of the chemical agent.  Therefore, participant selection for 
phase I trials involving cytotoxic oncology drugs are often comprised of study 
participants who have failed to respond to previous treatment regimens.  Eisenhauer, 
O'Dwyer, Christian, and Humphrey (2000) contend that little has changed over the past 
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20 years regarding the manner in which Phase I clinical trials are conducted with regard 
to oncology drugs.  The authors state: 
Phase I trial design in cancer therapeutics has changed little in 20 years.  Unlike 
most therapeutic areas, there are two goals in cancer trials: precise definition of 
an optimal (recommended phase II) dose and safe treatment of the individual 
patient at doses that are close to therapeutic. (p. 684) 
 
The authors contented that oncology drugs should be studied at dose levels that are 
close to therapeutic levels.  The authors further assert that finding an optimal 
methodology for dose escalation in phase I oncology trials well help ensure “new 
anticancer agents are not to suffer undue delays in phase I evaluation” (p. 684).  After a 
pharmaceutical agent passes phase I, it moves on to phase II trials.   
Hollon and Komaromy (2000) state, “once a drug passes the safety tests of 
phase I, it advances to a phase II trial with up to 200 participants” (p. 3).  The authors 
further explain that phase II trials are used to learn more about the drug’s efficacy, 
safety, side effects, and most importantly to optimize dosing.  Another important 
distinction of phase II trials is that during phase II patients are studied who are suffering 
from the condition the drug is formulated to treat.  In oncology care, Zelen (2003) states 
that “the goal is to determine if the therapy has any beneficial effect.  The patient 
population in phase II trials sometimes is composed of newly diagnosed patients with 
advanced cancer” (para. 3).  Once a drug completes phase II trials, it then progresses 
to phase III. 
Zelen explains that that Phase III trials “are always comparative trials; one or 
more experimental therapies are compared with the best standard therapy or 
competitive therapies.  They tend to have many more participants than Phase II trials, 
and they often require patients from many cooperating hospitals” (para. 4).  Hollon and 
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Komaromy (2000) explain that phase III trials may consist of hundreds or even 
thousands of study participants.  The authors assert that the main purpose of phase III 
trials is to make a definitive determination of a drug’s efficacy and to get “an extensive 
look at the drug’s side effects” (p. 4).  There are numerous variations in the manner 
phase III clinical trials are designed. 
One of the most common phase III trial designs is known as a double-blinded, 
controlled, and randomized trial.  The U.S. Department of Health and Human Services, 
Agency for Healthcare Research and Quality (2015a) defines blinding as: 
A way of making sure that the people involved in a research study — 
participants, clinicians, or researchers — do not know which participants are 
assigned to each study group. Blinding usually is used in research studies that 
compare two or more types of treatment for an illness. Blinding is used to make 
sure that knowing the type of treatment does not affect a participant's response 
to the treatment, a health care provider's behavior, or assessment of the 
treatment effects. (para. 1) 
 
Another important concept related to study design is randomization.  Randomization 
within the context of clinical trials is also defined by The U.S. Department of Health and 
Human Services, Agency for Healthcare Research and Quality (2015b) as follows: 
A method of assigning participants in clinical trials into two or more groups 
randomly (by chance). One group receives the treatment or drug being 
researched, and one group receives either no treatment, a placebo (inactive 
substance), or another drug. Participants are assigned to a group by various 
methods. (para. 1) 
 
Using the complimentary concepts of blinding and randomization together is known as a 
double-blinded randomized controlled clinical trial.  Double-blinding means that neither 
the treating prescribers nor study participants know which patients are receiving the 
pharmaceutical agent being studied or which are receiving a placebo or inactive agent.  
The group receiving a placebo is referred to as the control group.  Hollon and 
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Komaromy (2000) state a, “double-blind [clinical trial] means that neither the doctor nor 
the trial participant knows whether the participant is receiving the experimental 
treatment” (p. 5).  According to the authors, this type of clinical trial design serves to 
eliminate study bias in two ways.  First, by ensuring that study participants are unaware 
of their participation in a control group or the group actually receiving the medication.  
Secondly, “they prevent doctors from acting on preconceived notions they may have 
about whether or not the drug works” (p. 5).  The authors go on to assert that other 
types of clinical trials exist including open, factorial, crossover, and orphan drug trials.  
However, these clinical trial designs are used less often. 
Once all phases of a clinical trial end an application for approval accompanied by 
the clinical trial data are submitted to the FDA.  If the FDA deems a drug to be both safe 
and effective, the drug is approved.  Approval of a drug allows the pharmaceutical 
manufacturer to market the drug to prescribers and to the general public.  If the FDA 
remains uncertain of a drug’s safety or efficacy, it may request additional data before 
making a final determination.  However, if the FDA is unconvinced of the drug’s safety 
or efficacy based on the results of clinical trials, the application will be rejected.  The 
reported or published results of clinical trials are referred to as medical evidence. 
As stated in the introduction of Chapter I, the sheer volume of clinical trial or 
medical evidence being reported is daunting.  It is virtually impossible for physicians, 
midlevel providers, and pharmacists to remain abreast of all reported medical evidence.  
With such a rapid increase in clinical trial volume, it is virtually impossible for prescribers 
such as physicians, midlevel providers, and pharmacists to critically appraise the results 
of clinical trials.  Furthermore, a high degree of variation exists in the manner clinical 
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trials are conducted and the results reported in the published medical literature.  In 
some cases, a dearth of medical evidence may exist.  For example, for extremely rare 
health conditions limited or no medical evidence exists because the number of 
individuals affected by the health condition is small.  In these cases, healthcare 
providers must rely on clinical judgment and expert opinion to treat such conditions.  
It seems obvious that the evaluation of medical evidence is important in hospital 
formulary decision-making.  However, as stated previously, it is virtually impossible for 
healthcare provides to evaluate the enormous volumes of medical evidence being 
produced by clinical trials.  As a result, several evidence based medicine taxonomies 
have been developed by various entities.  These taxonomies serve to rank and 
summarize medical evidence resulting from clinical trials to aid healthcare providers in 
their evaluation of such medical evidence.  Evidence based medicine taxonomies are 
described in the following section. 
 
Evidence Based Medicine (EBM) Taxonomies 
The practice of using medical evidence from the scientific literature to inform 
patient care decisions is known as evidence-based medicine (EBM).  EBM is defined by 
Shortliffe and Cimino (2006) as, “an approach to medical practice whereby the best 
possible evidence from the medical literature is incorporated in decision-making.  
Generally, such evidence is derived from controlled clinical trials” (p. 939).  However, 
the phrase “the best possible evidence from the literature” is problematic.  To determine 
“the best possible evidence” among the various reported results and among varying 
healthcare providers is problematic.  Problems arise when individual prescribers must 
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evaluate vast quantities of scientific literature and determine what constitutes “the best 
possible evidence.”  
As stated previously, medical evidence is being produced quickly and in large 
volumes.  Furthermore, if medical evidence is to be acted upon by prescribers, it must 
first be critically evaluated, adopted, and subsequently translated into routine practice.  
Healthcare environments are notoriously complex and impacted by numerous factors 
which tend to slow the dissemination of medical evidence into mainstream medical 
practice.  The U.S. Institute of Medicine, Committee on Quality of Health Care in 
America (2001) asserts: 
Substantial investments have been made in clinical research and development 
over the last 30 years, resulting in an enormous increase in the medical 
knowledge base and the availability of many drugs and devices.  Unfortunately, 
Americans are not reaping the full benefit of these investments.  The lag between 
the discovery of more efficacious forms of treatment as their incorporation into 
routine patient care is unnecessarily long, in the range of about 15 to 20 years.  
Even then, adherence of clinical practice to the evidence is highly uneven. (p. 
145) 
 
Supporting the Institute of Medicine’s assertion, Balas and Boren (2000) state, “studies 
suggest that it takes an average of 17 years for research evidence to reach clinical 
practice” (p. 66).  Furthermore, clinical evidence is often unstructured and not in a form 
that is readily usable or actionable by healthcare providers.  The authors further contend 
that “actionable knowledge representation is needed to make a difference in the 
process and outcome of patient care.  Unfortunately, the current publication standards 
often do not provide information in the necessary structure and cannot be converted into 
it” (p. 68).  One proposed solution to speed the rate of dissemination and adoption of 
medical evidence into clinical practice is to develop systems for ranking clinical 
evidence.   
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EBM taxonomies and other codification mechanisms have been developed to aid 
prescribers in their efforts to evaluate medical evidence.  Taylor (2004) defines the term 
taxonomy as, “a classification, usually in a restricted subject field that is arranged to 
show presumed natural relationships” (p. 380).  This definition certainly applies to EBM 
taxonomies.  EBM taxonomies are restricted to the subject of published medical 
evidence and show presumed relationships between various forms of published medical 
evidence.  In other words, EBM taxonomies serve to categorize medical evidence 
based upon certain clinical trial characteristics.  In virtually all EBM taxonomies, certain 
types of reported medical evidence are deemed to provide a stronger or higher level of 
medical evidence than others.  For example, study results from a multi-center controlled 
double-blinded randomized trial are considered a higher level of evidence than 
published results from a single case from a single hospital.   
The U.S. Department of Health and Human Services, Agency for Healthcare 
Research and Quality (2002) “summarized more than 100 sources of information on 
systems for assessing study quality and strength of evidence for systematic reviews and 
technology assessments” (p. 7).  It would be impossible to describe all sources which 
rank medical evidence.  However, two EBM taxonomies will be explored as exemplars 
of EBM taxonomies.  The two EBM taxonomies described are the Oxford Center for 
Evidence Based Medicine (OCEBM) taxonomy and the strength of recommendation 
taxonomy (SORT).  As the name suggests, the OCEBM was developed by the Oxford 
Center in the United Kingdom and the SORT is currently used in the U.S. to summarize 
medical evidence published in various family practice and primary care journals. 
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The OCEBM 2011 levels of evidence developed by Howick et al. (2011b) 
classifies the various types of medical evidence into 5 primary levels.  The levels are 
assigned numeral values from 1 to 5.  The highest or strongest level of evidence is 
assigned a level 1 and the lowest is assigned a level of 5.  Level 1 is characterized by 
published systematic reviews with various forms of validation.  Level 2 is characterized 
by an individual cross-sectional study with consistently applied reference standards, or 
studies that present a “dramatic effect” (column 2).  Level 3 is characterized by non-
randomized or studies without consistently applied reference standards.  Level 4 
represents case-studies or a case-series with poor or non-independent reference 
standards.  The lowest level in the OCEBM taxonomy is Level 5, consists of 
“mechanism-based reasoning” (column 6). 
The SORT is an EBM taxonomy used by U.S. medical journals specifically in the 
specialties of family practice and primary care.  Ebell et al. (2004) explain that the 
SORT resulted from a collaboration between family medicine and primary care journal 
editors.  The purpose was to develop a standardized manner for ranking medical 
evidence among the various publications.  The authors state: 
Therefore, the editors of the US family medicine and primary care journals (ie, 
American Family physician, Family Medicine, Journal of Family Practice, Journal 
of the American Board of Family Practice, and BMJ-USA) and the Family 
Practice Inquiries Network (FPIN) came together to develop a united taxonomy 
for the strength of recommendations based on a body of evidence.  The new 
taxonomy should include the following attributes:  (1) be uniform in most family 
medicine journals and electronic databases; (2) allow authors to evaluate the 
strength of recommendation of a body of evidence; (3) allow authors to rate the 
level of evidence for an individual study; (4) be comprehensive and allow authors 
to evaluate studies of screening, diagnosis, therapy, prevention, and prognosis; 
(5) be easy to use and not too time-consuming for authors, reviewers, and 
editors who may be content experts but not experts in critical appraisal or clinical 
epidemiology; and (6) be straightforward enough that primary care physicians 
can readily integrate the recommendations into daily practice. (pp. 59-60). 
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The authors go on to explain that the SORT was designed, at least in part, for ease of 
use.  The authors explain, “we also were committed to creating a grading scale that 
could be applied by authors with varying degrees of expertise in evidence-based 
medicine and clinical epidemiology and interpreted by physicians with little or no formal 
training in these areas” (p. 61).   
The SORT algorithm assigns a combination of a letter “A”, “B”, or “C” (p. 62, Fig. 
1) for its strength of recommendation followed by an integer value.  A value of “A” is 
assigned for a recommendation based on consistent and good quality patient-oriented 
evidence, “B” is assigned for a recommendation based on inconsistent or limited quality 
patient-oriented evidence, and “C” is a recommendation based on consensus, usual 
practice, opinion, disease-oriented, evidence, and case series for studies of diagnosis, 
treatment, prevention, or screening.  The strength of recommendation letter assignment 
is followed a numerical level ranking from 1 to 3 based on study quality.  Level 1 studies 
are deemed good quality patient-oriented evidence, Level 2 is for limited quality patient-
oriented evidence, and Level 3 is for other types of medical evidence. 
Both the OCEBM taxonomy and SORT are attempts to standardize the manner 
in which medical evidence is summarized the goal of which is to assist with the 
assessment of the large volume and complexity of medical evidence.  Although such 
attempts are laudable, no single EBM taxonomy or ranking system for medical evidence 
has emerged.   
   Schaafsma, Hulshof, van Dijk, and Verbeek (2004) conducted a study on behalf 
of the Finnish Institute of Occupational Health, to evaluate physician attitudes toward 
EBM.  The study did not include other prescriber groups such as midlevel providers, or 
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pharmacists.  The study used a questionnaire sent to a random sample of 144 
registered physicians with an average response rate of 54%.  Their conclusions related 
to EBM were: 
Three-quarters of the respondents indicated that they were interested in 
evidence-based medicine, but only one-third actually applied evidence-based 
medicine methods when possible … personal interest in evidence-based 
medicine strongly correlated with the expectation that evidence-based medicine 
would become more important for occupation health in the future.  (p. 329) 
 
In conclusion, EBM is an important component of medical decision-making not only as it 
relates to decision-making by hospital P&T committees but in many facets of patient 
care.  However, no standardized taxonomy or method for evaluating and ranking 
medical evidence has emerged. 
 
Aspects of Pharmacy and Therapeutics (P&T) Committees 
P&T Committees Definition and Composition 
As stated previously, the majority of large hospitals and hospital systems rely 
upon P&T committees to develop and manage their medication formulary as well as 
various aspects of the medication use process.  P&T committees are usually comprised 
of licensed and credentialed physicians, midlevel providers, and pharmacists.  P&T 
committees may also involve administrative staff responsible for ordering and procuring 
drugs and other decision-makers within the organization.  In most cases, P&T 
committees formalize decisions by a simple majority vote representing the majority 
consensus of voting committee members.   
Kelly and Bender (1983) define a P&T committee as a “medical staff committee 
… charged with maintaining the formulary system” (p. 976).   A complimentary definition 
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is put forward by Tyler, Cole, May, Millares, Valentino, Vermeulen, and Wilson (2008) 
who state:   
A P&T committee is responsible for managing the formulary system.  It is 
composed of actively practicing physicians, other prescribers, pharmacists, 
nurses, administrators, quality-improvement managers, and other health care 
professionals and staff who participate in the medication-use process.  
Customarily, P&T committee member appointments are based on guidance from 
medical staff.  (p. 172) 
 
A review of the composition of P&T committees was conducted by Duran-Garcia, 
Santos-Ramos, Puigventos-Latorre, and Ortega (2011). The authors analyzed 
publications from 1997 to 2009 from five western English and Spanish speaking 
countries including the U.S.  The authors found that “pharmacy and therapeutics 
committees were present in 90% of the hospitals in four of the five countries examined” 
(p. 475).  Individuals represented on P&T committees varied but included: physicians, 
midlevel providers, pharmacists, nurses, and hospital administrators.  The authors 
further surmised that P&T committee composition variation may be attributed to 
differences in hospital size and organizational structure.  
 
P&T Committees’ Role 
The role of P&T committees was studied by Segal and Pathak (1988).  The 
authors conducted their study using a combination of both face-to-face interviews and 
surveys of P&T committee members from five hospitals located in Ohio.  Each of the 
hospitals utilized a closed medication formulary and managed their medication 
formulary using a P&T committee structure.  Twenty-three P&T committee members 
were interviewed and surveyed.  The medical staff included both physicians and 
pharmacists.  The study participants were asked to rank the perceived importance of 
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various drug-related information elements which they deemed important.  Nine 
elements were identified by the physicians and pharmacists.  These 9 elements were 
then ranked using a scale from 0 to 6 with 0 being least important and 6 being most 
important.  Following is the ranked list of medication-related factors from the most 
important 1, to the least important 9: 
1) Therapeutic advantage ... over existing drugs already on the formulary 2) 
pharmacokinetic features of the drug 3) profile of adverse effects compared to 
existing drugs 4) justification for adding the drug by the requesting physician 5) 
review of good clinical studies of the drug in patients similar to patients in your 
hospital  6) costs relative to other drugs already in the formulary  7) 
recommendation by the pharmacy department to either add or not add the drug 
to the formulary  8)  the drug’s acquisition cost and 9) dosage regimen advantage 
over existing formulary drugs.  
(p. 176, Table 2) 
 
By closely examining the list of nine factors perceived by study participants as the most 
important, the item listed fifth on the list is “review of good clinical studies of the drug in 
patients similar to patients in your hospital” (p. 176, Table 2).   
As P&T committees make medication formulary decisions, it is unclear if medical 
evidence or the practice of EBM is deemed important.  It is also unclear if EMB 
taxonomies or classifications serve to ease or augment hospital formulary decision-
making.  Furthermore, other factors may impact medical formulary decision-making 
including individual professional opinion and the professional opinion of colleagues. 
 
Theoretical Framework 
According to Patel, Kaufman, and Kannampallil (2013), decision-making is 
impacted by individual, social, political, economic, information artifacts, and system 
factors.  The conceptualization of these factors in research has been a long-standing 
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research area within the field of Information Science.  A notable example can be found 
in the third volume of the Annual Review of Information Science and Technology.  
Paisley (1968) warns against “shallow conceptualization” of information use within 
complex systems: 
Shallow conceptualization is something else again.  Even small projects can 
demonstrate awareness of the complex systems that affect the flow of 
information.  Shallow conceptualization implies a failure to consider these factors: 
 
1. The full array of information sources that are available. 
2. The uses to which the information will be put. 
3. The background, motivation, professional orientation, and other individual 
characteristics of the user. 
4. The social, political, economic, and other systems that powerfully affect 
the user and his work. 
5. The consequences of information use – e.g., productivity. 
 
As a result, in many studies, it is hard to glimpse a real scientist or technologist at 
work, under constraints and pressures, creating products, drawing upon the 
elaborate communication network that connects him with sources of necessary 
knowledge.  (p. 2) 
 
The author concludes that numerous factors must be considered to adequately 
conceptualize information use within broader system contexts.  In addition to individual 
factors, research into information behavior must also consider social, political, 
economic, and the impact of other systems.  Later research in the field of Information 
Science led to the development of two notable task-oriented information seeking models 
(Hansen, 2005; Leckie, Pettigrew, & Sylvain, 1996).  These models were explained in 
greater detail in the section entitled Task Oriented Information Behavior.  These models 
illustrate the processes by which individuals within certain professional groups including 
healthcare providers seek, retrieve, and use recorded information.  Furthermore, the 
Hansen (2005) model represents information behavior which occurs within the broader 
contexts of social and collaborative environments.   
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Another important theoretical framework in Information Science is that decision-
making is enhanced when decisions are based on reliable, verifiable, and trusted 
information.  Various scholars have identified characteristics attributed to data and 
information quality.  Tan (2001) describes major desirable data characteristics which 
include: “accessibility, accuracy, appropriateness, comprehensibility, 
comprehensiveness, consistency, relevance, reliability, timeliness, and usefulness” (p. 
57, Table 3-1).  Similarly, Case (2008) defines information quality as “the perceived 
attributes of information that make it of value to a potential user in a specific context.  
Some components of quality include relevance, timeliness, accuracy, specificity, 
comprehensiveness, and authoritativeness” (p. 333).  Finally, Cleveland and Cleveland 
(2009) state, “it should be remembered that accurate, timely, and appropriate 
information enhances the potential of good decision making but does not guarantee it.  
The final decision is the responsibility of humans” (p. 48).  A complementary framework 
proposed by Patel, Kaufman, and Kannampallil (2013) states that cognition or 
reasoning in collaborative environments is not relegated to individuals.  This theoretical 
framework contends that cognition and reasoning in complex environments extends 
beyond the individual to groups, material artifacts, and cultures: 
The distributed view of cognition represents a shift in the study of cognition from 
being the sole property of the individual to being “stretched” across groups, 
material artifacts, and cultures.  This viewpoint is gaining increase acceptance in 
cognitive science, HCI [Human Computer Interaction], and human factors 
research …Distributed cognition has two central points of inquiry, one that 
emphasizes the social and collaborative nature of cognition (e.g., doctors, 
nurses, and other personnel jointly contributing to a decision process) and one 
that characterizes the mediating effects of technology or other artifacts on 




This “distributed view” of cognition recognizes that in addition to individual factors, 
social, collaborative, and material artifacts are also factors affecting decision-making in 
complex systems.   
 
Summary 
This chapter presents a review of the literature related to the study in the areas of 
hospital formularies, decision-making for hospital formularies, aspects of pharmacy and 
therapeutics (P&T) committees, medical decision-making, and a description of the 
theoretical framework for the study.  Chapter III describes the research methodology 






This chapter describes the methods and procedures used to conduct the study.  
Specifically, this chapter includes the following sections: Introduction, Research 
Questions and Hypotheses, Theoretical Framework, Research Design, Methods, 
Validity and Reliability, Selection of Participants, Institutional Review Board (IRB) 
Processes, Pilot Study, Data Collection and Analysis, Online Self-Administered Survey, 
and the Summary. 
 
Research Questions and Hypotheses 
Group 1:  Physicians 
Q1. What is the ranked order of factors that influence hospital formulary decision-
making by physicians? 
 
Hypothesis 1.1:  For physicians, individual evaluation of medical evidence 
has a lower ranking of influence on hospital formulary decision-making 
than does the evaluation of medications by expert physicians.  
Hypothesis 1.2:  For physicians, the evaluation of medications by expert 
physicians has a higher ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations. 
Hypothesis 1.3:  For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the number of 
patients affected. 
Hypothesis 1.4:  For physicians, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the institution. 
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Hypothesis 1.5:  For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the patient. 
Hypothesis 1.6:  For physicians, individual evaluation of medical evidence 
has a higher ranking of influence on hospital formulary decision-making 
than does the opportunity for new treatment options. 
Group 2:  Midlevel Providers 
Q2. What is the ranked order of factors that influence hospital formulary decision-
making by midlevel providers? 
 
Hypothesis 2.1:  For midlevel providers, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-
making than does the evaluation of medications by expert physicians. 
Hypothesis 2.2:  For midlevel providers, the evaluation of medications by 
expert physicians has a higher ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations.  
Hypothesis 2.3:  For midlevel providers, a pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has a higher 
ranking of influence on hospital formulary decision-making than does the 
number of patients affected. 
Hypothesis 2.4:  For midlevel providers, pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has a higher 
ranking of influence on hospital formulary decision-making than does the 
financial impact of the treatment for the institution. 
Hypothesis 2.5:  For midlevel providers, a pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has higher 
ranking of influence on hospital formulary decision-making than does the 
financial impact of the treatment for the patient. 
Hypothesis 2.6:  For midlevel providers, individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-
making than does the opportunity for new treatment options. 
Group 3:  Pharmacists 
Q3. What is the ranked order of factors that influence hospital formulary decision-




Hypothesis 3.1:  For pharmacists, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-
making than does the evaluation of medications by expert physicians. 
Hypothesis 3.2:  For pharmacists, the evaluation of medications by expert 
physicians has a lower ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence 
including formulary recommendations. 
Hypothesis 3.3:  For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the number of 
patients affected. 
Hypothesis 3.4:  For pharmacists, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the institution. 
Hypothesis 3.5:  For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the patient. 
Hypothesis 3.6:  For pharmacists, individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-
making than does the opportunity for new treatment options. 
 
Theoretical Framework 
Decision-making is impacted by numerous factors including individual, social, 
political, economic, system, and those associated with information artifacts.  
Conceptualization of these factors has been a long- standing research area within the 
field of information science.  Paisley (1968) concludes that to properly conceptualize 
information use within complex systems, numerous factors must be considered.  Later 
research in the field of Information Science led to the development of two notable task-
oriented information seeking models (Hansen, 2005; Leckie, Pettigrew, & Sylvain, 
1996).  Furthermore, these task-oriented models illustrate the complexity of information 
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seeking within the broader contexts of social and collaborative environments.  Both 
models are described in detail in Chapter II. 
Another important theoretical framework in information science is that the 
decision-making process is enhanced when decisions are based on reliable, verifiable, 
and trusted information.  Various scholars have identified characteristics attributed to 
data and information quality.  Tan (2001) describes major desirable data characteristics 
including: “accessibility, accuracy, appropriateness, comprehensibility, 
comprehensiveness, consistency, relevance, reliability, timeliness, and usefulness” (p. 
57, Table 3-1).  Similarly, Case (2008) defines information quality as “the perceived 
attributes of information that make it of value to a potential user in a specific context.  
Some components of quality include relevance, timeliness, accuracy, specificity, 
comprehensiveness, and authoritativeness” (p. 333).  Finally, Cleveland and Cleveland 
(2009) state, “it should be remembered that accurate, timely, and appropriate 
information enhances the potential of good decision making but does not guarantee it.  
The final decision is the responsibility of humans” (p. 48). 
A complementary and more contemporary framework proposed by Patel, 
Kaufman, and Kannampallil (2013) states that cognition or reasoning in collaborative 
environments is not relegated to individuals.  This theoretical framework contends that 
cognition and reasoning in complex environments, such as healthcare environments, 
extends beyond the individual.  This “distributed view” of cognition proposes that 
reasoning and ultimately decision-making extends beyond the individual to groups, 




A survey also referred to as a questionnaire was administered to address the 
research questions and hypotheses stated.  According to Bernard (2006), 
questionnaires are a form of structured interview and have been used in social science 
research for decades.  In recent years, the use of online survey software has become 
more commonplace.  The author describes three common methods for administering 
surveys to study participants including: “(1) personal, face-to-face interviews, (2) self-
administered [emphasis added] questionnaires, and (3) telephone interviews.  All three 
of these methods can be either assisted by, or fully automated with, computers” (p. 
252).  For the purpose of this study, self-administered surveys were conducted.  All 
study participants were asked to complete an online version of the survey represented 
in Appendix E.  An email was sent to study participants explaining the study and asking 
for their participation this email is represented in Appendix D.  Furthermore, the email 
included a link or uniform resource locator (URL) which allowed the participants to 
access and complete the online survey.  The online survey instrument represented in 
Appendix E was developed using Qualtics© (2017) online survey software. 
 
Methods 
As stated previously, the survey was administered using Qualtrics© (2017) online 
survey software.  According to the Qualtrics© website, the software allows researchers 
to create surveys which may include over 100 question types including Likert scale 
questions as described by Bernard (2006).  The software facilitates reporting and some 
functionality for online analyses of survey response and participation rates.  Additionally, 
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the software allows the survey administrator to export survey data.  Exporting data 
allows the researcher to perform additional statistical analyses in software such as 
SPSS© (2017). 
One round of online surveys was conducted.  Study participants were asked to 
complete all online survey questions as well as rank the various hospital formulary 
decision-making factors.  The survey questions were based on the enumerated 
research questions and hypotheses.  After participants responded to individual 
questions related to each of the hospital formulary decision-making factors on a 5-point 
Likert scale, they were also asked to rank the factors from 1 being the most important to 
7 being the least important.  A complete representation of the survey is included in 
Appendix E. 
 
Validity and Reliability 
Bernard (2006) states, “validity [emphasis added] refers to the accuracy and 
trustworthiness of instruments, data, and findings in research.  Nothing in research is 
more important than validity” (p. 53).  Subsequently, the author states that “reliability 
[emphasis added] refers to whether or not you get the same answer by using an 
instrument to measure something more than once” (p. 54).  For the purpose of this 
study, an assumption is being made that the University of Texas, MD Anderson Cancer 
Center P&T committee members both current and past are a representative sample of 
hospital formulary decision-makers.  It is further assumed that these licensed healthcare 
providers exhibit decision-making characteristics as they exist in the professional, 
social, and collaborative environment of a P&T committee. 
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Selection of Participants 
The Department of Medication Management and Finance (MM&F) within the 
University of Texas, MD Anderson Cancer Center’s Division of pharmacy is responsible 
for managing the composition and ongoing organizational activities of the P&T 
committee.  MM&F departmental staff are responsible for ensuring that the committee’s 
medical staff composition adheres to appropriate numbers of physicians, midlevel 
providers / advanced practice providers, and pharmacists based on the P&T committee 
charter.  MM&F staff are responsible for various aspects of P&T committee activities 
including:  maintaining membership rosters, preparing meeting agendas, keeping 
records of meeting attendance, preparing meeting minutes, keeping historical records of 
decisions made by the committee, and operationalizing committee decisions.  
Furthermore, MM&F staff ensure the hospital’s electronic systems appropriately reflect 
the hospital’s formulary, formulary restrictions, and decisions made by the P&T 
committee.  As stated previously, the P&T committee is a medical staff committee that 
is physician led.  The committee is both chaired and co-chaired by physicians currently 
on the hospital’s medical staff. 
The hospital’s credentialing process ensures that healthcare providers serving on 
the medical staff at the University of Texas, MD Anderson Cancer Center are practicing 
with valid professional credentials and appropriate licensure.  Study participants must 
belong to one of following licensed healthcare provider groups including:  1) physicians, 
2) midlevel providers / advanced practice providers, or 3) pharmacists.  Participants 
were identified from the University of Texas, MD Anderson Cancer Center P&T 
committee fiscal year rosters from 2007 to 2018.  To participate in the study, 
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participants must currently serve or previously served as voting members of the 
University of Texas, MD Anderson Cancer Center P&T committee.  P&T committee 
rosters were obtained from the division of pharmacy’s department of MM&F.  P&T 
committee service ensures participants can appropriately respond to the hospital 
decision-making survey questions posed to them.  A total of 65 prescribers met the 
study criteria comprised of 50 physicians, 9 pharmacists, and 6 midlevel providers / 
advanced practice providers. 
 
Selection of Physicians 
 
Physicians asked to participate in the study were selected from both the current 
P&T committee roster and previous rosters.  Physicians invited to participate must serve 
on the medical staff at the University of Texas, MD Anderson Cancer Center during the 
time the survey was administered.  Fifty (50) physicians met the selection criteria. 
 
Selection of Midlevel Providers 
 
Midlevel providers asked to participate in the study were selected from both the 
current P&T committee roster and previous rosters.  Midlevel providers invited to 
participate must serve on the medical staff at the University of Texas, MD Anderson 
Cancer Center during the time the survey was administered.  Six (6) midlevel providers / 
advanced practice providers met the selection criteria. 
 
Selection of Pharmacists 
 
Pharmacists asked to participate in the study were selected from both the current 
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P&T committee roster and previous rosters.  Pharmacists invited to participate must 
serve on the medical staff at the University of Texas, MD Anderson Cancer Center 
during the time the survey was administered.  Nine (9) pharmacists met the selection 
criteria. 
 
Institutional Review Board (IRB) Processes 
This study followed both the University of North Texas and the University of 
Texas, MD Anderson Cancer Center guidelines for research.  Appropriate 
documentation was submitted to the institutional review boards (IRBs) of both 
institutions.  Upon formal approval by both institutions included in Appendix A and B 
respectively, the study was conducted.  No modification requests were submitted to the 
IRBs for changes to the research protocol. 
 
Pilot Study 
A pilot study was conducted and included one physician, one midlevel provider, 
and one pharmacist. The purpose of the pilot study was to determine if any questions 
posed in the online survey required clarification and to ensure the validity and reliability 
of the survey. Based on feedback from the pilot study, a clarification of the prescriber 
role of “midlevel provider” was made to include a more contemporary and inclusive title 
of “advanced practice provider.”  In the end, both titles were included for consistency 
resulting in “midlevel provider/advanced practice provider.” 
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Data Collection and Analysis 
A single survey was sent electronically to each study participant meeting the 
criteria beginning on November 1, 2017.  Specifically, the survey was administered and 
tracked using Qualtrics© (2017) online survey software.  The survey is represented in 
table form in Appendix E.  The online survey was transmitted by an email containing a 
URL to all physicians, midlevel providers, and pharmacists meeting the selection 
criteria.  A number of follow up emails were sent requesting participation.  After an 
acceptable response rate was achieved for each prescriber group the survey concluded 
on Monday, December 18, 2017.  The time period was extended past its original two-
week estimated duration to improve upon initial low response rates after two weeks. 
Participants were coded when the data were exported to SPSS© (2017) software 
to ensure confidentiality.  The results from the survey included in this work include no 
individually identifying data elements.  Survey results were analyzed using the various 
reports and statistical analysis functionality available from the Qualtics© (2017) and 
SPSS© (2017) software.  The reports were used to determine survey response rates 
from each provider category and to obtain certain descriptive statistics.  SPSS© was 
also used to perform additional analyses including inferential statistics.  Specifically, 
Kruskal-Wallis H Tests were performed to determine if statistically significant differences 
between the three prescriber groups from the data obtained in Parts II and III of the 
online survey. 
 
Online Self-Administered Survey 
Appendix E contains an exact representation of the questions asked of the 
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participants by way of the online self-administered survey.  As stated previously, the 
survey was administered using the Qualtics© (2017) software.  In Part I, the survey 
contains questions related to the background of the participants, Part II contains 
independent statements related to each of the identified hospital formulary decision-
making factors, Part III asks participants to rank the various decision-making factors, 
and Part IV provides an opportunity for participants to express additional factors or other 
information considered when making hospital formulary decisions. 
 
Summary 
This chapter provides an overview of the qualitative research design for a 
comparison of major factors that affect hospital formulary decision-making by three 
groups of prescribers.  The design of the study includes questions related to each factor 
impacting hospital formulary decision-making factors as well as a ranking of decision-
making factors by each participant.  The results are included in Chapter IV as well as 






This chapter presents the results of the study which collected data from the P&T 
committee of a large multi-facility oncology hospital.  The chapter contains a description 
of the data collected from the survey and subsequently relates the results of the study to 
the research questions and hypotheses. 
The purpose of the study was to identify, rank, and compare major factors 
impacting hospital formulary decision-making among three prescriber groups serving on 
a hospital P&T committee.  Prescribers were selected from the University of Texas, MD 
Anderson Cancer Center which is a large, multi-facility, academic oncology hospital.  
Specifically, the prescriber groups studied were comprised of physicians, midlevel 
providers / advanced practice providers, and pharmacists.  To participate in the study, 
prescribers must have served on the University of Texas, MD Anderson Cancer Center 
P&T committee and still on the medical staff of the hospital. 
A total of 65 prescribers were identified who met the study criteria.  The 
participant email, included in Appendix D, was transmitted to all 65 eligible prescribers 
with a link to the online survey.  An initial email was sent to eligible study participants on 
November 1, 2017 inviting them to participate in the study.  After reminder emails were 
sent, it was determined that collection of survey data would conclude on December 19, 
2017.  The 65 eligible participants were comprised of 50 physicians, 6 midlevel 
providers, and 9 pharmacists.  Upon completion of survey data collection, 16 of 50 
eligible physicians responded resulting in a 32.0% response rate for physicians.  All 6 
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midlevel / advanced practice providers responded achieving a 100.0% response rate for 
this category of prescriber.  Finally, 8 pharmacists of the eligible 9 participated 
producing an 88.9% response rate for pharmacists.  In total, 30 prescribers responded 
of the eligible 65 resulting in a total overall response rate of 46.2%. 
The online self-administered surveys comprised four parts.  Part I included 
demographic questions regarding the participant’s age, gender, months and years as a 
licensed healthcare provider, months and years as a licensed healthcare provider at the 
University of Texas, MD Anderson Cancer Center, prescribing role, current service on 
the P&T committee, and all previous fiscal years of service on the committee.    In Part 
II of the survey, 7 statements were presented.  Each statement applied to one of the 
seven identified decision-making factors.  Participants were asked to rate their level of 
agreement or disagreement based on a 5-point Likert scale. Part III of the survey asked 
prescribers to rank the 7 decision-making factors in relation to one another with a “1” for 
the most important factor to a “7” representing the least important factor.  Part IV of the 
survey asked participants to provide, by entering textual responses, any additional 
factors or information considered when making formulary decisions.  Finally, 
participants were asked if they would like a summary of the study results.  If study 
results were requested, the participant was asked to supply their name and email 
address. 
The research questions and related hypotheses for each prescriber groups 





Group 1:  Physicians 
Research Question 1:  What is the ranked order of factors that influence hospital 
formulary decision-making by physicians? 
 
Hypothesis 1.1:  For physicians, individual evaluation of medical evidence 
has a lower ranking of influence on hospital formulary decision-making 
than does the evaluation of medications by expert physicians.  
Hypothesis 1.2:  For physicians, the evaluation of medications by expert 
physicians has a higher ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations. 
Hypothesis 1.3:  For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the number of 
patients affected. 
Hypothesis 1.4:  For physicians, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the institution. 
Hypothesis 1.5:  For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the patient. 
Hypothesis 1.6:  For physicians, individual evaluation of medical evidence 
has a higher ranking of influence on hospital formulary decision-making 
than does the opportunity for new treatment options. 
Group 2:  Midlevel Providers 
Research Question 2:  What is the ranked order of factors that influence hospital 
formulary decision-making by midlevel providers? 
 
Hypothesis 2.1:  For midlevel providers, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-
making than does the evaluation of medications by expert physicians. 
Hypothesis 2.2:  For midlevel providers, the evaluation of medications by 
expert physicians has a higher ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations.  
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Hypothesis 2.3:  For midlevel providers, a pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has a higher 
ranking of influence on hospital formulary decision-making than does the 
number of patients affected. 
Hypothesis 2.4:  For midlevel providers, pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has a higher 
ranking of influence on hospital formulary decision-making than does the 
financial impact of the treatment for the institution. 
Hypothesis 2.5:  For midlevel providers, a pharmacy staff’s evaluation of 
medical evidence including formulary recommendations has higher 
ranking of influence on hospital formulary decision-making than does the 
financial impact of the treatment for the patient. 
Hypothesis 2.6:  For midlevel providers, individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-
making than does the opportunity for new treatment options. 
Group 3:  Pharmacists 
Research Question 3:  What is the ranked order of factors that influence hospital 
formulary decision-making by pharmacists? 
 
Hypothesis 3.1:  For pharmacists, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-
making than does the evaluation of medications by expert physicians. 
Hypothesis 3.2:  For pharmacists, the evaluation of medications by expert 
physicians has a lower ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence 
including formulary recommendations. 
Hypothesis 3.3:  For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the number of 
patients affected. 
Hypothesis 3.4:  For pharmacists, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of 
influence on hospital formulary decision-making than does the financial 
impact of the treatment for the institution. 
Hypothesis 3.5:  For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of 
influence on hospital formulary decision-making than does the financial 




Hypothesis 3.6:  For pharmacists, individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-
making than does the opportunity for new treatment options. 
 
 
Survey – Part I 
In Part I of the online self-administered survey, the prescribers provided 
demographic information.  Table 1 provides an overview of the demographics of the 
prescribers in terms of age, gender, years as a licensed healthcare provider, years as a 
licensed healthcare provider at the University of Texas, MD Anderson Cancer Center, 
prescribing role, current membership status on the P&T committee, and any previous 
years of service on the P&T committee.  To summarize prescriber age range, of the 30 
participants 11 prescribers range in age from 35 to 44 years and 10 from 45 to 54 years.  
Therefore, most of the prescribers 21 total are between the ages of 35 and 54 years.  Of 
physicians 8 (50%) are between the ages of 35 and 44, 4 (25.0%) are between the ages 
of 45 and 54, 1 (6.3%) is between the ages of 55 and 64, 2 (12.5%) are between the 
ages of 65 and 74, and 1 (6.3%) is greater than 75 years of age.  For midlevel 
providers, 1 (16.7%) is between the ages of 35 and 44 years, 2 (33.3%) are between 
the ages of 45 and 54, 2 (33.3%) are between the ages of 55 and 64, and 1 (16.7%) is 
between the ages of 65 and 74.  For pharmacists, 2 (25.0%) are between the ages of 
35 and 44, 4 (50.0%) are between the ages of 45 and 54, and 2 (25.0%) are between 
the ages of 55 and 64.   
In terms of gender composition of physicians 11 (68.8%) were male, and 5 
(31.3%) were female.  For midlevel providers 2 (33.3%) were male and 4 (66.7%) were 
female.  For pharmacists 4 (50.0%) were male, and 4 (50.0%) were female. For all 




Demographic Characteristics Frequencies and Percentages (n=30) 
Demographic Characteristic f % 
Age 
35-44 11 36.7 
45-54 10 33.3 
55-64 5 16.7 
65-74 3 10.0 
75 or older 1 3.3 
Gender 
Male 17 56.7 
Female 13 43.3 




5-9 3 10.0 
10-14 4 13.3 
15-19 9 30.0 
20-24 5 16.7 
25-29 2 6.7 
30-34 3 10.0 
35-39 1 3.3 
40-44 2 6.7 
45-49 1 3.3 
Years As a 
Licensed 
Healthcare 
Provider at MD 
Anderson Cancer 
Center 
0-4 3 10.0 
5-9 5 16.7 
10-14 11 36.7 
15-19 2 6.7 
20-24 2 6.7 
25-29 2 6.7 
30-34 2 6.7 
35-39 2 6.7 
40-44 1 3.3 
Prescribing Role 
physician 16 53.3 
midlevel provider/advanced practice provider 6 20.0 
pharmacist 8 26.7 
Current Member of 
P&T committee 
Yes 21 70.0 
No 9 30.0 
Previous Years 
Serving on P&T 
committee 
Fiscal Year 2017 (9/1/2016 – 8/31/2017) 20 66.7 
Fiscal Year 2016 (9/1/2015 – 8/31/2016) 20 66.7 
Fiscal Year 2015 (9/1/2014 – 8/31/2015) 21 70.0 
 
(table continues)  
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Demographic Characteristic f % 
Previous Years 
Serving on P&T 
committee (cont.) 
Fiscal Year 2014 (9/1/2013 – 8/31/2014) 15 50.0 
Fiscal Year 2013 (9/1/2012 – 8/31/2013) 13 43.3 
Fiscal Year 2012 (9/1/2011 – 8/31/2012) 15 50.0 
Fiscal Year 2011 (9/1/2010 – 8/31/2011) 14 46.7 
Fiscal Year 2010 (9/1/2009 – 8/31/2010) 13 43.3 
Fiscal Year 2009 (9/1/2008 – 8/31/2009) 11 36.7 
Fiscal Year 2008 (9/1/2007 – 8/31/2008) 9 30.0 
Fiscal Year 2007 (9/1/2006 – 8/31/2007) 8 26.7 
Note.  f = frequency; % = percentage (of total). 
 
A review of the participants’ years as licensed healthcare providers was 
performed.  These data include the timeframe from obtaining a professional license and 
including any subsequent residencies for all three prescribing groups studied.  Refer to 
Table 1.  For physicians 2 (12.5%) have been professionally licensed from 5 to 9 years, 
3 (18.8%) for 10 to 14 years, 5 (31.3%) for 15 to 19 years, 1 (6.25%) for 20 to 24 years, 
1 (6.25%) for 25 to 29 years, 1 (6.25%) from 30 to 34 years, 2 (12.5%) from 40 to 44 
years, and 1 (6.25%) from 45 to 49 years.  For midlevel providers, 1 (16.7%) has been 
professionally licensed for 5 to 9 years, 1 (16.7%) for 10 to 14 years, 1 (16.7%) for 15 to 
19 years, and 3 (50.0%) for 20 to 24 years.  For pharmacists, 3 (37.5%) have been 
licensed from 15 to 19 years, 1 (12.5%) for 20 to 24 years, 1 (12.5%) for 25 to 29 years, 
2 (25.0%) from 30 to 34 years, and 1 (12.5%) for 35 to 39 years.  For all prescribers 
(n=30) a total of 3 (10.0%) have been professionally licensed from 5 to 9 years, 4 
(13.3%) for 10 to 14 years, 9 (30.0%) for 15 to 19 years, 5 (16.7%) for 20 to 24 years, 2 
(6.7%) for 25 to 29 years, 3 (10.0%) from 30 to 34 years, 1 (3.3%) from 35 to 39 years, 
2 (6.7%) from 40 to 44 years, and 1 (3.3%) from 45 to 49 years. 
The next demographic question was to determine how long participants had 
served as a licensed healthcare provider at the University of Texas, MD Anderson 
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Cancer Center.  For physicians 2 (12.5%) have been licensed healthcare providers at 
the University of Texas, MD Anderson Center for 0 to 4 years, 3 (18.8%) for 5 to 9 
years, 6 (37.5%) for 10 to 14 years, 2 (12.5%) for 15 to 19 years, 1 (6.3%) for 30 to 34 
years, 1 (6.3%) for 35 to 39 years, and 1 (6.3%) for 40 to 44 years.  For midlevel 
providers having served as licensed healthcare providers at the University of Texas, MD 
Anderson Cancer Center 1 (16.7%) for 5 to 9 years, 3 (50.0%) for 10 to 14 years, 1 
(16.7%) for 20 to 24 years, and 1 (16.7%) for 25 to 29 years.  For pharmacists 1 
(12.5%) has been a licensed healthcare provider at the University of Texas, MD 
Anderson Center for 0 to 4 years, 1 (12.5%) for 5 to 9 years, 2 (25.0%) for 10 to 14 
years, 1 (12.5%) for 20 to 24 years, 1 (12.5%) for 25 to 29 years, 1 (12.5%) for 30 to 34 
years, and 1 (12.5%) for 35 to 39 years.  For all providers 3 (10.0%) have been licensed 
healthcare providers at the University of Texas, MD Anderson Center for 0 to 4 years, 5 
(16.7%) for 5 to 9 years, 11 (36.7%) for 10 to 14 years, 2 (6.7%) for 15 to 19 years, 2 
(6.7%) for 20 to 24 years, 2 (6.7%) for 25 to 29 years, 2 (6.7%) for 30 to 34 years, 2 
(6.7%) for 35 to 39 years, and 1 (3.3%) for 40 to 44 years. 
Next participants were asked to indicate their prescribing role at the University of 
Texas, MD Anderson Cancer Center.  Of the 30 participants, 16 (53.3%) were 
physicians, 8 (26.7%) pharmacists, and 6 (20.0%) midlevel providers.  Prescribing role 
was used in subsequent sections to address the various research questions and 
hypotheses and identify similarities and differences concerning the three groups of 
prescribers. 
The final demographic question was to ascertain the current service and previous 
years of service on the institution’s P&T committee.  Participants indicating service on 
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the current fiscal year’s (9/1/2017 to 8/31/2018) P&T committee was 21 (70%) while 9 
(30%) of those who responded are not serving on the fiscal year 2018 committee.  The 
next highest frequencies indicated by the participants on the P&T committee was for 
fiscal year 2015 (9/1/2014 – 8/31/2015) with 21 (70.0%), and two fiscal years with 
identical frequencies fiscal year 2017 (9/1/2016 – 8/31/2017) and fiscal year 2016 
(9/1/2015 – 8/31/2016) both with 20 (66.7%).     
 
Table 2 displays the average years of service by prescriber group.  The 
prescriber group with the highest average years of service on the P&T committee was 
pharmacists with an average of 7.0 (SD=4.6) years, followed by midlevel providers with 
4.8 (SD=2.9) years, and physicians with 4.6 (SD=3.2) years.  The standard deviation 
among the prescriber groups regarding their years of service indicates that pharmacists 
had the highest standard deviation of 4.6 years, physicians with 3.2 years, and midlevel 
providers with 2.9 years.  Across all prescriber groups the standard deviation was 3.6 
years. 
Table 2 
Prescriber Group Years of Service Means and Standard Deviations 
Prescriber Group n M SD 
Physician 16 4.6 3.2 
Midlevel provider 6 4.8 2.9 
Pharmacist 8 7.0 4.6 
Total 30 5.3 3.6 





Survey – Part II 
In Part II of the survey, the prescribers responded to seven statements related to 
each of the identified hospital formulary decision-making factors.  Each of the 
statements were formed to illicit a level of agreement measured on a 5-point Likert 
scale.  A response of strongly agree was assigned a value of 5, agree a value of 4, 
neutral a value of 3, disagree a value of 2, and strongly disagree a value of 1.  SPSS© 
(2017)  statistical software was used to compute the frequency, mean, and standard 
deviation values for each statement and the associated agreement score by prescriber 
group and for all prescribers in aggregate.   
Table 3 presents the frequencies of responses to each of the decision-making 
statements by prescriber group followed by the aggregate scores for all prescribers.  In 
response to the statement, “I rely upon my individual evaluation of medical evidence to 
make hospital medication formulary decisions.”  A total of 3 (18.8%) of physicians 
strongly agreed, 9 (56.3%) agreed, 2 (12.5%) were neutral, none selected disagree, and 
2 (12.5%) strongly disagreed.  For midlevel providers, none strongly agreed, a total of 5 
(83.3%) of prescribers agreed, 1 (16.7%) was neutral, none selected disagree, and 
none strongly disagreed.  For pharmacists, 1 (12.5%) strongly agreed, a total of 2 
(25.0%) prescribers agreed, 1 (12.5%) was neutral, 3 (37.5%) selected disagree, and 1 
(12.5%) strongly disagreed.  For all prescribers, a total of 4 (13.3%) of prescribers 
strongly agreed, 16 (53.3%) agreed, 4 (13.3%) were neutral, 3 (10%) selected disagree, 






Prescriber Group Frequencies of Responses for Decision-Making Statements 
(Physicians n=16, Midlevel Providers n=6, Pharmacists n=8, All Prescribers n=30) 
 
 5 - Strongly Agree 4-Agree 3-Neutral 2-Disagree 
1-Strongly 
Disagree 
I rely upon my individual evaluation of medical evidence to make hospital medication formulary 
decisions. 
Physician 3 9 2 0 2 
Midlevel provider 0 5 1 0 0 
Pharmacist 1 2 1 3 1 
All prescribers 4 16 4 3 3 
I rely upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make hospital 
medication formulary decisions. 
Physician 7 8 1 0 0 
Midlevel provider 5 1 0 0 0 
Pharmacist 4 3 0 0 1 
All prescribers 16 12 1 0 1 
I rely upon the evaluation of medications by expert physicians to make hospital medication 
formulary decisions. 
Physician 6 8 2 0 0 
Midlevel provider 0 6 0 0 0 
Pharmacist 1 3 3 1 0 
All prescribers 7 17 5 1 0 
I consider the number of patients affected by adding, removing, or modifying a drug on the 
formulary when making a hospital medication formulary decision. 
Physician 2 9 1 4 0 
Midlevel provider 3 3 0 0 0 
Pharmacist 0 5 2 1 0 
All prescribers 5 17 3 5 0 
I consider the financial impact of the treatment to the institution in terms of drug cost and potential 
reimbursement when making hospital medication formulary decisions. 
Physician 2 9 2 3 0 
Midlevel provider 1 5 0 0 0 
Pharmacist 4 3 1 0 0 




 5 - Strongly Agree 4-Agree 3-Neutral 2-Disagree 
1-Strongly 
Disagree 
I consider the financial impact of the treatment to the patient in terms of the out-of-pocket 
expenses they may incur when making hospital medication formulary decisions. 
Physician 6 6 1 3 0 
Midlevel provider 2 3 0 1 0 
Pharmacist 3 1 0 4 0 
All prescribers 11 10 1 8 0 
In my role as a medication prescriber, I consider the opportunity for new treatment options when 
adding or expanding the use of a hospital formulary medication. 
Physician 4 9 2 1 0 
Midlevel provider 2 4 0 0 0 
Pharmacist 3 4 1 0 0 
All prescribers 9 17 3 1 0 
 
 In response to the statement, “I rely upon the pharmacy staff’s evaluation of 
medical evidence including formulary recommendations (e.g. drug monograph, 
medication use evaluation, etc.) to make hospital medication formulary decisions.”  By 
reviewing the frequencies in Table 3, physicians indicating they strongly agreed was 7 
(43.8%), those who agreed were 8 (50.0%), 1 (6.3%) was neutral, and 0 (0.0%) 
disagreed or strongly disagreed with this statement.  Midlevel providers indicating they 
strongly agreed was 5 (83.3%), those who agreed was 1 (16.7%), none were neutral, 
none disagreed, and none strongly disagreed with this statement.  By reviewing the 
frequencies in Table 3, pharmacists indicating they strongly agreed was 4 (50.0%), 3 
(37.5%) agreed, none were neutral, none disagreed, and 1 (12.5%) strongly disagreed 
with this statement.  Among all prescribers indicating they strongly agreed was 16 
(53.3%), those who agreed were 12 (40.0%), 1 (3.3%) was neutral, and none 
disagreed, and 1 (3.3%) strongly disagreed with this statement. 
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For the hospital formulary decision-making statement, “I rely upon the evaluation 
of medications by expert physicians to make hospital medication formulary decisions.”  
6 (37.5%) physicians strongly agreed with the statement while 8 (50.0%) agreed with 
the statement.  A total of 2 (12.5%) indicated a response of neutral and no physicians 
disagreed or strongly disagreed with the statement.  For this hospital formulary 
decision-making statement, all 6 (100.0%) midlevel providers agreed with the 
statement.  No other agreement levels were selected.  For pharmacists, 1 (12.5%) 
pharmacist strongly agreed, 3 (37.5%) agreed, 3 (37.5%) were neutral, 1 (12.5%) 
agreed, and none strongly disagreed with the statement.  For all prescribers 7 (23.3%) 
prescribers strongly agreed with the statement while 17 (56.7%) agreed with the 
statement.  A total of 5 (16.7%) indicated a response of neutral, 1 (3.3%) prescriber 
disagreed, and none strongly disagreed with the statement. 
In response to the statement, “I consider the number of patients affected by 
adding, removing, or modifying a drug on the formulary when making a hospital 
medication formulary decision.”  A total of 2 (12.5%) physicians strongly agreed, 9 
(56.3%) agreed, 1 (6.3%) was neutral, 4 (25.0%) disagreed, and none strongly 
disagreed with the statement.  For midlevel providers, a total of 3 (50.0%) strongly 
agreed, 3 (50.0%) agreed, none were neutral, none disagreed, and none strongly 
disagreed with the statement.  For pharmacists, 0 (0.0%) pharmacists strongly agreed 
with the statement, 5 (62.5%) agreed, 2 (25.0%) were neutral, 1 (12.5%) disagreed, and 
none strongly disagreed with the statement.  Among all prescribers, A total of 5 (16.7%) 
prescribers strongly agreed, 17 (56.7%) agreed, 3 (10.0%) were neutral, 5 (16.7%) 
disagreed, and none strongly disagreed with the statement. 
73 
 
For the next statement, “I consider the financial impact of the treatment to the 
institution in terms of drug cost and potential reimbursement when making hospital 
medication formulary decisions.”  A total of 2 (12.5%) of physicians strongly agreed, 9 
(56.3%) agreed, 2 (12.5%) were neutral, and 3 (18.8%) disagreed with the statement.  
For midlevel providers, a total of 1 (16.7%) strongly agreed, 5 (83.3%) agreed, none 
were neutral, none disagreed, and none strongly disagreed with the statement.  For the 
pharmacists response, a total of 4 (50.0%) pharmacists strongly agreed, 3 (37.5%) 
agreed, 1 (12.5%) was neutral, none disagreed, and none strongly disagreed with the 
statement.  Among all prescribers, a total of 7 (23.3%) of prescribers strongly agreed, 
17 (56.7%) agreed, 3 (10.0%) were neutral, and 3 (10.0%) disagreed, and none strongly 
disagreed with the statement. 
The next statement in Table 3 is, “I consider the financial impact of the treatment 
to the patient in terms of the out-of-pocket expenses they may incur when making 
hospital medication formulary decisions.”  A total 6 (37.5%) physicians strongly agreed, 
6 (37.5%) agreed, 1 (6.3%) was neutral, while 3 (18.8%) disagreed with the statement, 
and no physicians strongly disagreed.  For midlevel providers, a total 2 (33.3%) strongly 
agreed, 3 (50.0%) agreed, 0 (0.0%) were neutral, while 1 (16.7%) disagreed, and no 
midlevel providers strongly disagreed.  Regarding pharmacists, a total of 3 (37.5%) 
strongly agreed, 1 (12.5%) agreed, 0 (0.0%) were neutral, while 4 (50.0%) disagreed 
with the statement, and no pharmacists strongly disagreed.  Among all prescribers, 11 
(36.7%) prescribers strongly agreed, 10 (33.3%) agreed, 1 (3.3%) was neutral, while 8 
(26.7%) disagreed with the statement, and no prescribers strongly disagreed. 
For the final statement, “In my role as a medication prescriber, I consider the 
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opportunity for new treatment options when adding or expanding the use of a hospital 
formulary medication.”  For physicians total of 4 (25.0%) indicated strong agreement, 9 
(56.3%) indicated agreement, 2 (12.5%) indicated a response of neutral, 1 (6.3%) 
disagreed, and none strongly disagreed.  For midlevel providers, a total of 2 (33.3%) 
indicated strong agreement, 4 (66.7%) indicated agreement, none indicated a response 
of neutral, none disagreed, and none strongly disagreed.  For pharmacists, a total of 3 
(37.5%) indicated strong agreement, 4 (50.0%) indicated agreement, 1 (12.5%) 
indicated a response of neutral, none disagreed, and none strongly disagreed.  Among 
all prescribers, a total of 9 (30.0%) indicated strong agreement, 17 (56.7%) indicated 
agreement, 3 (10.0%) indicated a response of neutral, 1 (3.3%) disagreed, and none 
strongly disagreed. 
In the following sections, the research questions and hypotheses are address by 
the three prescriber groups studied. 
 
Group 1:  Physician 
Q1:  What is the ranked order of factor that influence hospital formulary decision-
making? 
   
Table 4 indicates the total number of physician participants is 16 (n=16).  For 
physicians, the highest level of agreement with an average of 4.38 (SD=0.62) was in 
response to the statement, “I rely upon the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations (e.g. Drug Monograph, Medication Use 
Evaluation, etc.) to make hospital medication formulary decisions.”  By reviewing the 
frequencies in Table 3, physicians indicating they strongly agreed was 7 (43.8%), those 
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who agreed were 8 (50.0%), 1 (6.3%) was neutral, and 0 (0.0%) disagreed or strongly 
disagreed with this statement.   
The second highest level of agreement with an average of 4.25 (SD=0.68) was in 
response to the statement “I rely upon the evaluation of medications by expert 
physicians to make hospital medication formulary decisions.”  For this hospital formulary 
decision-making statement, 6 (37.5%) physicians strongly agreed with the statement 
while 8 (50.0%) agreed with the statement.  Therefore, 14 (87.5%) of physicians either 
strongly agreed or agreed with this statement.  A total of 2 (12.5%) indicated a response 
of neutral and no physicians disagreed or strongly disagreed with the statement.   
The third highest level of agreement with a mean of 4.00 (SD=0.82) was in 
response to the statement, “In my role as a medication prescriber, I consider the 
opportunity for new treatment options when adding or expanding the use of a hospital 
formulary medication.”  A total of 4 (25.0%) indicated strong agreement, 9 (56.3%) 
indicated agreement, 2 (12.5%) indicated a response of neutral, 1 (6.3%) disagreed, 
and none strongly disagreed.   
The fourth highest level of agreement with a mean of 3.94 (SD=1.12) was related 
to the statement “I consider the financial impact of the treatment to the patient in terms 
of the out-of-pocket expenses they may incur when making hospital medication 
formulary decisions.”  A total 6 (37.5%) physicians strongly agreed, 6 (37.5%) agreed, 1 
(6.3%) was neutral, while 3 (18.8%) disagreed with the statement, and no physicians 
strongly disagreed.   
The fifth level of agreement with a mean of 3.69 (SD=1.20) was in response to 
the statement “I rely upon my individual evaluation of medical evidence to make hospital 
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medication formulary decisions.”  A total of 3 (18.8%) of prescribers strongly agreed, 9 
(56.3%) agreed, 2 (12.5%) were neutral, none selected disagree, and 2 (12.5%) 
strongly disagreed.   
The sixth level of agreement with a mean of 3.63 (SD=0.96) was to the statement 
“I consider the financial impact of the treatment to the institution in terms of drug cost 
and potential reimbursement when making hospital medication formulary decisions.”  A 
total of 2 (12.5%) of physicians strongly agreed, 9 (56.3%) agreed, 2 (12.5%) were 
neutral, and 3 (18.8%) disagreed with the statement.   
The seventh statement with the lowest level of agreement at 3.56 (SD=1.03) was 
to the statement, “I consider the number of patients affected by adding, removing, or 
modifying a drug on the formulary when making a hospital medication formulary 
decision.”  A total of 2 (12.5%) physicians strongly agreed, 9 (56.3%) agreed, 1 (6.3%) 
was neutral, 4 (25.0%) disagreed, and none strongly disagreed with the statement. 
 
Physician Hypotheses 
Hypothesis 1.1: “For physicians, individual evaluation of medical evidence has a 
lower ranking of influence on hospital formulary decision-making than does the 
evaluation of medications by expert physicians.”   
 
By reviewing of the mean value order presented in Table 4, the statement “I rely 
upon my individual evaluation of medical evidence to make hospital medication 
formulary decisions” was fifth in terms of agreement score with a mean of 3.69 
(SD=1.20).  In response to the statement “I rely upon the evaluation of medications by 
expert physicians to make hospital medication formulary decisions,” this statement was 
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ranked second based on the Likert scale with a mean of 4.25 (SD=0.68).  Therefore, 
this hypothesis is accepted. 
Hypothesis 1.2: “The evaluation of medications by expert physicians has a higher 
ranking of influence on hospital formulary decision-making than does the 
pharmacy staff’s evaluation of medical evidence including formulary 
recommendations.”   
 
By reviewing of the sorted mean values in Table 4, the statement “I rely upon the 
evaluation of medications by expert physicians to make hospital medication formulary 
decisions,” this statement was ranked second based on the Likert scale with a mean of 
4.25 (SD=0.68).  However, in response to the statement “I rely upon the pharmacy 
staff’s evaluation of medical evidence including formulary recommendations (e.g. Drug 
Monograph, Medication Use Evaluation, etc.) to make hospital medication formulary 
decisions,” this statement was first in terms of agreement score with a mean of 4.38 
(SD=0.62).  This hypothesis for physicians is rejected. 
Hypothesis 1.3: “For physicians, pharmacy staff’s evaluation of medical evidence 
including formulary recommendations has a higher ranking of influence on 
hospital formulary decision-making than does the number of patients affected.”   
 
By reviewing the sorted mean scores in Table 4, in response to the statement “I 
rely upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions,” this statement was first in terms of agreement 
score with a mean of 4.38 (SD=0.62).  The statement “I consider the number of patients 
affected by adding, removing, or modifying a drug on the formulary when making 
hospital medication formulary decisions” was ranked last or seventh with a mean score 
of 3.26 (SD=1.03).  Consequently, this hypothesis is accepted. 
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Hypothesis 1.4:  “For physicians, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the institution.”   
 
Upon evaluation of the sorted mean scores in Table 4, in response to the 
statement, “I rely upon the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to 
make hospital medication formulary decisions,” for physicians this statement was first in 
terms of agreement score with a mean of 4.38 (SD=0.62).  For the corresponding 
statement, “I consider the financial impact of the treatment to the institution in terms of 
drug cost and potential reimbursement when making hospital medication formulary 
decisions,” the statement was ranked sixth with a mean agreement score of 3.63 
(SD=0.96).  As a result, this hypothesis is accepted. 
Hypothesis 1.5: “For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the patient.”   
 
The sorted mean scores in Table 4, indicate in response to the statement “I rely 
upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions,” this statement was first in terms of agreement 
score with a mean of 4.38 (SD=0.62).  The statement “I consider the financial impact of 
the treatment to the patient in terms of the out-of-pocket expenses they may incur when 
making hospital medication formulary decisions” has a ranking of fourth with a mean of 
3.94 (SD=1.12).  Therefore, this hypothesis is accepted. 
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Hypothesis 1.6: “For physicians, individual evaluation of medical evidence has a 
higher ranking of influence on hospital formulary decision-making than does the 
opportunity for new treatment options.”   
 
By reviewing of the mean value order presented in Table 4, the statement “I rely 
upon my individual evaluation of medical evidence to make hospital medication 
formulary decisions” was fifth in terms of agreement score with a mean of 3.69 
(SD=1.20).  In response to the statement, “in my role as a medication prescriber, I 
consider the opportunity for new treatment options when adding or expanding the use of 
a hospital formulary medication,” this statement was ranked third based on the Likert 
scale with a mean of 4.00 (SD=0.82).  Therefore, this hypothesis is rejected for 
physicians.  
 
Group 2:  Midlevel Provider 
Q2:  What is the ranked order of factors that influence hospital formulary 
decision-making by midlevel providers?”   
 
For midlevel providers (n=6) as seen in Table 4, indicates the highest level of 
agreement with an average of 4.83 (SD=0.41) was in response to the statement, “I rely 
upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions.”  By reviewing the frequencies in Table 3, 
midlevel providers indicating they strongly agreed was 5 (83.3%), those who agreed 
was 1 (16.7%), none were neutral, and none disagreed or strongly disagreed with this 
statement.   
The statement with the second highest level of agreement at 4.50 (SD=0.55) was 
to the statement, “I consider the number of patients affected by adding, removing, or 
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modifying a drug on the formulary when making a hospital medication formulary 
decision.”  A total of 3 (50.0%) of midlevel providers strongly agreed, 3 (50.0%) agreed, 
none were neutral, none disagreed, and none strongly disagreed with the statement.  
The third highest level of agreement 4.33 (SD=0.52) was with the statement, “In 
my role as a medication prescriber, I consider the opportunity for new treatment options 
when adding or expanding the use of a hospital formulary medication.”  A total of 2 
(33.3%) indicated strong agreement, 4 (66.7%) indicated agreement, none indicated a 
response of neutral, none disagreed, and none strongly disagreed.   
The fourth level of agreement with a mean of 4.17 (SD=0.41) was to the 
statement “I consider the financial impact of the treatment to the institution in terms of 
drug cost and potential reimbursement when making hospital medication formulary 
decisions.”  A total of 1 (16.7%) midlevel provider strongly agreed, 5 (83.3%) agreed, 
none were neutral, none disagreed, and none strongly disagreed with the statement.  
The fifth level of agreement with an average of 4.00 (SD=0.00) was in response 
to the statement “I rely upon the evaluation of medications by expert physicians to make 
hospital medication formulary decisions.”  For this hospital formulary decision-making 
statement, all 6 (100.0%) agreed with the statement.  No other agreement levels were 
selected.   
The sixth level of agreement is tied with a mean of 4.00 (SD=1.10) to the 
previous statement.  This mean value is related to the statement “I consider the financial 
impact of the treatment to the patient in terms of the out-of-pocket expenses they may 
incur when making hospital medication formulary decisions.”  A total 2 (33.3%) midlevel 
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providers strongly agreed, 3 (50.0%) agreed, 0 (0.0%) were neutral, while 1 (16.7%) 
disagreed, and no midlevel providers strongly disagreed.   
The seventh and lowest level of agreement for midlevel providers with a mean of 
3.83 (SD=0.41) was in response to the statement “I rely upon my individual evaluation 
of medical evidence to make hospital medication formulary decisions.”  For this 
statement, none strongly agreed, a total of 5 (83.3%) of prescribers agreed, 1 (16.7%) 
was neutral, none selected disagree, and none strongly disagreed. 
 
Midlevel Provider Hypotheses 
Hypothesis 2.1: “For midlevel providers, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-making 
than does the evaluation of medications by expert physicians.”   
 
By reviewing of the mean value order presented in Table 4, the statement “I rely 
upon my individual evaluation of medical evidence to make hospital medication 
formulary decisions” was last or seventh in terms of agreement score with a mean of 
3.83 (SD=0.41).  In response to the statement “I rely upon the evaluation of medications 
by expert physicians to make hospital medication formulary decisions,” this statement 
was ranked fifth based on the Likert scale with a mean of 4.00 (SD=0.00).  Therefore, 
this hypothesis is accepted for midlevel providers. 
Hypothesis 2.2: “For midlevel providers, the evaluation of medications by expert 
physicians has a higher ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations.”   
 
By reviewing of the sorted mean values in Table 4, the statement “I rely upon the 
evaluation of medications by expert physicians to make hospital medication formulary 
decisions,” this statement was ranked fifth based on the Likert scale with a mean of 4.00 
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(SD=0.00).  However, in response to the statement “I rely upon the pharmacy staff’s 
evaluation of medical evidence including formulary recommendations (e.g. Drug 
Monograph, Medication Use Evaluation, etc.) to make hospital medication formulary 
decisions,” this statement was first in terms of agreement score with a mean of 4.83 
(SD=0.41).  This hypothesis for midlevel providers is rejected. 
Hypothesis 2.3: “For midlevel providers, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the number of patients 
affected.”   
 
By reviewing the sorted mean scores in Table 4, in response to the statement “I 
rely upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions,” this statement was first in terms of agreement 
score with a mean of 4.83 (SD=0.41).  The statement “I consider the number of patients 
affected by adding, removing, or modifying a drug on the formulary when making a 
hospital medication formulary decision” was ranked second with a mean score of 4.50 
(SD=0.55).  Consequently, this hypothesis is accepted. 
Hypothesis 2.4: “For midlevel providers, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the institution.”   
 
Upon evaluation of the sorted mean scores in Table 4, in response to the 
statement “I rely upon the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to 
make hospital medication formulary decisions,” for physicians this statement was first in 
terms of agreement score with a mean of 4.83 (SD=0.41).  For the corresponding 
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statement, “I consider the financial impact of the treatment to the institution in terms of 
drug cost and potential reimbursement when making hospital medication formulary 
decisions,” the statement was ranked fourth with a mean agreement score of 4.17 
(SD=0.41).  As a result, this hypothesis is accepted. 
Hypothesis 2.5: “For midlevel providers, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the patient.”   
 
The sorted mean scores in Table 4, indicate in response to “I rely upon the 
pharmacy staff’s evaluation of medical evidence including formulary recommendations 
(e.g. Drug Monograph, Medication Use Evaluation, etc.) to make hospital medication 
formulary decisions”, this statement was first in terms of agreement score with a mean 
of 4.83 (SD=0.41).  The statement “I consider the financial impact of the treatment to the 
patient in terms of the out-of-pocket expenses they may incur when making hospital 
medication formulary decisions” has a ranking of sixth with a mean of 4.00 (SD=1.10).  
Therefore, this hypothesis is accepted for midlevel providers. 
Hypothesis 2.6: “For midlevel providers, “individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-making 
than does the opportunity for new treatment options.”   
 
By reviewing of the mean value order presented in Table 4, the statement “I rely 
upon my individual evaluation of medical evidence to make hospital medication 
formulary decisions” was seventh or last in terms of agreement score with a mean of 
3.83 (SD=0.41).  In response to the statement, “in my role as a medication prescriber, I 
consider the opportunity for new treatment options when adding or expanding the use of 
a hospital formulary medication,” this statement was ranked third based on the Likert 
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scale with a mean of 4.33 (SD=0.52).  Therefore, this hypothesis is rejected for midlevel 
providers. 
 
Group 3:  Pharmacist 
Q3: “What is the ranked order of factors that influence hospital formulary 
decision-making by pharmacists?”   
 
For pharmacists (n=8) referring to Table 4 indicates the highest level of 
agreement with an average of 4.38 (SD=0.74) was in response to the statement, “I 
consider the financial impact of the treatment to the institution in terms of drug cost and 
potential reimbursement when making hospital medication formulary decisions.”  A total 
of 4 (50.0%) pharmacists strongly agreed, 3 (37.5%) agreed, 1 (12.5%) was neutral, 
none disagreed, and none strongly disagreed with the statement.   
The second highest level of agreement 4.25 (SD=0.71) was with the statement, 
“In my role as a medication prescriber, I consider the opportunity for new treatment 
options when adding or expanding the use of a hospital formulary medication.”  A total 
of 3 (37.5%) indicated strong agreement, 4 (50.0%) indicated agreement, 1 (12.5%) 
indicated a response of neutral, none disagreed, and none strongly disagreed.   
The third factor in terms of pharmacists’ level of agreement with a mean of 4.13 
(SD=1.36) was to the statement, “I rely upon the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations (e.g. Drug Monograph, Medication Use 
Evaluation, etc.) to make hospital medication formulary decisions.”  By reviewing the 
frequencies in Table 3, pharmacists indicating they strongly agreed was 4 (50.0%), 3 
(37.5%) agreed, none were neutral, none disagreed, and 1 (12.5%) strongly disagreed 
with this statement.   
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The fourth level of agreement with an average of 3.50 (SD=0.93) was in 
response to the statement “I rely upon the evaluation of medications by expert 
physicians to make hospital medication formulary decisions.”  For this hospital formulary 
decision-making statement, 1 (12.5%) pharmacist strongly agreed, 3 (37.5%) agreed, 3 
(37.5%) were neutral, 1 (12.5%) agreed, and none strongly disagreed with the 
statement.   
The fifth level of agreement is tied with the fourth with an average of 3.50 
(SD=0.76) was in response to the statement, “I consider the number of patients affected 
by adding, removing, or modifying a drug on the formulary when making a hospital 
medication formulary decision.”  For this hospital formulary decision-making statement, 
0 (0.0%) pharmacists strongly agreed with the statement, 5 (62.5%) agreed, 2 (25.0%) 
were neutral, 1 (12.5%) disagreed, and none strongly disagreed with the statement.     
The next to last, or sixth level of agreement, with a mean of 3.38 (SD=1.51) was 
related to the statement “I consider the financial impact of the treatment to the patient in 
terms of the out-of-pocket expenses they may incur when making hospital medication 
formulary decisions.”  A total 3 (37.5%) pharmacists strongly agreed, 1 (12.5%) agreed, 
0 (0.0%) were neutral, while 4 (50.0%) disagreed with the statement, and no 
pharmacists strongly disagreed.   
The seventh and lowest level of agreement for pharmacists with a mean of 2.88 
(SD=1.36) was in response to the statement “I rely upon my individual evaluation of 
medical evidence to make hospital medication formulary decisions.”  For this statement, 
1 (12.5%) strongly agreed, a total of 2 (25.0%) of prescribers agreed, 1 (12.5%) was 




Hypothesis 3.1: “For pharmacists, individual evaluation of medical evidence has 
a lower ranking of influence on hospital formulary decision-making than does the 
evaluation of medications by expert physicians.” 
 
By reviewing of the mean value order presented in Table 4, the statement “I rely 
upon my individual evaluation of medical evidence to make hospital medication 
formulary decisions” was last or seventh in terms of agreement score with a mean of 
2.88 (SD=1.36).  In response to the statement “I rely upon the evaluation of medications 
by expert physicians to make hospital medication formulary decisions,” this statement 
was ranked fourth based on the Likert scale with a mean of 3.50 (SD=0.93).  Therefore, 
this hypothesis is accepted for pharmacists. 
Hypothesis 3.2: “For pharmacists the evaluation of medications by expert 
physicians has a lower ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations.”   
 
By reviewing of the sorted mean values in Table 4, the statement “I rely upon the 
evaluation of medications by expert physicians to make hospital medication formulary 
decisions,” this statement was ranked fourth based on the Likert scale with a mean of 
3.50 (SD=0.93).  However, in response to the statement “I rely upon the pharmacy 
staff’s evaluation of medical evidence including formulary recommendations (e.g. Drug 
Monograph, Medication Use Evaluation, etc.) to make hospital medication formulary 
decisions,” this statement was third in terms of agreement score with a mean of 4.13 
(SD=1.36).  This hypothesis for pharmacists is accepted. 
Hypothesis 3.3: “For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the number of patients 




By reviewing the sorted mean scores in Table 4, in response to the statement “I 
rely upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions,” this statement was third in terms of agreement 
score with a mean of 4.13 (SD=1.36).  The statement “I consider the number of patients 
affected by adding, removing, or modifying a drug on the formulary when making 
hospital medication formulary decisions” was tied for the fourth position with a mean 
score of 3.50 (SD=0.76).  Consequently, this hypothesis is accepted. 
Hypothesis 3.4: “For pharmacists, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the institution.”   
 
Upon evaluation of the sorted mean scores in Table 4, in response to the 
statement “I rely upon the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to 
make hospital medication formulary decisions,” for pharmacists this statement was third 
in terms of agreement score with a mean of 4.13 (SD=1.36).  For the corresponding 
statement, “I consider the financial impact of the treatment to the institution in terms of 
drug cost and potential reimbursement when making hospital medication formulary 
decisions,” the statement was ranked first with a mean agreement score of 4.38 
(SD=0.74).  As a result, this hypothesis is rejected. 
Hypothesis 3.5: “For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 




The sorted mean scores in Table 4, indicate in response to the statement “I rely 
upon the pharmacy staff’s evaluation of medical evidence including formulary 
recommendations (e.g. Drug Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions,” this statement was third in terms of agreement 
score with a mean of 4.13 (SD=1.36).  The statement “I consider the financial impact of 
the treatment to the patient in terms of the out-of-pocket expenses they may incur when 
making hospital medication formulary decisions” has a ranking of sixth with a mean of 
3.38 (SD=1.51).  Therefore, this hypothesis is accepted for pharmacists. 
Hypothesis 3.6: “For pharmacists, “individual evaluation of medical evidence has 
a higher ranking of influence on hospital formulary decision-making than does the 
opportunity for new treatment options.”   
 
By reviewing of the mean value order presented in Table 4, the statement “I rely 
upon my individual evaluation of medical evidence to make hospital medication 
formulary decisions” was seventh or last in terms of agreement score with a mean of 
2.88 (SD=1.36).  In response to the statement, “in my role as a medication prescriber, I 
consider the opportunity for new treatment options when adding or expanding the use of 
a hospital formulary medication,” this statement was ranked second based on the Likert 




Although no research questions or hypotheses were stated for all prescribers 
irrespective of provider type, the following results provide the ranked order of the 
decision-making statements across all prescriber groups.  This provides insight into the 
89 
 
factors with the highest to the lowest agreement level across all three prescriber groups 
and for the P&T committee analyzed in its entirety.   
For all prescribers surveyed comprised of physicians, midlevel providers, and 
pharmacists (n=30) Table 4 indicates the highest level of agreement with an average of 
4.40 (SD=0.86) in response to the statement, “I rely upon the pharmacy staff’s 
evaluation of medical evidence including formulary recommendations (e.g. Drug 
Monograph, Medication Use Evaluation, etc.) to make hospital medication formulary 
decisions.”  By reviewing the frequencies in Table 3, prescribers indicating they strongly 
agreed was 16 (53.3%), those who agreed were 12 (40.0%), 1 (3.3%) was neutral, and 
none disagreed, and 1 (3.3%) strongly disagreed with this statement.   
The second highest level of agreement 4.13 (SD=0.73) was with the statement, 
“In my role as a medication prescriber, I consider the opportunity for new treatment 
options when adding or expanding the use of a hospital formulary medication.”  A total 
of 9 (30.0%) indicated strong agreement, 17 (56.7%) indicated agreement, 3 (10.0%) 
indicated a response of neutral, 1 (3.3%) disagreed, and none strongly disagreed.   
The third highest level of agreement with an average of 4.13 (SD=0.73) was in 
response to the statement “I rely upon the evaluation of medications by expert 
physicians to make hospital medication formulary decisions.”  For this hospital formulary 
decision-making statement, 7 (23.3%) prescribers strongly agreed with the statement 
while 17 (56.7%) agreed with the statement.  A total of 5 (16.7%) indicated a response 
of neutral, 1 (3.3%) prescriber disagreed, and none strongly disagreed with the 
statement.   
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The fourth level of agreement with a mean of 3.93 (SD=0.87) was to the 
statement “I consider the financial impact of the treatment to the institution in terms of 
drug cost and potential reimbursement when making hospital medication formulary 
decisions.”  A total of 7 (23.3%) of prescribers strongly agreed, 17 (56.7%) agreed, 3 
(10.0%) were neutral, and 3 (10.0%) disagreed, and none strongly disagreed with the 
statement.   
The fifth highest level of agreement with a mean of 3.80 (SD=1.21) was related to 
the statement “I consider the financial impact of the treatment to the patient in terms of 
the out-of-pocket expenses they may incur when making hospital medication formulary 
decisions.”  A total 11 (36.7%) prescribers strongly agreed, 10 (33.3%) agreed, 1 (3.3%) 
was neutral, while 8 (26.7%) disagreed with the statement, and no prescribers strongly 
disagreed.   
The sixth statement with a mean level of agreement at 3.73 (SD=0.94) was to the 
statement, “I consider the number of patients affected by adding, removing, or modifying 
a drug on the formulary when making a hospital medication formulary decision.”  A total 
of 5 (16.7%) prescribers strongly agreed, 17 (56.7%) agreed, 3 (10.0%) were neutral, 5 
(16.7%) disagreed, and none strongly disagreed with the statement.   
The seventh and lowest level of agreement with a mean of 3.50 (SD=1.17) was 
in response to the statement “I rely upon my individual evaluation of medical evidence 
to make hospital medication formulary decisions.”  A total of 4 (13.3%) of prescribers 
strongly agreed, 16 (53.3%) agreed, 4 (13.3%) were neutral, 3 (10%) selected disagree, 






Prescriber Group Means and Standard Deviations for Decision-Making Factor 
Statements (Physician n=16, Midlevel Provider n=6, Pharmacist n=8, All Prescribers 
n=30) 
 
 M SD 
Physician 
1) pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 4.38 0.62 
2) evaluation of medications by expert physicians 4.25 0.68 
3) opportunity for new treatment options 4.00 0.82 
4) financial impact of the treatment to the patient 3.94 1.12 
5) individual evaluation of medical evidence 3.69 1.20 
6) financial impact of the treatment to the institution 3.63 0.96 
7) number of patients affected  3.56 1.03 
Midlevel Provider 
1) pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 4.83 0.41 
2) number of patients affected 4.50 0.55 
3) opportunity for new treatment options 4.33 0.52 
4) financial impact of the treatment to the institution 4.17 0.41 
5) evaluation of medications by expert physicians 4.00 0.00 
5) financial impact of the treatment to the patient 4.00 1.10 
6) individual evaluation of medical evidence 3.83 0.41 
Pharmacist 
1) financial impact of the treatment to the institution 4.38 0.74 
2) opportunity for new treatment options 4.25 0.71 
3) pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 4.13 1.36 
4) evaluation of medications by expert physicians 3.50 0.93 
4) number of patients affected 3.50 0.76 
5) financial impact of the treatment to the patient 3.38 1.51 




 M SD 
All Prescribers 
1) pharmacy staff’s evaluation of medical evidence including formulary 
   recommendations 4.40 0.86 
2) opportunity for new treatment options 4.13 0.73 
3) evaluation of medications by expert physicians 4.00 0.74 
4) financial impact of the treatment to the institution 3.93 0.87 
5) financial impact of the treatment to the patient 3.80 1.21 
6) number of patients affected 3.73 0.94 
7) individual evaluation of medical evidence 3.50 1.17 
Note.  M = mean; SD = standard deviation.  For midlevel providers, two factors are ranked fifth with 






In addition to the descriptive statistical analyses performed previously, inferential 
statistics were performed using data obtained from Part II of the online survey.  These 
analyses were performed to determine if statistically significant differences exist 
between the prescriber groups and the seven decision-making factors identified from 
the literature.  As stated previously, Part II of the survey posed independent questions 
to the prescribers with level of agreement responses measured on a 5-point Likert 
scale.   
The data for this study have several characteristics that must be understood in 
order to select the most appropriate statistical tests.  Most importantly, the study data 
are not normally distributed.  Normal distribution of the data was tested using SPSS© 
(2017) statistical software to produce values using the Kolmogorov-Shmirnov and 
Shapiro-Wilk tests for normality (Lund Research Ltd., Laerd Statistics , 2013c).  For all 
independent variables associated with the seven decision-making factors in both Part II 
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and Part III of the survey, the Kolmogorov-Shmirnov and Shapiro-Wilk tests for 
normality indicate values less than 0.05, in most cases 0.00, indicating that the data are 
not normally distributed.  The next consideration is that the sample size for this study is 
small.  The data are comprised of only 30 participants made up of 16 physicians, 6 
midlevel providers, and 8 pharmacists.  Furthermore, the dependent variable is 
categorical while the independent variables for the decision-making factors are ordinal 
for Part II and Part III of the survey.  Specifically, the data collected for both Part II is 
measured on a 5-point ordinal Likert scale while Part III was measured on a 7-point 
ordinal ranking scale.   
According to Laerd Statistics (Lund Research Ltd., Laerd Statistics, 2013b) 
traditional analysis of variance statistical tests such as ANOVA tolerate some violations 
of normality.  However, the normality issue is exacerbated when combined with a small 
sample size.  Therefore, since the study data are not normally distributed and the 
sample size is small, traditional ANOVA statistical tests were not appropriate. 
Nonparametric statistical methods provide an alternative as they do not require 
the normality assumption to be met.  Furthermore, certain nonparametric tests are also 
appropriate for small data sets.  Upon review of the various nonparametric statistical 
tests, it was determined that the most appropriate statistical tests considering the 
characteristics of the study data is the Kruskal-Wallace H Test, also known as a one-
way analysis of variance for ranking (Lund Research Ltd., Laerd Statistics, 2013a; 
Hinkle, Wiersma, & Jurs, 2003). 
Hinkle, Wiersma, and Jurs (2003), indicate that the Kruskal-Wallis test is 
appropriate for ordinal data with K-Sample cases.  As stated previously, the dependent 
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variable or K-Sample cases for this study is categorical consisting of physicians, 
midlevel providers, and pharmacists.  According to Lund Research Ltd., Laerd Statistics 
(2013a), the Kruskal-Wallis H test is appropriate if four assumptions are met:  1) the 
dependent variable should be measured at the ordinal or continuous level, 2) the 
independent variable should consist of two or more categorical, independent groups, 3) 
independence of observations, which means there is no relationship between the 
observations in each group, and 4) the distribution of scores for each group of the 
independent variable should have the same shape (which means the same variability).  
For these study data, all four of these assumptions are met.  A statistical test was 
performed to determine if assumption of homogeneity of variance was met.  To 
determine if the homogeneity of variance assumption is met, SPSS was used to 
compute the Levene Statistic (Lund Research Ltd., Laerd Statistics, 2013a; Hinkle, 
Wiersma, & Jurs, 2003).  The Levene statistic may be used to determine the 
Homogeneity of Variance for the various independent variables.   
Table 5 provides the results of Levene’s test for homogeneity of variance.  Upon 
review of the data in Table 5, one variable does not meet the homogeneity of variance 
requirement.  For the decision-making statement “I rely upon the evaluation of 
medications by expert physicians to make hospital medication formulary decisions,” the 
Levene p value is 0.002 which is < 0.05.  Therefore, the null hypothesis for the Levene 
test is rejected for this decision-making statement and the assumption of homogeneity 
of variance is not met.  Therefore, this independent variable will be ignored should a 
Kruskal-Wallis H test determine that a statistically significant difference exist between 




Levene’s Homogeneity of Variance Test for Decision-Making Factor Statements 
Decision-making Factor Statement Levene Statistic df1 df2 p 
I rely upon my individual evaluation of medical 
evidence to make hospital medication formulary 
decisions 
2.574 2 27 0.095 
I rely upon the pharmacy staff’s evaluation of 
medical evidence including formulary 
recommendations (e.g. Drug Monograph, 
Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions 
2.107 2 27 0.141 
I rely upon the evaluation of medications by 
expert physicians to make hospital medication 
formulary decisions 
8.100 2 27 0.002 
I consider the number of patients affected by 
adding, removing, or modifying a drug on the 
formulary when making a hospital medication 
formulary decisions 
1.657 2 27 0.209 
I consider the financial impact of the treatment 
to the institution in terms of drug cost and 
potential reimbursement when making hospital 
medication formulary decisions 
2.554 2 27 0.096 
I consider the financial impact of the treatment 
to the patient in terms of the out-of-pocket 
expenses they may incur when making hospital 
medication formulary decisions 
2.446 2 27 0.106 
In my role as a medication prescriber, I consider 
the opportunity for new treatment options when 
adding or expanding the use of a hospital 
formulary medication 
0.093 2 27 0.912 
Note.  df = degrees of freedom; p = p statistic for Levene’s test.  For the decision-making statement “I rely 
upon the evaluation of medications by expert physicians to make hospital medication formulary 
decisions,” the Levene p value is 0.002 which is < 0.05.  Therefore, the null hypothesis for the Levene test 
is rejected for this statement and the assumption of homogeneity of variance is not met. 
 
Table 6 provides the results of the independent samples Kruskal-Wallis H test 
obtained by running the test using SPSS© (2017) statistical software.  Upon review of 
Table 6, one of the variables indicates a statistically significant difference between the 
three groups of providers.  For the hospital formulary decision-making factor, “I consider 
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the number of patients affected by adding, removing, or modifying a drug on the 
formulary when making hospital medication formulary decisions,” a Kruskal-Wallis H 
test indicated a statistically significant difference in mean agreement score between the 
prescriber groups α = 0.05, X2 = 6.055, p = 0.048.  The mean rank agreement score for 
is 14.25 for physicians, 22.50 for midlevel providers, and 12.75 for pharmacists. No 
other decision-making factors for Part II of the survey indicate a statistically significant 
difference in agreement scores between the prescriber groups based on the results of 
the Kruskal-Wallis H test. 
Table 6 
Kruskal-Wallis H Test Results for Hospital Formulary Decision-making Statements 
Hospital Formulary Decision-making Statement X2 df p 
I rely upon my individual evaluation of medical evidence to 
make hospital medication formulary decisions 2.846 2 0.241 
I rely upon the pharmacy staff’s evaluation of medical 
evidence including formulary recommendations (e.g. Drug 
Monograph, Medication Use Evaluation, etc.) to make 
hospital medication formulary decisions 
2.695 2 0.260 
I rely upon the evaluation of medications by expert 
physicians to make hospital medication formulary decisions 4.859 2 0.088 
I consider the number of patients affected by adding, 
removing, or modifying a drug on the formulary when 
making a hospital medication formulary decisions 
6.055 2 0.048 
I consider the financial impact of the treatment to the 
institution in terms of drug cost and potential 
reimbursement when making hospital medication formulary 
decisions 
4.389 2 0.111 
I consider the financial impact of the treatment to the 
patient in terms of the out-of-pocket expenses they may 
incur when making hospital medication formulary decisions 
0.669 2 0.716 
In my role as a medication prescriber, I consider the 
opportunity for new treatment options when adding or 
expanding the use of a hospital formulary medication 
0.902 2 0.637 
Note.  X2 = chi square, df = degrees of freedom; p = p statistic for Kruskal-Wallis H test.  For the decision-
making statement “I consider the number of patients affected by adding, removing, or modifying a drug on 
the formulary when making hospital medication formulary decisions”, the p value is 0.048 which is < 
0.050.  Therefore, the null hypothesis for the Kruskal-Wallis H test is rejected for this statement. 
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Survey – Part III 
In Part III of the survey, prescribers were asked to rank each of the seven 
hospital formulary decision-making factors in relationship to each other.  The ranking 
used a 7-point scale with a value of 1 assigned for the most important factor to 7 for the 
least important factor.  SPSS© (2017) statistical software was used to compute 
frequencies, means, and standard deviations values for each response.  The responses 
where then categorized by prescriber group.  The associated ordered ranking for each 
prescriber group was determined by sorting the mean values for each group from the 
lowest mean to the highest mean.  This ranked order was then used to address the 
research questions and hypotheses for each of the three prescriber groups.   
Table 7 presents the frequencies of responses to the ranking of each of the 
decision-making factors by each prescriber group followed by the aggregate 
frequencies for all prescribers.  For the factor, “Individual evaluation of medical 
evidence,” a total of 6 (37.5%) physicians ranked this as the most important factor, 1 
(6.3%) ranked it second, 3 (18.8%) ranked it third.  Physicians raking it fourth was 1 
(6.3%), fifth 2 (12.5%), none ranked it sixth, and 3 (18.8%) ranked it least important or 
seventh.  A total of 0 (0.0%) midlevel providers ranked this as the most important factor, 
1 (16.7%) ranked it second, 2 (33.3%) ranked it third.  Midlevel providers raking it fourth 
was 0 (0.0%), fifth 0 (0.0%), while 2 (33.3%) ranked it sixth, and 1 (16.7%) ranked it 
least important or seventh.  For all prescribers, 7 (23.3%) prescribers ranked this factor 
as most important while 4 (13.3%) ranked the factor second.  A total of 6 (20.0%) 
ranked it third, 2 (6.7%) ranked it fourth, 3 (10.0%) ranked it fifth, 2 (6.7%) ranked it 
sixth, and 6 (20.0%) of prescribers ranked it seventh or last. 
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For the factor, “pharmacy staff’s evaluation of medical evidence including 
formulary recommendations” the following were the frequencies for physicians.  By 
reviewing the frequencies in Table 7, 5 (31.3%) ranked it first, those who ranked it as 
the second most important was 6 (37.5%), and 3 (18.8%) ranked the factor third.  The 
number of physicians ranking it fourth was 1 (6.3%), fifth most important was 1 (6.3%), 
0 (0.0%) ranked it sixth, and 0 (0.0%) ranked it last or least important.  The number of 
midlevel providers who deemed this as the most important factor was 4 (66.7%), those 
who ranked it as the second most important was 1 (16.7%), and 0 (0.0%) ranked the 
factor third.  The number of midlevel providers ranking it fourth was 1 (16.7%), none 0 
(0.0%) ranked it fifth, sixth, or seventh.  The number of pharmacists who deemed this as 
the most important factor was 5 (62.5%), those who ranked it as the second most 
important was 2 (25.0%), and 1 (12.5%) ranked the factor third.  The number of 
pharmacists ranking it fourth, fifth, sixth, or last was 0 (0.0%).  For all prescribers, those 
ranking this factor first was 14 (46.67%), second were 9 (30.0%), and third were 4 
(13.3%).  A total of 2 (6.7%) ranked the factor fourth, 1 (3.3%) ranked it fifth, and 0 
(0.0%) ranked it sixth or seventh. 
For the hospital formulary decision-making factor “Evaluation of medications by 
expert physicians,” 4 (25.0%) physicians ranked this as the most important factor while 
2 (12.5%) ranked it as the second most important factor.  Physicians ranking it third was 
6 (37.5%), fourth was 3 (18.8%).  Physicians ranking it fifth was 1 (6.3%), while none 0 
(0.0%) ranked it sixth or seventh.  For midlevel providers, 1 (16.7%) ranked this as the 
most important factor while 2 (33.3%) ranked it as the second most important factor.  
Midlevel providers ranking it third was 1 (16.7%), fourth was 1 (16.7%).  No midlevel 
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providers ranked it fifth 0 (0.0%), while 1 (16.7%) ranked it sixth, and none 0 (0.0%) 
ranked it seventh.  Pharmacists frequencies were, 1 (12.5%) ranked this as the most 
important factor, 1 (12.5%) ranked it second, 2 (25.0%) ranked it third.  Pharmacists 
raking it fourth was 1 (12.5%), fifth 2 (25.0%), none ranked it sixth, and 1 (12.5%) 
ranked it least important or seventh.  For all prescribers, a total of 6 (20.0%) ranked this 
factor first, 5 (16.7%) second, 9 (30.0%) third, 5 (16.7%) fourth, 3 (10.0%) fifth, 1 (3.3%) 
sixth, and 1 (3.3%) seventh. 
For the decision-making factor “Number of patients affected by adding, removing, 
or modifying a formulary medication,” 1 (6.3%) physician considered this factor most 
important, 1 (6.3%) considered it second most important, 2 (12.5%) considered it third in 
importance, while 2 (12.5%) considered it fourth.  Finally, 5 (31.3%) considered it fifth, 3 
(18.8%) sixth, and 2 (12.5%) considered it the least most important hospital decision-
making factor.  For midlevel providers, those ranking it the most important factor was 0 
(0.00%), those ranking it second was 0 (0.0%), and third was 2 (33.3%).  This raking it 
fourth was 2 (33.3%), while 0 (0.0%) ranked it fifth, 0 (0.0%) ranked it sixth, and 2 
(33.3%) ranked it seventh or least important.  No pharmacists 0 (0.0%) ranked this 
factor first or most important, 0 (0.0%) ranked it second, 0 (0.0%) ranked it third, and 1 
(12.5%) ranked it fourth. In the last three ranking positions, 2 (25.0%) ranked it fifth, 3 
(37.5%) sixth, and 2 (25.0%) ranked it the factor they considered last.  Among all 
prescribers, 1 (3.3%) prescriber ranked the factor first, 1 (3.3%) second, 4 (13.3%) third, 
5 (16.7%) fourth.  Finally, 7 (23.3%) prescribers ranked the factor fifth, 6 (20.0%) sixth, 
with the same number 6 (20.0%) ranked the factor seventh or last. 
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For the factor, “Financial impact of treatment for the institution in terms of drug 
costs and potential reimbursement,” no physicians 0 (0.0%) ranked this factor first or 
most important, 1 (6.3%) ranked it second, 1 (6.3%) ranked it third, and 2 (12.5%) 
ranked it fourth. In the last three ranking positions, 2 (12.5%) ranked it fifth, 6 (37.5%) 
sixth, and 4 (25.0%) ranked it the factor they considered last.  For midlevel providers, a 
total of 0 (0.0%) considered this hospital formulary decision-making factor most 
important, 1 (16.7%) considered it second most important, 0 (0.0%) considered it third in 
importance, and 0 (0.0%) considered it fourth.  Finally, 5 (83.3%) considered it fifth, and 
none 0 (0.0%) considered it as the sixth or seventh in terms of ranking the hospital 
decision-making factors.  For pharmacists, 1 (12.5%) ranked this as the most important 
factor while 2 (25.0%) ranked it as the second most important factor.  Pharmacists 
ranking it third was 1 (12.5%), fourth was 3 (37.5%), 0 (0.0%) ranked it fifth or sixth, 
while 1 (12.5%) ranked it seventh.  For all prescribers, 1 (3.3%) ranked this factor first, 4 
(13.3%) second, 2 (6.7%) third, and 5 (16.7%) ranked the factor fourth.  In addition, 7 
(23.3%) prescribers ranked the factor fifth, 6 (20.0%) sixth, and 5 (16.7%) ranked it 
seventh or last. 
For the factor, “Financial impact of the treatment for the patient in terms of 
potential out-of-pocket expenses,” physicians raking this as the most important factor 
was 0 (0.00%), those ranking it second was 4 (25.0%), and third was 1 (6.3%).  No 
physicians 0 (0.0%) ranked it fourth, while 3 (18.8%) ranked it fifth, 4 (25.0%) ranked it 
sixth, and 4 (25.0%) ranked it seventh or least important.  According to Table 7, a total 
of 0 (0.0%) midlevel providers considered this hospital formulary decision-making factor 
most important, 1 (16.7%) considered it second most important, 0 (0.0%) considered it 
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third in importance, and 0 (0.0%) considered it fourth.  Finally, 5 (83.3%) considered it 
fifth, and none 0 (0.0%) considered it as the sixth or seventh in terms of ranking the 
hospital decision-making factors.  Pharmacists raking this as the most important factor 
was 0 (0.0%), those ranking it second was also 0 (0.0%), and third were 2 (25.0%).  The 
number of pharmacists ranking it fourth was 1 (12.5%), 1 (12.5%) ranked it fifth, while 4 
(50.0%) ranked it sixth, and 0 (0.0%) ranked it seventh or least important.  Among all 
prescribers, a total of 0 (0.0%) prescribers ranked the factor first, 5 (16.7%) second, 4 
(13.3%) third, and 1 (3.3%) fourth.  In the last three positions, 4 (13.3%) prescribers 
ranked in fifth, 11 (36.7%) ranked it sixth, and 5 (16.7%) ranked it seventh. 
For the decision-making factor “Opportunity for new treatment options,” no 
physicians 0 (0.0%) ranked it first, 1 (6.3%) ranked it second, 0 (0.0%) ranked it third, 
and 7 (43.8%) ranked it fourth. A total of 2 (12.5%) physicians ranked it fifth, 3 (18.8%) 
sixth, and 3 (18.8%) ranked it last or seventh.  For midlevel providers, 1 (16.7%) ranked 
it first, 0 (0.0%) ranked it second, 0 (0.0%) ranked it third, and 2 (33.3%) ranked it 
fourth. A total of 1 (16.7%) midlevel provider ranked it fifth, 0 (0.0%) sixth, and 2 
(33.3%) ranked it last or seventh.  For pharmacists, 0 (0.0%) ranked it first, 1 (12.5%) 
ranked it second, 1 (12.5%) ranked it third, and 1 (12.5%) ranked it fourth. A total of 2 
(25.0%) ranked it fifth, 1 (12.5%) sixth, and 2 (25.0%) ranked it last or seventh.  For all 
prescribers, 1 (3.3%) prescriber ranked this factor first, 2 (6.7%) second, 1 (3.3%) third, 
while 10 (33.3%) ranked the factor fourth.  A total of 5 (16.7%) prescribers ranked it fifth, 






Prescriber Group Frequencies for Responses for Decision-Making Factor Ranking 




1 2 3 4 5 6 7 
Individual evaluation of medical evidence 
Physician 6 1 3 1 2 0 3 
Midlevel provider 0 1 2 0 0 2 1 
Pharmacist 1 2 1 1 1 0 2 
All prescribers 7 4 6 2 3 2 6 
pharmacy staff’s evaluation of medical evidence including formulary recommendations 
Physician 5 6 3 1 1 0 0 
Midlevel provider 4 1 0 1 0 0 0 
Pharmacist 5 2 1 0 0 0 0 
All prescribers 14 9 4 2 1 0 0 
Evaluation of medications by expert physicians 
Physician 4 2 6 3 1 0 0 
Midlevel provider 1 2 1 1 0 1 0 
Pharmacist 1 1 2 1 2 0 1 
All prescribers 6 5 9 5 3 1 1 
Number of patients affected by adding, removing, or modifying a formulary medication 
Physician 1 1 2 2 5 3 2 
Midlevel provider 0 0 2 2 0 0 2 
Pharmacist 0 0 0 1 2 3 2 
All prescribers 1 1 4 5 7 6 6 
Financial impact of the treatment for the institution in terms of drug costs and potential 
reimbursement 
Physician 0 1 1 2 2 6 4 
Midlevel provider 0 1 0 0 5 0 0 
Pharmacist 1 2 1 3 0 0 1 






1 2 3 4 5 6 7 
Financial impact of the treatment for the patient in terms of potential out-of-pocket expenses 
Physician 0 4 1 0 3 4 4 
Midlevel provider 0 1 1 0 0 3 1 
Pharmacist 0 0 2 1 1 4 0 
All prescribers 0 5 4 1 4 11 5 
Opportunity for new treatment options 
Physician 0 1 0 7 2 3 3 
Midlevel provider 1 0 0 2 1 0 2 
Pharmacist 0 1 1 1 2 1 2 
All prescribers 1 2 1 10 5 4 7 
 
Table 8 presents each prescriber group’s calculated average ranking and 
standard deviation values based on the 7-point ranking scale for each decision-making 
factor.  For the ranking scores, 1 is assigned for the factor considered most important 
while 7 is assigned to the factor deemed least important.  Therefore, the decision-
making factors in Table 8 are sorted in ascending order for each prescriber group.  In 
other words, the factor associated with the lowest mean ranking score and considered 
most important is listed first.  The factor with the highest mean raking score and 
considered least important is listed last.  Table 8 also provides the standard deviation 
for each factor across all prescriber groups with and the aggregate standard deviation 
for each factor for all prescribers.  Finally, SPSS© (2017) was used to perform inferential 
statistics namely, a Kruskal-Wallis H test, for the hospital formulary decision-making 




Physician Research Question 
Q1: “What is the ranked order of factors that influence hospital formulary 
decision-making by physicians?”    
 
Table 8 indicates the total number of physician participants is 16 (n=16), the 
factor with the highest ranking with an average of 2.19 (SD=1.17) was in ranking the 
factor, “pharmacy staff’s evaluation of medical evidence including formulary 
recommendations.”  By reviewing the frequencies in Table 7, the number of physicians 
who deemed this as the most important factor was 5 (31.3%), those who ranked it as 
the second most important was 6 (37.5%), and 3 (18.8%) ranked the factor third.  The 
number of physicians ranking it fourth was 1 (6.3%), fifth most important was 1 (6.3%), 
0 (0.0%) ranked it sixth, and 0 (0.0%) ranked it last or least important.   
The factor with the second highest level of agreement with an average of 2.69 
(SD=1.25) was in ranking the factor “evaluation of medications by expert physicians.”  
For this hospital formulary decision-making factor, 4 (25.0%) of physicians ranked this 
as the most important factor while 2 (12.5%) ranked it as the second most important 
factor.  Physicians ranking it third was 6 (37.5%), fourth was 3 (18.8%).  Physicians 
ranking it fifth was 1 (6.3%), while none 0 (0.0%) ranked it sixth or seventh.   
The third highest ranked factor with a mean of 3.25 (SD=2.32) was in response 
to the factor, “Individual evaluation of medical evidence.”  A total of 6 (37.5%) 
physicians ranked this as the most important factor, 1 (6.3%) ranked it second, 3 
(18.8%) ranked it third.  Physicians raking it fourth was 1 (6.3%), fifth 2 (12.5%), none 
ranked it sixth, and 3 (18.8%) ranked it least important or seventh.   
The fourth highest factor with a mean of 4.63 (SD=1.71) was related to the factor 
“number of patients affected.”  A total of 1 (6.3%) physicians considered this factor most 
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important, 1 (6.3%) considered it second most important, 2 (12.5%) considered it third in 
importance, while 2 (12.5%) considered it fourth.  Finally, 5 (31.3%) considered it fifth, 3 
(18.8%) sixth, and 2 (12.5%) considered it the least most important hospital decision-
making factor.   
The fifth ranked factor with a mean of 4.88 (SD=2.00) was the, “financial impact 
of treatment to the patient.”  Physicians raking this as the most important factor was 0 
(0.00%), those ranking it second was 4 (25.0%), and third was 1 (6.3%).  No physician 0 
(0.0%) ranked it fourth, while 3 (18.8%) ranked it fifth, 4 (25.0%) ranked it sixth, and 4 
(25.0%) ranked it seventh or least important. 
The factor ranked sixth for physicians with a mean of 4.94 (SD=1.44) was in 
response to the, “Opportunity for new treatment options.”  No physicians 0 (0.0%) 
ranked it first, 1 (6.3%) ranked it second, 0 (0.0%) ranked it third, and 7 (43.8%) ranked 
it fourth. A total of 2 (12.5%) physicians ranked it fifth, 3 (18.8%) sixth, and 3 (18.8%) 
ranked it last or seventh.   
The seventh factor ranked last with a mean of 5.44 (SD=1.50) was regarding the 
factor, “financial impact of treatment the treatment for the institution in terms of drug 
costs and potential reimbursement.”  No physicians 0 (0.0%) ranked this factor first or 
most important, 1 (6.3%) ranked it second, 1 (6.3%) ranked it third, and 2 (12.5%) 
ranked it fourth. In the last three ranking positions, 2 (12.5%) ranked it fifth, 6 (37.5%) 





Hypothesis 1.1: “For physicians, individual evaluation of medical evidence has a 
lower ranking of influence on hospital formulary decision-making than does the 
evaluation of medications by expert physicians.”   
 
By reviewing of the mean value order presented in Table 8, the factor “individual 
evaluation of medical evidence” was third in terms of its ranking with a mean of 3.25 
(SD=2.32).  In ranking the factor “evaluation of medications by expert physicians,” this 
factor was ranked second with a mean of 2.69 (SD=1.25).  Therefore, this hypothesis is 
accepted for physicians. 
Hypothesis 1.2: “For physicians, the evaluation of medications by expert 
physicians has a higher ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations.”   
 
By reviewing of the sorted mean values in Table 4, the factor which states, 
“evaluation of medications by expert physicians” was ranked second based on the 
ranking with a mean of 2.69 (SD=1.25).  However, in response to the factor “pharmacy 
staff’s evaluation of medical evidence including formulary recommendations”, this 
statement was first in terms of ranking with a mean of 2.19 (SD=1.17).  Therefore, this 
hypothesis for physicians is rejected. 
Hypothesis 1.3: “For physicians, pharmacy staff’s evaluation of medical evidence 
including formulary recommendations has a higher ranking of influence on 
hospital formulary decision-making than does the number of patients affected.”   
 
By reviewing the sorted mean scores in Table 8, by reviewing the order of the 
factor which states “pharmacy staff’s evaluation of medical evidence including formulary 
recommendations”, this factor was ranked first with a mean of 2.19 (SD=1.17).  For the 
factor statement “number of patients affected” was ranked fourth with a mean ranking of 
4.63 (SD=1.71).  Consequently, this hypothesis is accepted. 
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Hypothesis 1.4: “For physicians, pharmacy staff’s evaluation of medical evidence 
including formulary recommendations has a higher ranking of influence on 
hospital formulary decision-making than does the financial impact of the 
treatment for the institution.”   
 
As stated previously, in response to the ranked factor “pharmacy staff’s 
evaluation of medical evidence including formulary recommendations,” for physicians 
this statement was first in terms of agreement score with a mean of 2.19 (SD=1.17).  
For the corresponding factor, “financial impact of the treatment to the institution,” the 
statement was ranked seventh or last with a mean agreement score of 5.44 (SD=1.50).  
As a result, this hypothesis is accepted. 
Hypothesis 1.5: “For physicians, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the patient.”   
 
The sorted mean scores in Table 8, indicate in ranking the factor “pharmacy 
staff’s evaluation of medical evidence including formulary recommendations,” this 
statement was first in terms of agreement score with a mean of 2.19 (SD=1.17).  The 
factor “financial impact of the treatment to the patient” has a ranking of fifth with a mean 
of 4.88 (SD=2.00).  Therefore, this hypothesis is accepted. 
Hypothesis 1.6: “For physicians, individual evaluation of medical evidence has a 
higher ranking of influence on hospital formulary decision-making than does the 
opportunity for new treatment options.”   
 
By reviewing of the mean value order presented in Table 8, the factor “individual 
evaluation of medical evidence” was third in terms of ranking with a mean of 3.25 
(SD=2.32).  In response to the factor statement, “opportunity for new treatment options” 
it was ranked sixth with a mean of 4.94 (SD=1.44).  Therefore, this hypothesis is 
accepted for physicians. 
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Midlevel Provider Research Question 
Q2: “What is the ranked order of factors that influence hospital formulary 
decision-making by midlevel providers?”   
 
The total number of midlevel providers participants is 6 (n=6) see Table 8, the 
factor with the highest ranking with an average of 1.67 (SD=1.21) is the factor, 
“pharmacy staff’s evaluation of medical evidence including formulary 
recommendations.”  By reviewing the frequencies in Table 7, the number of midlevel 
providers who deemed this as the most important factor was 4 (66.7%), those who 
ranked it as the second most important was 1 (16.7%), and 0 (0.0%) ranked the factor 
third.  The number of midlevel providers ranking it fourth was 1 (16.7%), none 0 (0.0%) 
ranked it fifth, sixth, or seventh.   
The factor with the second highest level of agreement with an average of 3.00 
(SD=1.79) was in ranking the factor “evaluation of medications by expert physicians.”  
For this hospital formulary decision-making factor, 1 (16.7%) midlevel provider ranked 
this as the most important factor while 2 (33.3%) ranked it as the second most important 
factor.  Midlevel providers ranking it third was 1 (16.7%), fourth was 1 (16.7%).  No 
midlevel providers ranked it fifth 0 (0.0%), while 1 (16.7%) ranked it sixth, and none 0 
(0.0%) ranked it seventh.   
The third highest ranked factor with a mean of 4.50 (SD=2.07) was in response 
to the factor, “Individual evaluation of medical evidence.”  A total of 0 (0.0%) midlevel 
providers ranked this as the most important factor, 1 (16.7%) ranked it second, 2 
(33.3%) ranked it third.  Midlevel providers raking it fourth was 0 (0.0%), fifth 0 (0.0%), 
while 2 (33.3%) ranked it sixth, and 1 (16.7%) ranked it least important or seventh.   
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Tied for third highest factor with a mean of 4.50 (SD=1.23) was related to the 
factor “financial impact of the treatment to the institution.”  A total of 0 (0.0%) midlevel 
providers considered this hospital formulary decision-making factor most important, 1 
(16.7%) considered it second most important, 0 (0.0%) considered it third in importance, 
and 0 (0.0%) considered it fourth.  Finally, 5 (83.3%) considered it fifth, and none 0 
(0.0%) considered it as the sixth or seventh in terms of ranking the hospital decision-
making factors.   
The fourth ranked factor with a mean of 4.67 (SD=1.86) was the, “number of 
patients affected.”  Midlevel providers raking this as the most important factor was 0 
(0.00%), those ranking it second was 0 (0.0%), and third was 2 (33.3%).  Two of the 
midlevel providers 2 (33.3%) ranked it fourth, while 0 (0.0%) ranked it fifth, 0 (0.0%) 
ranked it sixth, and 2 (33.3%) ranked it seventh or least important.   
The factor tied for the fourth ranking for midlevel providers with a mean of 4.67 
(SD=2.25) was in response to the, “Opportunity for new treatment options.”  One 
midlevel provider 1 (16.7%) ranked it first, 0 (0.0%) ranked it second, 0 (0.0%) ranked it 
third, and 2 (33.3%) ranked it fourth. A total of 1 (16.7%) midlevel providers ranked it 
fifth, 0 (0.0%) sixth, and 2 (33.3%) ranked it last or seventh.   
The last factor ranked fifth with a mean of 5.00 (SD=2.00) was regarding the 
factor, “financial impact of the treatment to the patient.”  No midlevel provider 0 (0.0%) 
ranked this factor first or most important, 1 (16.7%) ranked it second, 1 (16.7%) ranked 
it third, and 0 (0.0%) ranked it fourth. In the last three ranking positions, 0 (0.0%) ranked 
it fifth, 3 (50.0%) sixth, and 1 (16.7%) ranked it the factor they considered last. 
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Midlevel Provider Hypotheses 
Hypothesis 2.1:  “For midlevel providers, individual evaluation of medical 
evidence has a lower ranking of influence on hospital formulary decision-making 
than does the evaluation of medications by expert physicians.”   
 
By reviewing of the mean value order presented in Table 8, the factor “individual 
evaluation of medical evidence” was third in terms of its ranking with a mean of 4.50 
(SD=2.07).  In ranking the factor “evaluation of medications by expert physicians,” this 
factor was ranked second with a mean of 3.00 (SD=1.79).  Therefore, this hypothesis is 
accepted for midlevel providers. 
Hypothesis 2.2:  “For midlevel providers, the evaluation of medications by expert 
physicians has a higher ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations.”   
 
By reviewing of the sorted mean values in Table 4, the factor which states, 
“evaluation of medications by expert physicians” was ranked second based on the 
ranking with a mean of 3.00 (SD=1.79).  However, in response to the factor “pharmacy 
staff’s evaluation of medical evidence including formulary recommendations”, this 
statement was first in terms of ranking with a mean of 1.67 (SD=1.21).  This hypothesis 
for midlevel providers is rejected. 
Hypothesis 2.3: “For midlevel providers, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the number of patients 
affected.”   
 
By reviewing the sorted mean scores in Table 8, the factor which states 
“pharmacy staff’s evaluation of medical evidence including formulary 
recommendations”, was ranked first with a mean of 1.67 (SD=1.21).  For the factor 
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statement “number of patients affected” was tied in rank for fourth with a mean ranking 
of 4.67 (SD=1.86).  Consequently, this hypothesis is accepted. 
Hypothesis 2.4: “For midlevel providers, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the institution.”   
 
As stated previously, in response to the ranked factor “pharmacy staff’s 
evaluation of medical evidence including formulary recommendations,” for midlevel 
providers this factor was first in terms of ranking score with a mean of 1.67 (SD=1.21).  
For the corresponding factor, “financial impact of the treatment to the institution,” the 
statement was tied for third with a mean agreement score of 4.50 (SD=1.23).  As a 
result, this hypothesis is accepted. 
Hypothesis 2.5: “For midlevel providers, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the patient.”   
 
The sorted mean scores in Table 8, indicate in ranking the factor “pharmacy 
staff’s evaluation of medical evidence including formulary recommendations,” this 
statement was first in terms of agreement score with a mean of 1.67 (SD=1.21).  The 
factor “financial impact of the treatment to the patient” was ranked last with a mean of 
5.00 (SD=2.00).  Therefore, this hypothesis is accepted. 
Hypothesis 2.6: “For midlevel providers is, “individual evaluation of medical 
evidence has a higher ranking of influence on hospital formulary decision-making 
than does the opportunity for new treatment options.”   
 
By reviewing of the mean value order presented in Table 8, the factor “individual 
evaluation of medical evidence” was tied for third in terms of ranking with a mean of 
4.50 (SD=2.07).  In response to the factor statement, “opportunity for new treatment 
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options” it was ranked and tied for fourth with a mean of 4.67 (SD=2.25).  Therefore, this 
hypothesis is accepted for midlevel providers. 
 
Pharmacist Research Question 
Q3: “What is the ranked order of factors that influence hospital formulary 
decision-making by pharmacists?”   
 
Upon review of Table 8, the total number of pharmacist participants is 8 (n=8), 
the factor with the highest ranking with an average of 1.50 (SD=0.76) was in ranking the 
factor, “pharmacy staff’s evaluation of medical evidence including formulary 
recommendations.”  By reviewing the frequencies in Table 7, the number of pharmacists 
who deemed this as the most important factor was 5 (62.5%), those who ranked it as 
the second most important was 2 (25.0%), and 1 (12.5%) ranked the factor third.  The 
number of pharmacists ranking it fourth, fifth, sixth, or last was 0 (0.0%).   
The factor with the second highest ranking with an average of 3.38 (SD=1.85) 
was in ranking the factor “financial impact of the treatment for the institution.”  For this 
hospital formulary decision-making factor, 1 (12.5%) of pharmacist ranked this as the 
most important factor while 2 (25.0%) ranked it as the second most important factor.  
Pharmacists ranking it third was 1 (12.5%), fourth was 3 (37.5%), 0 (0.0%) ranked it fifth 
or sixth, while 1 (12.5%) ranked it seventh.   
The third highest ranked factor with a mean of 3.75 (SD=1.91) was in response 
to the factor, “evaluation of medications by expert physicians.”  A total of 1 (12.5%) 
pharmacist ranked this as the most important factor, 1 (12.5%) ranked it second, 2 
(25.0%) ranked it third.  Pharmacists raking it fourth was 1 (12.5%), fifth 2 (25.0%), 
none ranked it sixth, and 1 (12.5%) ranked it least important or seventh.   
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The fourth highest factor with a mean of 3.88 (SD=2.30) was related to the factor 
“individual evaluation of medical evidence.”  A total of 1 (12.5%) of pharmacists 
considered this factor most important, 2 (25.0%) considered it second most important, 1 
(12.5%) considered it third in importance, and 1 (12.5%) considered it fourth.  Finally, 1 
(12.5%) considered it fifth, 0 (0.0%) sixth, and 2 (25.0%) considered it the least 
important hospital formulary decision-making factor.   
The fifth ranked factor with a mean of 4.88 (SD=1.36) was the, “financial impact 
of treatment to the patient.”  Pharmacists raking this as the most important factor was 0 
(0.0%), those ranking it second was also 0 (0.0%), and third were 2 (25.0%).  The 
number of pharmacists ranking it fourth was 1 (12.5%), 1 (12.5%) ranked it fifth, while 4 
(50.0%) ranked it sixth, and 0 (0.0%) ranked it seventh or least important.   
The factor tied for fifth for pharmacists with a mean of 4.88 (SD=1.81) was in 
response to the factor, “opportunity for new treatment options.”  No pharmacists 0 
(0.0%) ranked it first, 1 (12.5%) ranked it second, 1 (12.5%) ranked it third, and 1 
(12.5%) ranked it fourth. A total of 2 (25.0%) ranked it fifth, 1 (12.5%) sixth, and 2 
(25.0%) ranked it last or seventh.   
The factor ranked last with a mean of 5.75 (SD=1.50) was regarding the factor, 
“number of patients affected.”  No pharmacists 0 (0.0%) ranked this factor first or most 
important, 0 (0.0%) ranked it second, 0 (0.0%) ranked it third, and 1 (12.5%) ranked it 
fourth. In the last three ranking positions, 2 (25.0%) ranked it fifth, 3 (37.5%) sixth, and 2 




Hypothesis 3.1: “For pharmacists, individual evaluation of medical evidence has 
a lower ranking of influence on hospital formulary decision-making than does the 
evaluation of medications by expert physicians.”   
 
By reviewing of the mean value order presented in Table 8, for the factor 
“individual evaluation of medical evidence” was ranked fourth with a mean of 3.88 
(SD=1.36).  In response to the factor “evaluation of medications by expert physicians,” 
this statement was ranked third based on the ranking scores with a mean of 3.75 
(SD=1.91).  Therefore, this hypothesis is accepted for pharmacists. 
Hypothesis 3.2: “For pharmacists, the evaluation of medications by expert 
physicians has a lower ranking of influence on hospital formulary decision-
making than does the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations.”   
 
By reviewing of the sorted mean values in Table 8, the factor “evaluation of 
medications by expert physicians,” was ranked third based rankings with a mean of 3.75 
(SD=1.91).  However, in response to factor “pharmacy staff’s evaluation of medical 
evidence,” this was first in terms with a mean of 1.50 (SD=0.76).  This hypothesis for 
pharmacists is accepted. 
Hypothesis 3.3: “For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the number of patients 
affected.”   
 
By reviewing the sorted mean scores in Table 8, in response to the factor 
“pharmacy staff’s evaluation of medical evidence,” this statement was first in terms of 
mean ranking score with a mean of 1.50 (SD=0.76).  The factor “number of patients 




Hypothesis 3.4: “For pharmacists, pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the institution.”   
 
Upon evaluation of the sorted mean scores in Table 8, in response to factor 
“pharmacy staff’s evaluation of medical evidence including formulary 
recommendations,” for pharmacists this statement was first in terms of the sorted 
ranked factors with a mean of 1.50 (SD=0.76).  For the corresponding factor, “financial 
impact of the treatment to the institution,” was ranked second with a mean agreement 
score of 3.38 (SD=1.85).  As a result, this hypothesis is accepted. 
Hypothesis 3.5: “For pharmacists, a pharmacy staff’s evaluation of medical 
evidence including formulary recommendations has higher ranking of influence 
on hospital formulary decision-making than does the financial impact of the 
treatment for the patient.”   
 
The sorted mean scores in Table 8, indicate in response to the factor “pharmacy 
staff’s evaluation of medical evidence including formulary recommendations,” this factor 
was first with a mean of 1.50 (SD=0.76).  The factor “financial impact of the treatment to 
the patient,” has tied for fourth with a mean of 4.88 (SD=1.36).  Therefore, this 
hypothesis is accepted for pharmacists. 
Hypothesis 3.6: “For pharmacists, “individual evaluation of medical evidence has 
a higher ranking of influence on hospital formulary decision-making than does the 
opportunity for new treatment options.”   
 
By reviewing of the mean value order presented in Table 8, the factor “individual 
evaluation of medical evidence,” was fourth in terms of agreement score with a mean of 
3.88 (SD=2.30).  In response to the factor, “opportunity for new treatment options” the 
factor was tied for fifth with a mean of 4.88 (SD=1.81).  Therefore, this hypothesis is 




Although no research questions or hypotheses were stated for all prescribers 
irrespective of provider type, the following results provide the ranked order of all 
prescribers.  These results provide insight into the factors with the highest to the lowest 
ranking across all three prescriber groups.  For all prescribers surveyed including 
physicians, midlevel providers, and pharmacists (n=30) Table 8 indicates the factor with 
the highest ranking with an average of 1.90 (SD=1.09).  The factor, “pharmacy staff’s 
evaluation of medical evidence including formulary recommendations” was ranked first.  
By reviewing the frequencies in Table 7, the number of prescribers ranking this factor 
first was 14 (46.67%), second were 9 (30.0%), and third were 4 (13.3%).  A total of 2 
(6.7%) ranked the factor fourth, 1 (3.3%) ranked it fifth, and 0 (0.0%) ranked it sixth or 
seventh.   
The second highest level of agreement 3.03 (SD=1.56) was regarding the factor, 
“evaluation of medications by expert physicians.”  A total of 6 (20.0%) ranked this factor 
first, 5 (16.7%) second, 9 (30.0%) third, 5 (16.7%) fourth, 3 (10.0%) fifth, 1 (3.3%) sixth, 
and 1 (3.3%) seventh.   
The third highest level of agreement with an average of 3.67 (SD=2.25) was in 
response to the factor “individual evaluation of medical evidence.”  For this hospital 
formulary decision-making factor, 7 (23.3%) prescribers ranked this factor as most 
important while 4 (13.3%) ranked the factor second.  A total of 6 (20.0%) ranked it third, 
2 (6.7%) ranked it fourth, 3 (10.0%) ranked it fifth, 2 (6.7%) ranked it sixth, and six 
(20.0%) of prescribers ranked it seventh or last.   
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The factor ranked fourth with a mean of 4.70 (SD=1.75) was regarding the factor 
which states “financial impact of the treatment to the institution.”  A total of 1 (3.3%) of 
prescribers ranked this factor first, 4 (13.3%) second, 2 (6.7%) third, and 5 (16.7%) 
ranked the factor fourth.  In addition, 7 (23.3%) prescribers ranked the factor fifth, 6 
(20.0%) sixth, and 5 (16.7%) ranked it seventh or last.   
The fifth highest ranking with a mean of 4.87 (SD=1.66) was related to the factor 
“opportunity for new treatment options.”  A total of 1 (3.3%) prescriber ranked this factor 
first, 2 (6.7%) second, 1 (3.3%) third, while 10 (33.3%) ranked the factor fourth.  A total 
of 5 (16.7%) prescribers ranked it fifth, 4 (13.3%) sixth, while 7 (23.3%) ranked it last.   
The sixth ranked factor with a mean of 4.90 (SD=1.79) was related to the factor, 
“financial impact of treatment to the patient.”  A total of 0 (0.0%) prescribers ranked the 
factor first, 5 (16.7%) second, 4 (13.3%) third, and 1 (3.3%) fourth.  In the last positions, 
4 (13.3%) prescribers ranked in fifth, 11 (36.7%) ranked it sixth, and 5 (16.7%) ranked it 
seventh. 
The seventh and lowest ranking with a mean of 4.93 (SD=1.62) was in response 
factor “number of patients affected.”  A total of 1 (3.3%) of prescribers ranked the factor 
first, 1 (3.3%) second, 4 (13.3%) third, 5 (16.7%) fourth.  Finally, 7 (23.3%) prescribers 
ranked the factor fifth, 6 (20.0%) sixth, with the same number 6 (20.0%) ranking the 






Prescriber Group Means and Standard Deviations for Decision-Making Factor Ranking 
(Physician n=16, Midlevel Provider n=6, Pharmacist n=8, All Prescribers n=30) 
 
 M SD 
Physician 
1) pharmacy staff’s evaluation of medical evidence including formulary    
recommendations 2.19 1.17 
2) evaluation of medications by expert physicians 2.69 1.25 
3) individual evaluation of medical evidence 3.25 2.32 
4) number of patients affected 4.63 1.71 
5) financial impact of the treatment to the patient 4.88 2.00 
6) opportunity for new treatment options 4.94 1.44 
7) financial impact of the treatment to the institution 5.44 1.50 
Midlevel Provider 
1) pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 1.67 1.21 
2) evaluation of medications by expert physicians 3.00 1.79 
3) individual evaluation of medical evidence 4.50 2.07 
3) financial impact of the treatment to the institution 4.50 1.23 
4) number of patients affected 4.67 1.86 
4) opportunity for new treatment options 4.67 2.25 
5) financial impact of the treatment to the patient 5.0 2.00 
Pharmacist 
1) pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 1.50 0.76 
2) financial impact of the treatment to the institution 3.38 1.85 
3) evaluation of medications by expert physicians 3.75 1.91 
4) individual evaluation of medical evidence 3.88 2.30 
5) financial impact of the treatment to the patient 4.88 1.36 
5) opportunity for new treatment options 4.88 1.81 




 M SD 
All Prescribers 
1) pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 1.90 1.09 
2) evaluation of medications by expert physicians 3.03 1.56 
3) individual evaluation of medical evidence 3.67 2.25 
4) financial impact of the treatment to the institution 4.70 1.75 
5) opportunity for new treatment options   4.87 1.66 
6) financial impact of the treatment to the patient 4.90 1.79 
7) number of patients affected 4.93 1.62 
Note.  M = mean; SD = standard deviation.  For midlevel providers, two factors are ranked third with 
identical mean values of 4.50 and two are ranked fourth with identical mean values of 4.67.  For 





In addition to the descriptive statistical analyses performed, inferential statistics 
were performed.  These analyses were performed to determine if statistically significant 
differences exist between the prescriber groups and the seven ranked means for the 
decision-making factors.  Part III of the survey, as described previously, required the 
participants to rank the seven hospital formulary decision-making factors with a score of 
1 being the most important to 7 being the least important.  Similar descriptive and 
inferential statistics were performed for both Part II and Part III of the survey.   
As described previously, the data for this study are not normally distributed.  
Furthermore, the dependent variable is categorical while the independent variables for 
the ranked decision-making factors are ordinal.  For the rationale regarding the 
selection and use of the Kruskal-Wallis H test see the section entitled Survey - Part II 
and the subheading entitled Statistical Test Results.  Table 9 provides the results of 
Levene’s test for homogeneity of variance for the ranked decision-making factors. 
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Upon review of the data in Table 9, all variables meet the homogeneity of variance 
requirement.  Therefore, the null hypothesis for Levene’s test is accepted for the 
hospital formulary decision-making factors and the assumption of homogeneity of 
variance is met.  Therefore, calculations using the Kruskal-Wallis test may be used 
determine if statistically significant differences exist between the prescriber groups. 
Table 9 
Levene’s Homogeneity of Variance Test Results for Decision-Making Factor Ranking 
Hospital Formulary Decision-making Factor Levene Statistic df1 df2 p 
my individual evaluation of medical evidence 0.024 2 27 0.977 
pharmacy staff’s evaluation of medical evidence 
including formulary recommendations 0.466 2 27 0.632 
evaluation of medications by expert physicians 0.935 2 27 0.405 
number of patients affected 1.514 2 27 0.238 
financial impact of the treatment to the institution 0.610 2 27 0.551 
financial impact of the treatment to the patient 1.020 2 27 0.374 
opportunity for new treatment options  0.587 2 27 0.563 
Note.  df = degrees of freedom; p = p statistic for Levene’s test.   
 
Table 10 provides the results of the independent samples Kruskal-Wallis H test 
as determined by running the test using SPSS© (2017) statistical software.  Upon 
review of the table, one of the variables indicated a statistically significant difference 
between the three groups of prescribers.  A Kruskal-Wallis H test showed for the factor, 
“financial impact of treatment to the institution,” the following results: α = 0.05, X2 = 
2.720, p = 0.021.  For this factor, the mean rank score for physicians was 19.31, for 
midlevel providers 13.92, and for pharmacists 9.06. The significant difference is 
between Pharmacists and Physicians.  Pharmacists ranked this factor significantly 
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higher in terms of importance than did Physicians.  No other decision-making factors for 
Part III of the survey indicated a statistically significant difference in mean ranking 
scores between the prescriber groups based on the results of the Kruskal-Wallis H test. 
Table 10 
Kruskal-Wallis H Test for Results for Decision-Making Factor Ranking 
Hospital Formulary Decision-making Factor Chi-Square df p 
my individual evaluation of medical evidence 1.648 2 0.439 
pharmacy staff’s evaluation of medical evidence including 
formulary recommendations 2.950 2 0.229 
evaluation of medications by expert physicians 1.790 2 0.409 
number of patients affected 2.720 2 0.257 
financial impact of the treatment to the institution 7.716 2 0.021 
financial impact of the treatment to the patient 0.143 2 0.931 
opportunity for new treatment options  0.013 2 0.993 
Note:  df = degrees of freedom; p = p statistic for Kruskal-Wallis H Test.  For the decision-making factor 
“financial impact of treatment to the institution”, the p value is 0.021 which is < 0.050.  Therefore the null 




Survey – Part IV 
Additional Factors 
In Part IV of the survey, participants were asked to “List any additional factors 
you consider when making medication formulary decisions.”  A total of 8 (50.0%) 
physicians, 3 (50.0%) midlevel providers, and 3 (37.5%) pharmacists provided 





Prescriber Group Additional Hospital Formulary Decision-making Factors 
Group Responses 
Physician 
Redundancy to any current meds in formulary 
Ability to change the course of the disease ex. immunotherapy, Car T cell therapy 
etc. 
Existence of similar drugs in the formulary and weighing comparative efficacy 
Identification of potentials for misuse 
Prioritization of resource allocation 
Safety concerns- whether a REMS program exists 
Adverse event profile; incremental benefit over alternate options, and the cost of 
any perceived or real advantage. 
weight of evidence 
success of reimbursement 
We are not given out of pocket cost information for patients at the time we are 
making formulary decisions 
Unfortunately in my life I think about the cost/benefit of everything I do.  However, 
at the institution cost to the institution or patient do not seem to matter.  In most of 
the conditions we treat at MD Anderson there is only limited amount of years we 
can add to a patients [patient’s] life and they are very costly.  This is always a 
dilemma for me.  Now that the FDA is so easy in approving any agent with a p-
value the system is going to be more problematic when the national leader has set 
the bar so extremely low. 
man [main] consideration is the patent's [patient’s] financial status and affordability 
Midlevel 
Provider 
Similar drug options already available if any. 
Adverse reactions along with frequency and severity of these reactions observed 
in published studies. 
Efficacy of the drug. 
Risk of harm with inappropriate use (who will be allowed to prescribe the drug, and 
restrictions that need to be placed on prescribing) 
Do we have a substitute on formulary to provide the patients (especially like for 
combo blood pressure meds-can we provide each individual medication) 
If we add drugs do we need to take some off--for things like storage 
As MDACC has an in and out patient  should the drug be available only in the 










For the institution what is the present pay for drug by insurance company and do 
they have specific criteria 
--If they have specific criteria how do we make sure they are followed prior to 
prescribing or dispensing the drug 
Experience using the medication and the outcomes and safety of its use. 
Pharmacist 
Efficacy in comparative studies, particularly if one of the drugs being compared is 
already on formulary. 
Safety issues such as cost of treating side effects, severity of side effects 
I am only asked to participate in the P&T committee when it pertains to a drug I am 
familiar with, but it really depends on my own knowledge and experience with the 
disease state.  If I am more familiar, I rely on my own investigation more so than if 
I am not familiar.  If I am not familiar, I rely more on the pharmacy Med 
Management personnel's evaluation and/or expert testimony by physicians in the 
field. 
This may skew your results, but I have not officially been a member of P&T for 
many years.  I am asked to participate ad hoc or to fill in if [name removed] is not 
able to attend. 
Note.  Items in square brackets “[ ]” indicate typographical corrections or redacted text to ensure 





In Part IV of the survey participants were also asked to provide additional 
information considered when making hospital formulary decisions.  The specific survey 
question was, “Please provide additional information you consider when making 
medication formulary decisions.”  A total of 3 (18.8%) physicians, 2 (33.3%) midlevel 
providers, and 1 (12.5%) pharmacists provided responses.  The exact text of the 
responses by prescriber group are listed Table 12. 
Finally, participants were asked if they would like a summary of the study results.  
Of the 30 participants, a total of 7 (23.3%) requested a summary of the study results 
and included their names and respective email addresses.  Upon successful review and 
approval of this study by the work’s major professor, dissertation committee, and 
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successful defense of the work as stipulated by the University of North Texas, 
Interdisciplinary Information Science PhD program, a summary will be provided to all 
participants who requested a summary of the study results. 
Table 12 
Prescriber Group Additional Hospital Formulary Decision-Making Information 
Group Responses 
Physician 
Receiving feedback about the monitoring/oversight of institutional use 
Is it a useful drug 
will it truly help 
is it because the company paid the researcher 
Is there a bias 
whether the prescribing will be restricted to certain services 
Midlevel 
Provider 
For the new cancer drugs--what is the TRUE benefit in quality of life or 
prolonged life (for prolonged do not consider 2 weeks a true benefit) 
Also  if just approved by FDA--is there any other tumor types in  clinical 
trials that would show how this drug would benefit a bigger population (if 
approved for a rare tumor type) 
Also look at side effect profile and can they be managed fairly easily 
Impact of the medication on cancer and infections or the disease. 
Pharmacist The cost of the medication only comes into consideration after all other factors are considered and other alternatives evaluated. 
 
Summary 
This chapter presented the analysis and findings of the data collected from the 
online self-administered survey.  All participants have served on the University of Texas, 
MD Anderson Cancer Center pharmacy and Therapeutics Committee and are still on 
the medical staff of the institution.  The survey was completed by 30 prescribers 
comprised of 16 physicians, 6 midlevel providers, and 8 pharmacists.   
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In Part II of the survey, prescribers were asked to respond to 7 statements 
related to each of the hospital formulary decision-making factors.  Each statement was 
assign an agreement score associated with the 5-point Likert scale.  Means were then 
computed for each of the 7 statements and corresponding hospital formulary decision-
making factors.  Subsequently, the means were sorted to ascertain the highest to lowest 
level of agreement for each hospital formulary decision-making factor and for each 
prescriber group.  The primary research questions for all three prescriber groups was to 
determine the ranked order of the seven hospital formulary decision-making factors.  
These results are presented in Table 4.   
For the data obtained from Part II of the survey, a Kruskal-Wallis H test was 
performed to determine if any statistically significant differences exist.  The statistical 
test showed a significant difference in mean agreement score exists between prescriber 
groups for one hospital formulary decision-making factor.  In response to the statement, 
“I consider the number of patients affected by adding, removing, or modifying a drug on 
the formulary when making a hospital medication formulary decision.”  A Kruskal-Wallis 
H test showed there was a statistically significant difference in mean agreement score 
between the prescriber groups, α = 0.05, X2 = 6.055, p = 0.048.  A mean rank 
agreement score of 14.25 was observed for physicians, 22.50 for midlevel providers, 
and 12.75 for pharmacists. No other decision-making factors for Part II of the survey, 
regarding the agreement statements, indicated a statistically significant difference in 
agreement scores between the prescriber groups. 
In part III of the survey, prescribers were asked to rank the seven hospital 
formulary decision-making factors.  For this part of the survey, a score of 1 was 
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assigned for the factor considered most important factor to a score of 7 for the least 
important factor.  Means were then computed for each of the seven hospital formulary 
decision-making factors.  These means were sorted in ascending order to ascertain the 
factor ranked most important to the factor ranked least important for each prescriber 
group.  As mentioned previously, the primary research questions for all three prescriber 
groups was to ascertain the ranked order for the seven hospital formulary decision-
making factors.  These results are presented in Table 8 for each prescriber group and 
among all prescribers.  These results were also used to address the 6 hypotheses for 
each provider group.  These hypotheses were analyzed in detail and each hypothesis 
either accepted or rejected.  See the sections entitled Survey – Part III, and associated 
subsections entitled physician hypotheses, midlevel provider hypotheses, and 
pharmacist hypotheses.   
A Kruskal-Wallis H test was also performed for the hospital decision-making 
factor ranking data associated with Part III of the survey.  These data revealed a 
statistically significant difference in mean agreement score between the prescriber 
groups.   The difference was observed for the factor, “financial impact of treatment to 
the institution.”  The results of the Kruskal-Wallis H test were, α = 0.05, X2 = 2.720, p = 
0.02.  The mean rank score was 19.31 for physicians, 13.92 for midlevel providers, and 
9.06 for pharmacists. No other decision-making factors for Part III of the survey 
according the Kruskal-Wallis H test indicated a statistically significant difference. 
Part IV of the survey asked prescribers to provide any additional factors or 
information considered when making hospital formulary decisions.  Additional factors 
provided by the participants are included in Table 11.  Additional information considered 
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when making hospital formulary decisions are included in Table 12.  These additional 
factors and information are discussed in greater detail in Chapter V. 
The next chapter provides an overview of the study and conclusions.  In addition, 




CHAPTER V  
SUMMARY, CONCLUSIONS, AND RECOMMENDATIONS 
Introduction 
This chapter presents an overview of the study with the findings as they relate to 
the research questions, hypotheses, literature, and conclusions drawn from the study.  
In addition, the significance of the study and recommendations for future research are 
discussed. 
 
Overview of the Study 
The purpose of the study is to identify, rank, and compare major factors 
impacting hospital formulary decision-making among three prescriber groups serving on 
a hospital pharmacy and Therapeutics (P&T) committee.  Prescribers were selected 
from the University of Texas, MD Anderson Cancer Center which is a large, multi-
facility, academic oncology hospital.  Specifically, the prescriber groups studied were 
physicians, midlevel providers, and pharmacists. 
Upon review of the scientific literature, seven major hospital formulary decision-
making factors were identified and include:  
• Individual evaluation of medical evidence (Kelly & Bender, 1983)   
• pharmacy staff evaluation of medical evidence including formulary 
recommendations (Malone, Kier, & Stanovich, 2012)   
• Evaluation of medications by expert physicians (Segal & Pathak, 1988)  
• Number of patients affected (Kelly & Bender, 1983)  
• Financial impact of the treatment for the institution (Anagnostis, Wordell, 
Guharoy, Beckett, & Price, 2011) 
• Financial impact of the treatment for the patient (Deangelis, 2016) 
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• Opportunity for new treatment options (U.S. Institute of Medicine, Committee 
on Quality of Health Care in America, 2001) 
First, the seven identified factors were included in hospital formulary decision-making 
statements and scored by participants on a 5-point Likert scale indicating a level of 
agreement.  Second, the factors we ranked by participants on a 7-point ranking scale 
with 1 being most import to 7 least important.  The following section provides the 
summarized findings and addresses the stated research questions and hypotheses 
posed by the study. 
 
Hospital Formulary Decision-Making Statements 
The mean order based on agreement scores for hospital formulary decision-
making statements is summarized in Table 13.  Some factors are tied in terms of their 
agreement scores and appear as duplicate ranking values in the numerated lists.  This 
order serves to address the research questions and associated hypotheses for each 
prescriber group: 
Group 1:  Physicians 
Q1:  What is the ranked order of factors that influence hospital formulary 
decision-making by physicians? 
1. Pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
2. Evaluation of medications by expert physicians 
3. Opportunity for new treatment options 
4. Financial impact of the treatment to the patient 
5. Individual evaluation of medical evidence 
6. Financial impact of the treatment to the institution 
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7. Number of patients affected 
Group 2:  Midlevel Providers 
Q2. What is the ranked order of factors that influence hospital formulary decision-
making by midlevel providers? 
pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
1. Number of patients affected 
2. Opportunity for new treatment options 
3. Financial impact of the treatment to the institution 
4. Evaluation of medications by expert physicians 
5. Financial impact of the treatment to the patient 
6. Individual evaluation of medical evidence 
Group 3:  Pharmacists 
Q3. What is the ranked order of factors that influence hospital formulary decision-
making by pharmacists? 
1. Financial impact of the treatment to the institution 
2. Opportunity for new treatment options 
3. pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
4. Number of patients affected 
4. Evaluation of medications by expert physicians 
5. Financial impact of the treatment to the patient 






Prescriber Group Ordered Factors for Decision-Making Factor Statements 
(physician n=16, midlevel provider n=6, pharmacist n=8, all prescribers n=30) 
 
Decision-making factor Physician Midlevel Provider Pharmacist 
Pharmacy staff’s evaluation of medical evidence 
including formulary recommendations 1 1 3 
Evaluation of medications by expert physicians 2 5 (tie) 4 (tie) 
Opportunity for new treatment options 3 3 2 
Financial impact of the treatment to the patient 4 5 (tie) 5 
Individual evaluation of medical evidence 5 6 6 
Financial impact of the treatment to the institution 6 4 1 
Number of patients affected 7 2 4 (tie) 
Note.  For midlevel providers, two factors are tied for the fifth position.  For pharmacists, two factors are 
tied for fourth position. 
 
In addition to the three research questions, six hypotheses were developed for 
each prescriber group.  A summary of the hypotheses results based on the hospital 
formulary decision-making statements is presented in Table 14.  Hypotheses 2 is 
identical for physicians and midlevel providers.  However, Hypotheses 2 is stated 
differently for pharmacists.  All other hypotheses are identical for all prescriber groups. 
For physicians four hypotheses were accepted including 1, 3, 4 and 5 while two 
were rejected 2 and 6.  Midlevel providers’ hypotheses results are identical to 
physicians.  For pharmacists, Hypotheses 1, 2, 3 and 5 were accepted while two were 





Prescriber Group Hypotheses Results for Decision-Making Factor Statements 





1.1, 2.1, 3.1:  Individual evaluation of medical 
evidence has a lower ranking of influence on hospital 
formulary decision-making than does the evaluation 
of medications by expert physicians. 
accepted accepted accepted 
1.2, 2.2:  Evaluation of medications by expert 
physicians has a higher ranking of influence on 
hospital formulary decision-making than does the 
pharmacy staff’s evaluation of medical evidence 
including formulary recommendations. 
rejected rejected  
3.2:  Evaluation of medications by expert physicians 
has a lower ranking of influence on hospital formulary 
decision-making than does the pharmacy staff’s 
evaluation of medical evidence including formulary 
recommendations. 
  accepted 
Hypothesis 1.3, 2.3, 3.3:  pharmacy staff’s evaluation 
of medical evidence including formulary 
recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the 
number of patients affected. 
accepted accepted accepted 
Hypothesis 1.4, 2.4, 3.4:  pharmacy staff’s evaluation 
of medical evidence including formulary 
recommendations has a higher ranking of influence 
on hospital formulary decision-making than does the 
financial impact of the treatment for the institution. 
accepted accepted rejected 
Hypothesis 1.5, 2.5, 3.5: pharmacy staff’s evaluation 
of medical evidence including formulary 
recommendations has higher ranking of influence on 
hospital formulary decision-making than does the 
financial impact of the treatment for the patient. 
accepted accepted accepted 
Hypothesis 1.6, 2.6, 3.6:  Individual evaluation of 
medical evidence has a higher ranking of influence on 
hospital formulary decision-making than does the 
opportunity for new treatment options. 
rejected rejected rejected 
Note.  Hypothesis 2 is the same for physicians and midlevel providers, but different for pharmacists.  All 




Hospital Formulary Decision-Making Factor Ranking 
Prescribers were asked to rank the seven identified hospital formulary decision-
making factors on a 7-point ranking scale.  Table 15 provides a summary of the hospital 
formulary decision-making factors based on ranked order for each of the prescriber 
groups.  Some ranked factors have identical means and are tied in terms of ranked 
order.  The sorted mean values were used to address the research questions and 
hypotheses for each prescriber group including physicians, midlevel providers, and 
pharmacists: 
Group 1:  Physicians 
Q1:  What is the ranked order of factors that influence hospital formulary decision-
making by physicians? 
1. Pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
2. Evaluation of medications by expert physicians 
3. Individual evaluation of medical evidence 
4. Number of patients affected 
5. Financial impact of the treatment to the patient 
6. Opportunity for new treatment options 
7. Financial impact of the treatment to the institution 
Group 2:  Midlevel Providers 
Q2:  What is the ranked order of factors that influence hospital formulary 
decision-making by midlevel providers? 
1. Pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
2. Evaluation of medications by expert physicians 
3. Individual evaluation of medical evidence 
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3. Financial impact of the treatment to the institution 
4. Number of patients affected 
4. Opportunity for new treatment options 
5. Financial impact of the treatment to the patient 
Group 3:  Pharmacists 
Q3:  What is the ranked order of factors that influence hospital formulary 
decision-making by pharmacists? 
1. Pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
2. Financial impact of the treatment to the institution 
3. Evaluation of medications by expert physicians 
4. Individual evaluation of medical evidence 
5. Opportunity for new treatment options 
5. Financial impact of the treatment to the patient 
6. Number of patients affected 
Table 15 
 
Prescriber Group Ordered Factors for Decision-Making Factor Ranking (Physician 
n=16, Midlevel Provider n=6, Pharmacist n=8, All Prescribers n=30) 
 
Decision-Making Factor Physician Midlevel Provider 
Pharmacis
t 
Pharmacy staff’s evaluation of medical evidence 
including formulary recommendations 1 1 1 
Evaluation of medications by expert physicians 2 2 3 
Individual evaluation of medical evidence 3 3 (tie) 4 
Number of patients affected 4 4 (tie) 6 
Financial impact of the treatment to the patient 5 5 5 (tie) 
Opportunity for new treatment options 6 4 (tie) 5 (tie) 
Financial impact of the treatment to the institution 7 3 (tie) 2 





Provider Group Hypotheses Results for Decision-Making Factor Ranking 






Hypothesis 1.1, 2.1, 3.1: Individual evaluation of 
medical evidence has a lower ranking of influence 
on hospital formulary decision-making than does 
the evaluation of medications by expert physicians. 
accepted accepted accepted 
Hypothesis 1.2, 2.2:  Evaluation of medications by 
expert physicians has a higher ranking of influence 
on hospital formulary decision-making than does 
the pharmacy staff’s evaluation of medical evidence 
including formulary recommendations. 
rejected rejected  
Hypothesis 3.2:  Evaluation of medications by 
expert physicians has a lower ranking of influence 
on hospital formulary decision-making than does 
the pharmacy staff’s evaluation of medical evidence 
including formulary recommendations. 
  accepted 
Hypothesis 1.3, 2.3, 3.3:  pharmacy staff’s 
evaluation of medical evidence including formulary 
recommendations has a higher ranking of influence 
on hospital formulary decision-making than does 
the number of patients affected. 
accepted accepted accepted 
Hypothesis 1.4, 2.4, 3.4:  pharmacy staff’s 
evaluation of medical evidence including formulary 
recommendations has a higher ranking of influence 
on hospital formulary decision-making than does 
the financial impact of the treatment for the 
institution. 
accepted accepted accepted 
Hypothesis 1.5, 2.5, 3.5:  pharmacy staff’s 
evaluation of medical evidence including formulary 
recommendations has higher ranking of influence 
on hospital formulary decision-making than does 
the financial impact of the treatment for the patient. 
accepted accepted accepted 
Hypothesis 1.6, 2.6, 3.6:  Individual evaluation of 
medical evidence has a higher ranking of influence 
on hospital formulary decision-making than does 
the opportunity for new treatment options. 
accepted accepted accepted 
 
The summary of the hypotheses results based on hospital formulary decision-
making factor ranking is presented in Table 16.  Hypotheses 2 is identical for physicians 
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and midlevel providers.  However, this hypothesis is stated differently for pharmacists. 
For physicians five hypotheses were accepted including 1, 3, 4, 5, and 6 while 
Hypothesis 2 was rejected.  Results for midlevel providers are identical to physicians.  
For pharmacists, all six hypotheses were accepted. 
 
Conclusions 
There are five major conclusions to be drawn from the study including three 
similarities and two significant differences. 
Similarities: 
1. The factor, pharmacy staff’s evaluation of medical evidence including 
formulary recommendations was ranked highest for all three prescriber 
groups. 
2. The factor, evaluation of medications by expert physicians was ranked 
second for physicians and midlevel providers while pharmacists ranked it 
third. 
3. The factor, financial impact of the treatment to the patient was fifth in terms of 
hospital formulary decision-making statements order and ranked fifth on 
average by all three prescriber groups. 
The similar findings among the prescriber groups provides evidence of the 
following.  The factor, “pharmacy staff’s evaluation of medical evidence including 
formulary recommendations,” is deemed the most important hospital formulary decision-
making factor by all 3 prescriber groups and aids greatly in P&T committee hospital 
formulary decision-making.  It is also clear that the evaluation of medications by expert 
physicians is an important factor.  Expert physicians interject valuable clinical 
knowledge and expertise into the decision-making process.  Finally, the financial impact 
of treatment to the patient was consistently ranked among the bottom three factors.  
This is likely due to the difficulty in ascertaining out-of-pocket costs from insurance 
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carriers and determining a single out-of-pocket cost estimate.  Out-of-pocket expenses 
vary depending on a patient’s insurance status or on types of insurance coverage.  As a 
physician points out when responding to Part IV (see: Table 11) of the survey regarding 
additional decision-making factors, “We are not given out of pocket cost information for 
patients at the time we are making formulary decisions.”   
 
Significant Differences 
1. For the hospital-formulary decision-making statement, “I consider the number 
of patients affected by adding, removing, or modifying a drug on the formulary 
when making hospital medication formulary decisions.”  Midlevel providers 
considered this factor of significantly greater importance than did physicians 
or pharmacists. 
 
2. For the ranked hospital formulary decision-making factor, “financial impact of 
treatment to the institution.”  Pharmacists ranked this factor significantly 
higher than did physicians. 
 
It is unclear why a significant difference exists between midlevel providers as 
opposed to physicians and pharmacists when responding to the statement, “I consider 
the number of patients affected by adding, removing, or modifying a drug on the 
formulary when making a medication formulary decision.”  Greater insight into this 
difference could be ascertained by additional qualitative research.  The second 
significant difference was between pharmacists as compared to physicians when 
ranking the factor “financial impact of treatment to the institution.”  Pharmacists indicted 
a significantly higher ranking of importance than did physicians.  This could be attributed 
to the fact that the Division of pharmacy bears budgetary responsibility for both 
medication related acquisition expenses and the associated medication related income.  
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Such fiscal responsibility within the organization could explain this significantly higher 
ranking of importance for pharmacists serving on the P&T committee. 
 
Additional Points 
1. More variability existed between prescriber groups when responding to 
independent hospital formulary decision-making statements on a 5-point 
Likert scale than on a 7-point ranking scale.  
 
2. Greater homogeneity emerged among the prescriber groups based on the 
results of ranking the factors on a 7-point ranking scale.  This is especially 
true of physicians and midlevel providers. 
 
3. The decision-making statement, “I rely upon the evaluation of medications by 
expert physicians to make hospital medication formulary decisions” did not 
pass Leven’s homogeneity of variance test and was not considered during 
statistical analysis. 
 
Greater variability between the hospital formulary decision-making statements 
versus the ranked factors is likely a result of data characteristics.  For the decision-
making statements a 5-point Likert scale was used versus for the factors a 7-point 
ranking.  The ranking section of the survey required participants to arrive at a singular 
ranked order for each of the factors in relationship to one another.  The ranking data 
appears to have revealed greater homogeneity among the groups than did the Likert 
scale statements. Homogeneity related to hospital formulary decision-making factors is 
especially apparent among physicians and midlevel providers.  Finally, for the statement 
“I rely upon the evaluation of medications by expert physicians to make hospital 
medication formulary decisions,” all six midlevel providers selected “agree” for this 
statement.  In other words, no variance existed in the responses for the statement for 
among midlevel providers. 
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Significance of the Study 
The number of clinical trials for medications is increasing at an unprecedented 
rate in the United States.  Consequently, prescribers find it increasingly difficult to stay 
abreast of new and constantly changing medical evidence.  Hospitals and hospital 
systems are under increasing pressure to reduce cost while at the same time improving 
the quality of healthcare delivery and outcomes.  To address these issues, the majority 
of hospitals and hospital systems utilize a hospital formulary managed by a P&T 
committee comprised of its medical staff.  P&T committees are required to evaluate 
medications and determine which agents will be used to treat patients and which are 
effective for treatment and most economically advantageous.  How the various 
prescriber groups arrive at decisions related to the hospital formulary is not well 
understood. 
This study contributes to a greater understanding of the three prescriber groups 
serving on a P&T committee comprised of physicians, midlevel providers, and 
pharmacists.  Furthermore, the study identifies and ranks the major factors affecting 
hospital formulary decision-making.  The study contributes to the body of literature 
regarding decision-making processes in medicine and specifically factors impacting 
hospital formulary decision-making. Furthermore, this study has the potential to impact 
the operational guidelines for the P&T committee at the University of Texas, MD 
Anderson Cancer Center as well as other hospitals.  
 
Recommendations for Future Research 
Replicating the study at other hospitals that manage their hospital formulary 
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using a P&T committee structure will serve to produce more generalizable results.  A 
survey of various general and specialty hospitals would yield additional insights into 
hospital formulary decision-making which may occur outside of a specialty oncology 
hospital. 
Additional insight into the prescriber decision-making factors could occur by 
conducting content analysis based on historical P&T committee meeting minutes.  
Content analysis could potentially correlate the various decision-making factors 
identified in the study with the final decisions arrived at by the P&T committee.  
However, the difficulty with this approach, is that only summarized meeting minutes are 
produced by Division of pharmacy staff.  Furthermore, P&T committee meetings are not 
recorded nor are verbatim transcripts produced. 
There is the potential to identify other hospital formulary decision-making factors 
that are not explicitly apparent from a review of the literature.  Participants were asked 
to provide additional hospital formulary decision-making factors in Part IV of the survey.  
These additional factors are listed in Table 11 and should be considered for inclusion in 
future research.  Furthermore, in Part IV of the survey participants were asked to state 
any additional information used when making decisions these responses are listed in 
Table 12.  Determination of additional individual, collaborative, and information artifact 
decision-making factors (Patel, Kaufman, & Kannampallil, 2013) will require conducting 
focus groups or semi-structured interviews (Bernard, 2006) of P&T committee members 
from various types of hospitals.  
Of the differences identified between the prescriber groups, it is unclear the 
reasons for the differences and how the differences could be addressed.  A greater 
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understanding of the identified differences could facilitate greater collaboration and 
understanding among the prescriber groups and impact P&T committee decision-
making and operation.  
 
Summary 
This chapter presented an overview of the study findings in relation to the major 
hospital formulary decision-making factors identified in the literature.  It also addressed 
the stated research questions and hypotheses for physicians, midlevel providers, and 
pharmacists.  Five major conclusions were drawn regarding the prescriber groups 
including three similarities and two differences.  The significance of the study was also 
discussed in terms of insight gained by conducting the study.  Finally, recommendations 
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understand the following explanation of the purpose, benefits and risks of the study and 
how it will be conducted. 
Title of Study: A COMPARISON OF MAJOR FACTORS THAT AFFECT HOSPITAL 
FORMULARY DECISION-MAKING BY THREE GROUPS OF PRESCRIBERS 
Student Investigator:  James M. Spence, University of North Texas (UNT) Department 
of Information. Supervising Investigator: Ana Cleveland, PhD. 
Purpose of the Study: The purpose of the study is to identify, rank, and compare major 
factors impacting hospital formulary decision-making among three prescriber groups 
serving on a hospital pharmacy and Therapeutics (P&T) committee. 
Prescribers will be selected from The University of Texas, MD Anderson Cancer Center 
which is a large, multi-facility, academic oncology hospital.  Specifically, the prescriber 
groups studied are comprised of physicians, midlevel providers, and pharmacists. 
Study Procedures: You will be asked to respond to questions about each of the 
hospital formulary decision-making factors. Second, study participants will be asked to 
rank the various formulary decision-making factors from the factor deemed most 
important to the factor deemed least important. The online survey will take about 15 to 
20 minutes of your time. 
Foreseeable Risks: No foreseeable risks are involved in this study. 
Benefits to the Subjects or Others: Overall, the study is expected to provide a greater 
understanding of the three prescriber groups comprised of physicians, midlevel 
providers, and pharmacists who routinely serve on P&T committees. 
Furthermore, the study seeks to identify and rank the major factors affecting hospital 
formulary decision- making. The study may contribute to the body of literature regarding 
decision-making processes in medicine and specifically identify factors impacting 
hospital formulary decision-making. This study has the potential to impact the 
operational guidelines for the P&T committees. Study results cannot be guaranteed. 
Compensation for Participants: None 
Procedures for Maintaining Confidentiality of Research Records: Confidentiality 
will be maintained to the degree possible given the technology and practices used by 
the online survey company. Your participation in this online survey involves risks to 
confidentiality similar to a person’s everyday use of the internet.  Survey data will 
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remain confidential and securely stored on the University of Texas, MD Anderson 
Cancer and UNT campuses, and any data published will be aggregated. 
Questions about the Study: If you have any questions about the study, you may 
contact: James M. Spence at 713-563-3674 or by email jmspence@mdanderson.org, or 
jms0435@unt.edu, or Ana Cleveland at 940- 565-2445 or by email 
ana.cleveland@unt.edu 
Review for the Protection of Participants: This research study has been reviewed 
and approved by the UNT and University of Texas, MD Anderson Cancer Center 
Institutional Review Boards (IRBs). The UNT IRB can be contacted at 940- 565-4643 
with any questions regarding the rights of research subjects. The University of Texas, 
MD Anderson Cancer Center IRB can be contacted at 713- 792-2933. 
Research Participants’ Rights: 
Your participation in the survey confirms that you have read all of the above and that 
you agree to all of the following: 
• James M. Spence has explained the study to you and you have had an opportunity 
to contact him/her with any questions about the study. You have been informed of 
the possible benefits and the potential risks of the study. 
• You understand that you do not have to take part in this study, and your refusal to 
participate or your decision to withdraw will involve no penalty or loss of rights or 
benefits. The study personnel may choose to stop your participation at any time. 
• You understand why the study is being conducted and how it will be performed. 
• You understand your rights as a research participant and you voluntarily consent to 
participate in this study. 
• You understand you may print a copy of this form for your records. 
--------------------------------------------------------- 
I have read the description of the study, and I have decided to participate in the 
research project described here. I understand that I may refuse to answer any (or all) of 
the questions at this or any other time. I understand that there is a possibility that I might 
be contacted in the future about this, but that I am free to refuse any further participation 
if I wish. 
During the course of this study, the research team at UNT and The University of Texas, 
MD Anderson Cancer Center will be collecting information about me that they may 
share with health authorities, study monitors who check the accuracy of the information, 
individuals who put all the study information together in report form. By answering the 
questions, I am providing authorization for the research team to use and share my 
information at any time. If I do not want to authorize the use and disclosure of my 
information, I may choose not to answer these questions. There is no expiration date for 
the use of this information as stated in this authorization. 
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I may withdraw my authorization at any time, in writing, for any reason as long as that 
information can be connected to me. I can learn more about how to withdraw my 




ELECTRONIC MAIL MESSAGE TO PARTICIPANTS
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Dear current or previous pharmacy and Therapeutics Committee Member, 
 
My name is James Spence, and I am a doctoral candidate in the Interdisciplinary Ph.D. 
Program in Information Science at the University of North Texas. My faculty advisor is 
Dr. Ana D. Cleveland. 
 
I would like to invite you to participate in a qualitative survey-based study for my 
dissertation entitled “A Comparison of Major Factors That Affect Hospital Formulary 
Decision-Making by Three Groups of Prescribers.” The study engages physicians, 
midlevel providers/advanced practice providers, and pharmacists to participate, jointly 
but confidentially, in analyzing factors that impact hospital formulary decision-making. 
 
Based on your record on service on The University of Texas, MD Anderson Cancer 
Center pharmacy and Therapeutics Committee, you have been selected as a participant 
for this study. Your participation is voluntary, and your input is important as we discover 
the factors that impact hospital formulary decision-making. 
 
There will a single survey which will consist of a questionnaire that you will fill out 
electronically using Qualtrics, online survey software. It is anticipated that the survey will 
take approximately 15 to 20 minutes for you to complete. All information obtained will be 
confidential. 
 
If you agree to participate in this study, I have included a link or URL to the online 
survey below.  There will be no negative effects for agreeing or declining to participate 
in the study. 
 
Follow this link to the Survey:  
${l://SurveyLink?d=Take the Survey} 
 
Or copy and paste the URL below into your internet browser: 
${l://SurveyURL} 
 
Follow the link to opt out of future emails: 
${l://OptOutLink?d=Click here to unsubscribe} 
 
Thank you in advance for your participation in this study! If you have any questions, feel 
free to contact me at jmspence@mdanderson.org, jms0435@unt.edu, or 713-563-3674. 
 
James M. Spence, MLIS Doctoral Candidate 
Interdisciplinary Ph.D. Program in Information Science University of North Texas 
jms0435@unt.edu 
 
Ana Cleveland, Ph.D. Supervising Investigator 








Part I:  Please provide the following background information: 
1. What is your age (select one age range listed below) ? 
  18-24 years old 
  25-34 years old 
  35-44 years old 
  45-54 years old 
  55-64 years old 
  65-74 years old 
  75 years or older 
2. What is your gender (select one) ? 
  Male 
  Female 
3. How many years and months have you been a licensed healthcare provider 
(including any residencies)?  
Years   ______  
Months  ______ 
4. How long have you been a licensed healthcare provider at the University of Texas, 
MD Anderson Cancer Center (years and months) ?   
Years  ______ 




5. What is your prescribing role at The University of Texas, MD Anderson Cancer 
Center (select one) ? 
  physician 
  midlevel provider/Advanced Practice Provider (e.g. physician Assistant, 
Advanced Practice Nurse) 
 
  pharmacist 
  None of the above 
6. Are you a current member of the The University of Texas, MD Anderson Cancer 
Center pharmacy and Therapeutics (P&T) Committee? 
 Yes 
 No 
How many previous years have you served on The University of Texas, MD 
Anderson Cancer Center pharmacy and Therapeutics (P&T) Committee (select all 
previous years of service) ? 
    Fiscal Year 2017 (9/1/16-8/31/17) 
    Fiscal Year 2016 (9/1/15-8/31/16) 
    Fiscal Year 2015 (9/1/14-8/31/15) 
    Fiscal Year 2014 (9/1/13-8/31/14) 
    Fiscal Year 2013 (9/1/12-8/31/13) 
    Fiscal Year 2012 (9/1/11-8/31/12) 
    Fiscal Year 2011 (9/1/10-8/31/11) 
    Fiscal Year 2010 (9/1/09-8/31/10) 
    Fiscal Year 2009 (9/1/08-8/31/09) 
    Fiscal Year 2008 (9/1/07-8/31/08) 





Part II:  Using the 5-point scale, please rate your level of agreement or 
disagreement with the 7 P&T decision-making factor statements 
below: 
 
7. I rely upon my individual evaluation of medical evidence to make hospital 












8. I rely upon the pharmacy staff’s evaluation of medical evidence including 
formulary recommendations (e.g. Drug Monograph, Medication Use Evaluation, 












9. I rely upon the evaluation of medications by expert physicians to make hospital 












10.  I consider the number of patients affected by adding, removing, or modifying a 













11.   I consider the financial impact of the treatment to the institution in terms of 
drug cost and potential reimbursement when making hospital medication formulary 














12.   I consider the financial impact of the treatment to the patient in terms of the out-
of-pocket expenses they may incur when making hospital medication formulary 












13.   In my role as a medication prescriber, I consider the opportunity for new 
treatment options when adding or expanding the use of a hospital formulary 












Part III:  Please rank the decision-making factors listed below when 
making a hospital medication formulary decision.  Indicate a “1” for 
the most important factor and a “7” for the least important factor: 
 
14.   Rank the Formulary Decision Making Factors.  Indicate a “1” for the most important 
factor and “7” for the least important factor: 
Assigned 
Rank 
Decision making Factor 
 My individual evaluation of medical evidence 
 pharmacy staff’s evaluation of medical evidence including formulary 
recommendations 
 Evaluation of medications by expert physicians 
 Number of patients affected by adding, removing, or modifying a formulary 
medication 
 Financial impact of the treatment for the institution in terms of drug costs 
and potential reimbursement 
 Financial impact of the treatment for the patient in terms of potential out-of-
pocket expenses 




Part IV:  Please provide additional information. 








16.  Would you like a summary of study results upon its conclusion? 
 If yes, please provide your name and email address. 
 Yes 
 No 
If yes, please provide your name and email address 
Name:   _______________________________________ 
Email address:   _______________________________________ 
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